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ABSTRACT
Oysters are described as keystone species serving an important ecological role.
As filter-feeders they help in maintaining water quality. Oyster reefs provide refuge and
support to different organisms. The eastern oyster, Crassostrea virginica, native to the
East Coast of United States and Gulf of Mexico is a part of the rapidly growing
aquaculture industry. Aquaculture production depends on a healthy and constant supply
of oyster larvae that are provided by hatcheries. Several hatcheries on the east coast that
provide C. virginica seed to oyster farms face significant losses owing to Vibrio
infections causing massive larval mortalities. Use of antibiotics is avoided due to
possibility of development of antibiotic resistance. The probiotic bacteria, Phaeobacter
inhibens S4 and Bacillus pumilus RI06-95 have been shown to successfully protect C.
virginica larvae from V. coralliilyticus RE22 infection. Use of these probiotics in
hatcheries can reduce mortalities due to disease thereby avoiding significant economic
losses. In order to design best practices for probiotic use it is crucial to understand their
mechanisms of action. There has been great progress in understanding the components
of oyster immune system, its functioning in response to various stimuli and its
uniqueness as compared to other organisms. This is in part due to availability of
sophisticated tools like high throughput sequencing and various –omics analyses such
as proteomics, genomics and transcriptomics and partly due to interest in controlling
diseases affecting aquaculture. As such most of our knowledge is based on studies that
focus on oyster-pathogen or oyster-environmental stimuli interaction. Little is known
about the effect of bacteria other than pathogens on the oysters. Moreover, very little
about larval immunity of eastern oyster, C. virginica. This is the first study to investigate

the effect of both pathogen and probiotic bacteria on C. virginica larval immunity using
transcriptomes. The aim of this study is to test the safety and efficacy of formulated
probiotic Bacillus pumilus RI06-95 in a hatchery, understand the mechanisms of action
of both probiotics and to characterize the effect of V. coralliilyticus RE22 infection on
the larval immune system of eastern oysters.
Chapter 1 reviews the current knowledge of oyster immune system and the
mechanisms

of

action

of

probiotics

especially

mechanisms

related

to

immunomodulation of innate immunity. Previous studies have demonstrated successful
protection of C. virginica larvae from V. coralliilyticus RE22 infection in a laboratory
based setting as well as in a hatchery using laboratory grown cultures of probiotics. The
ultimate use of the probiotics is in a hatchery setting, which would require easy to use
and stable formulation of the probiotics instead of time consuming laboratory-grown
probiotic cultures that are viable for only a short duration of time.
Chapter 2 discusses methods of formulation of probiotic Bacillus pumilus RI0695, testing the formulation in a hatchery and its effect on larval survival at the hatchery
and post V. coralliilyticus RE22 experimental challenge in the laboratory. A spray dried
formulation of Bacillus pumilus RI06-95 was both shelf-stable and effective in
protecting C. virginica larvae from V. coralliilyticus RE22 challenge. The formulation
did not show any adverse effects on the larvae during the course of the trial.
Chapter 3 investigates the host–pathogen interaction between C. virginica larvae
and V. coralliilyticus RE22 using transcriptomes produced after experimental challenge.
Exposure of larvae to the pathogen for 6 hours provided information of the changes in
the larval oysterimmune system brought about by the pathogen in the early stages of

disease. Overall, despite upregulation of several pattern recognition receptors, immune
signaling pathways leading to the production of antimicrobial effectors, such as protease
inhibitors and the pore forming protein perforin-2, were suppressed by V. coralliilyticus
RE22. The transcriptomic evidence suggests that lack of an adequate immune response
to thwart the infection of RE22, combined with a high metabolic load and decreased
feeding, leads to large-scale mortalities of C. virginica larvae. This research allows for
a better understanding of the disease process caused by V. coralliilyticus RE22 in larval
eastern oysters.
Chapter 4 investigates the effect of exposure to non-pathogenic probiotic
bacteria P. inhibens S4 and B. pumilus RI06-95 on the immune system of the host, C.
virginica larvae. It presents evidence of immunomodulation of C. virginica larval
immunity by both probiotic organisms. High upregulation of immune effectors such as
serine protease inhibitors is seen in larval oysters after short exposures to the probiotic
(6 and 24h) in the laboratory as well as after exposure for several days during a hatchery
trial. Other important modulations that help larvae protect themselves from V.
coralliilyticus RE22 infection include activation of pathogen receptors and signaling
pathways, modulation of mucin genes, and upregulation of pore-forming protein
perforin-2.
Chapter 5 summarizes and advocates the of use of probiotics in the larviculture
of C. virginica and suggests their potential role in limiting vibriosis.
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PREFACE
This dissertation was written in accordance with the manuscript format guidelines
established by the Graduate School of the University of Rhode Island. The dissertation
includes an introduction and the following three manuscripts:
1. “Use of formulated probiotic Bacillus pumilus RI06-95 for preventing vibriosis
in larviculture of the eastern oyster Crassostrea virginica.” prepared for
submission to Journal of Shellfish Research.
2. “Characterizaton of Crassostrea virginica larval response to Vibrio
coralliilyticus RE22” prepared for submission to Developmental and
Comparative Immunology.
3. “Immunological response of Crassostrea virginica larvae to probiotics Bacillus
pumilus RI06-95 and Phaeobacter inhibens S4” prepared for submission to
Developmental and Comparative Immunology.
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CHAPTER 1

LITERATURE REVIEW: IMMUNITY IN OYSTERS AND GENERAL
MECHANISMS OF ACTION OF PROBIOTICS

1

Abstract
Oysters are a unique model of immunology since they lack a classic adaptive immune
system and only possess an innate immune system. Some research suggests presence of
memory although a lot more remains to be elucidated. Oysters possess a wide variety
of pattern recognition receptors. Most of the components of signaling pathways like
TLR, NF-kB and MAPK are known while others like the complement system are not
fully known yet. Immune effectors like antimicrobial peptides and enzymes like
lysozyme are important in oysters especially in mucosal immunity. Exposure to
probiotics leads to modulation of host immune genes that eventually provide protection
from pathogens. Probiotics can modulate expression of receptors, signaling pathways
and production of effectors in specific hosts. Immunomodulation as a mechanism of
action of probiotics is seen in a variety of organisms including invertebrates and
vertebrates alike and therefore may play an important role in the mechanism of
probiotics in oysters.

2

Immunity in oysters
Oysters are sessile filter feeding animals that provide important ecological and
economical services. As such immunological studies to understand disease resistance
and improve aquaculture practices has given a boost in our understanding of the oyster
immunology. Although some research suggests presence of immunological memory
(Green et al., 2015) it is generally recognized that oysters lack adaptive immunity and
only possess innate immunity. The circulating phagocytic hemocytes form the cellular
branch of the innate immunity in oysters. The production of antimicrobial effectors via
activated signaling pathways due to recognition of PAMPs (pathogen-associated
molecular patterns) by PRRs (pattern recognition receptors) forms the humoral branch
of innate immunity (Wang et al., 2018). Current research of the oyster immunity is
reviewed below with emphasis on (i) Recognition (ii) Signaling pathways (iii) Effectors
(iv) Apoptosis and autophagy and (v) Mucosal immunity. Immune-related genes in the
eastern oyster Crassostrea virginica are illustrated in Fig 1.

Recognition
Recognition of non-self is achieved via PRRs that comprise of peptidoglycan
recognition proteins (PGRPs), lectins, toll-like receptors (TLRs), Gram-negative
binding proteins (GNBPs), scavenger receptors (SRs) and fibrinogen-related proteins
(FREPs) (Gerdol et al., 2018, Wang et al., 2018). Lectins are further classified into
major families including C-type, F-type, R-type, H-type, P-type, X-type, I-type lectins,
pentraxins, galectins (formerly S-type lectins), ficolins, and others (Vasta et al. 2007).
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Several of these PRRs are highly diversified in oysters (Zhang et al., 2014, Zhang et al.,
2015). C-type lectins require a special mention since they are not only involved in
pathogen recognition but also in activation of complement cascade.

Signaling pathways
Signals transmitted by receptors allow activation of several signaling pathways like
TLR signaling pathway, NF-kB signaling pathway, mitogen-activated protein kinase
(MAPK) signaling cascade, prophenol/phenol oxidase cascade and complement
pathway in oysters. Sophisticated tools like whole genome sequencing and –omics
analysis have led to tremendous progress in understanding molecules involved in these
pathways that are common with other organisms as well unique to oysters. The
TLR/NF-kB signaling pathway is a crucial pathway that upon recognition by TLR
receptors activate transcription factors facilitating production of effectors like
cytokines, interleukins, antimicrobial peptides (AMPs) and others (Gerdol et al., 2018).
MyD88 serves as a critical cytosolic adaptor modulating TLR signaling pathway and
Pacific oyster genome encodes an expanded set of 10 MyD88 genes (Zhang et al., 2015).
MAPK pathway comprises of many protein kinases and its active involvement in oyster
immunity is evidenced by their activation upon bacterial exposures (Qu et al., 2016).
Although studies support existence of a complement pathway in bivalves (Gerdol et al.,
2015, Li et al., 2015) the exact components and mechanisms of activation remain to be
identified (Gerdol et al., 2018).

Effectors
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Broad ranged effectors are produced upon induction of signaling pathways by PRR
recognition and function in elimination of pathogens. These include antimicrobial
peptides (AMPs), defensins, lysozymes, cytokines, protease inhibitors, antioxidant
enzymes and acute phase proteins. Serine protease inhibitors have been identified for
their role as important effectors in granting resistance to pathogens (La Peyre et al. 2010,
Xue et al. 2006, McDowell et al., 2014). Enzymes, such as superoxide dismutase,
catalase and glutathione peroxidase defend oysters by eliminating reactive oxygen
species (ROS). They are important especially during increased oxidative stress caused
by pathogen infection. Another important member of effectors are the heat shock
proteins (HSPs) that help oysters modulate stress response and protect them from
environmentally induced cellular damage caused by a variety of stressors (Wang et al.,
2018).

Apoptosis and autophagy
Apoptosis, programmed cell death is an extremely important process in oysters involved
in immune system homeostasis and function, defense against parasite and pathogens
and self/non-self recognition. The baseline apoptosis rates observed in circulating and
resident hemocytes in oysters is high (Sokolova, 2009). Apoptosis in oysters has two
major pathways intrinsic and extrinsic. The main players consist of caspases and
inhibitors of apoptosis (IAPs) that regulate the process. Apoptosis limits the spread of
pathogen while preventing inflammatory damage of surrounding tissues (Sokolova,
2009). Although apoptosis has been studied for a long time the exact functional
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relevance of its modulation by biotic and abiotic factors is still unknown in bivalves
(Gerdol et al., 2018, Wang et al., 2018).
Autophagy plays a housekeeping role in organisms and is important in innate immunity.
It is activated in oysters in response to bacterial, viral and environmental stimuli (Gerdol
et al., 2018, Wang et al., 2018). Its role in protecting Pacific oysters from viral and
bacterial challenge was demonstrated recently (Moreau et al., 2015) but a lot more
remains to be investigated.

Mucosal immunity
Mucus forms an external barrier of defense and plays a key role in host-microbe
interactions. Mucus consisting of crosslinked glycoproteins forms a physical barrier to
microbes and contains a myriad of effectors that defend the host from infection (Allam
and Espinosa, 2016). These include enzymes like lysozymes, hydrolases and proteases,
AMPs, antioxidants and lectins to name a few (Espinosa et al., 2016). Mucus
composition can affect pathogen adhesion and production of components is often
regulated by them (Linden et al., 2008, Allam and Espinosa, 2016). This understudied
topic is a crucial part of the innate immunity in oysters and needs further exploration.

Most of the knowledge of oyster immunity is based on a large body of research that is
centered on bacterial and viral pathogens and environmental stressors but we know very
little about the impact of friendly or beneficial bacteria on the immune system of oysters.
Addressing this dearth of knowledge might reveal important novel insights in the oyster

6

immune system. The next section of this review discusses the effect of probiotics on
different organisms focusing especially on their impact on immune system.

General mechanisms of action of probiotics
Probiotics, as defined by Food and Agricultural Organization and World Health
Organization, are live microorganisms that when administered in adequate amounts
confer a health benefit on the host (FAO and WHO 2006). Although probiotic uses for
better growth, digestion, immunity and disease resistance of the host have been known
their mechanisms have not been fully elucidated yet. Some of the known mechanisms
of action are summarized in Fig 2 and discussed in detail below.

Nutrient availability
Probiotics improve the utilization of feed by the host by producing or stimulating
production of exoenzymes that digest ingredients in feed such as carbohydrates, proteins
and fat. This aid in increased digestibility of feed, boosts host growth. Probiotics
Bacillus subtilis, Lactococcus lactis and Saccharomyces cerevisiae showed increased
secretion of amylase, trypsin, protease and lipase in sea bass (Labeo rohita) (TovarRamirez et al., 2002, Mohapatra et al., 2012). Application of probiotic strains of Bacillus
in white shrimp (Litopenaeus vannamei) and Fenneropenaeus indicus feed, improved
feed digestibility resulting in increased size of the shrimp (Heizhao et al., 2004). In fact,
production of chitinases, proteases, cellulases, lipases and trypsin by the bacteria
isolated from the digestive tract of various aquatic organisms have been shown
contribute to fish nutrition (Vine et al., 2006, Ray et al. 2012). Increasing nutrient
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availability and stimulation of growth through increased volatile fatty acids production
by probiotics has been studied in poultry industry as well (Ajuwon., 2016).

Production of inhibitory compounds
Probiotics produce or stimulate production of several non-specific compounds that are
effective in inhibiting pathogen growth including, antimicrobial compounds (hydrogen
peroxide, nitric acid and bacteriocins), siderophores, proteases and lysozymes. A nonpathogenic strain Vibrio mediterranei 1 produces bacteriocin-like inhibitory substance
against Vibrio parahaemolyticus spp (Carraturo et al., 2006). In fact, bacteriocin
production allows probiotics to compete within complex microbial communities and
influence the health of the host (Dobson et al., 2012). Probiotics administered to tilapia
(Oreochromis niloticus) increased lysozyme activity in host (Taoka et al., 2006).
Phaeobacter inhibens S4 produces tropodiethic acid (TDA) that kill pathogenic V.
coralliilyticus RE22, Vibrio harveyi BB120 and Alioseovarius crassostreae CV919312T in oysters (Karim et al., 2013, Zhao et al., 2016). Enterococcus durans strain
LAB18s showed antimicrobial and antioxidant activity against several pathogenic
bacteria (Pieniz et al., 2014).

Competitive exclusion of pathogenic bacteria
Probiotics often compete with pathogenic bacteria for space and nutrients that hinder
their proliferation. Direct inhibition of pathogens by production of inhibitory
compounds as discussed above is one way they competitively exclude pathogens. Other
mechanisms include formation of biofilms, blocking adhesion sites and profuse
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probiotic growth. An oyster probiotic, P. inhibens S4 produces biofilms that inhibit the
growth of pathogens V. coralliilyticus and V. anguillarum (Zhao et al., 2016).
Lactobacilli reduced the adhesion of rainbow trout pathogens (Balcazar et al., 2007).
Exclusion of pathogenic bacteria by competition from probiotic bacteria was also shown
in poultry. Native bacteria from adult chickens were used to protect chicks from
infestation of Salmonella infantis (Rantala and Nurmi., 1973) as well as other
enteropathogens (Schneitz, 2005). Porcine probiotics Lactobacilli and Bifidobacteria
compete for attachment sites on epithelial cells and exclude pathogens in the intestine
(Gross et al., 2008).

Enhancement of the Epithelial Barrier
Gut is in constant contact with a large number of bacteria and its integrity is often one
of the most important barriers against invading pathogens. Increased expression of
genes involved in tight junction signaling due to probiotic treatment reinforces this
barrier (Anderson et al., 2010). Escherichia coli Nissle 1917 (EcN1917) has been shown
to not only prevent disruption of the mucosal barrier by enteropathogenic E. coli, but
also restore mucosal integrity (Anderson et al., 2010). Probiotics differentially modulate
epithelial cell responses via activation or suppression of distinct signaling pathways in
a strain-dependent manner (Llewellyn et al., 2017).

Immunity
Effects on mucosal immunity
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Mucus is made up of polymerized mucins that protect hosts from pathogens, enzymes,
toxins, dehydration and abrasion (Hardy et al., 2013). Lactobacillus plantarum 299v
and Lactobacillus rhamnosus GG have been shown to up-regulate production of MUC2
and MUC3 intestinal mucins that weakens the adherence of pathogenic Escherichia coli
O157:H7 (Mack et al., 1999). Probiotics mediate modulation of mucin expression as a
strategy for intestinal colonization of beneficial microbes to the host (Caballero-Franco
et al., 2007). Mucus contains lysozymes, antimicrobial substances, antibodies and
enzymes that have added benefits in controlling pathogenic invasion. Production of
these substances can be modulated by presence of probiotics. Probiotic treatment led to
increase in lysozyme production in Japanese flounder (Ye et al., 2011). Probiotic strains
such as Lactobacillus GG, Bifidobacterium actis Bb-12 (Rautava et al., 2006) and
Saccharomyces boulardii (Rodrigues et al., 2000) have been demonstrated to enhance
IgA production and secretion.

Immunomodulation
Probiotic research shows mounting evidence of probiotic-host communication through
pattern recognition receptors resulting in modulation on key signaling pathways such as
NF-kB and MAPK to enhance or suppress activation and influence downstream
pathways (Bermudez-Brito et al., 2012, Hardy et al., 2013, De et al., 2014). Probiotics
and pathogens share PAMPs/MAMPs that can induce innate inflammatory pathways.
Secondary and chronic exposure to probiotics induce suppressive /tolerogenic response
that modulate NF-kB and MAPK pathways (Llewellyn et al., 2017). Effect in humans
for some example probiotics is illustrated in Fig 3. L. casei CRL 431 interacts with
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epithelial cells through TLR2 and induces an increase in the number of CD-206 and
TLR2 receptors in the cells involved in the innate immune response in humans
(Vinderola et al., 2005). Lactobacillus stimulates TLR9 that induces cytoplasmic
accumulation of ubiquitinated IkB and inhibition of NF-kB activation (Lee et al., 2006).
L. reuteri and L. casei engage with C-type lectin, prime dendritic cells and that lead to
increased production of IL-10 (Smits et al., 2005). In contrast, L. reuteri strains DSM
17938 and ATCC PTA 4659 downregulates expression of TNF-a, TLR4 and NF-kB
and upregulates IL-10 expression in rats (Bermudez-Brito et al., 2012). Along with the
influence on innate immunity probiotics also have impacts on adaptive immunity
(Hardy et al., 2013).
In addition, increase in phagocytic activity in probiotic fed Nile tilapia (Oreochromis
niloticus) (Vieira et al., 2010) and increase in total hemocyte count and serum
agglutination activity in probiotic fed and challenged marine shrimp (Sayed et al., 2011)
are also documented. Probiotics have also been shown to confer protection against many
cellular stresses, which include oxidative stress-mediated apoptosis (Llewellyn et al.,
2017).
Thus, probiotic bacterial strains can be generalized to exert immune-activation, deviation or -regulation/suppression responses (Hardy et al., 2013). Selection of
probiotic strains especially in combination along with prebiotics can have beneficial
effects on hosts. However, it is crucial to gain full knowledge of their modulatory
capabilities and formulate their use with careful consideration.

Goals of this study
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There has been much progress in understanding immunity in mollusks especially in
bivalves but we still lack knowledge of larval immunity in eastern oyster C. virginica.
There is also a dearth of understanding in the effect of bacteria on larval immunity.
Probiotics protect several organisms from Vibrio spp infection including crayfish
(Cherax tenuimanus) (Ambas et al., 2013), brine shrimp (Artemia franciscana) (Giarma
et al., 2017), oyster (C. virginica) (Karim et al., 2013), turbot (Scophthalmus maximus)
(Villamil et al., 2002) as well as humans (Carraturo et al., 2006) using mechanisms like
antibiotic production and indications of immunomodulation. However, we need a
thorough investigation of the nature of their immunomodulatory ability.
The overall goal of this study was to understand the mechanism of action of probiotics
B. pumilis RI06-95 and P. inhibens S4 against pathogen V. coralliilyticus RE22 and
formulate them for use in the field.
Laboratory grown bacterial culture of B. pumilis RI06-95 was previously shown to
protect C. virginica larvae from infection of V. coralliilyticus RE22 (Karim et al., 2013).
The first aim was to formulate the probiotic such that it can be effectively used in
hatcheries and to test their efficacy. A series of formulations were prepared and tested
in lab as well as in hatcheries to establish their efficacy.
The second specific aim was to understand the immunological response of C. virginica
larvae to both probiotics B. pumilis RI06-95 and P. inhibens S4 in order to understand
if immunomodulation is one of the mechanisms of action of these probiotics. Next
generation RNA sequencing technology was used to obtain the transcriptomic response
of C. virginica larvae to probiotics in a lab controlled and a hatchery environment to
thoroughly investigate their effect on several larval genes at a time.
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The third specific aim was to understand the immunological response of C. virginica
larvae to pathogen V. coralliilyticus RE22 in order to understand its pathogenesis. To
investigate this, larval transcriptomes generated post challenge with V. coralliilyticus
RE22 were compared to control transcriptomes.
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Figure 1: Immune-related genes present in the eastern oyster, Crassostrea virginica.
Adapted from Zhang et al., 2014.
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Figure 2: Major mechanisms of action of probiotics. Illustration adapted from
Bermudez-Brito et al., 2012.
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Figure 3: Examples of modulation of innate immune response by probiotics. Adapted
from Bermudez-Brito et al., 2012.
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Abstract
Vibriosis is a major disease affecting larval eastern oysters, Crassostrea virginica,
causing sudden and massive larval mortalities. A candidate probiotic strain, Bacillus
pumilus RI06-95, was previously investigated as a disease prevention method and found
to reduce mortality due to vibriosis in oyster larvae and juveniles. The goal of this
research was to develop a stable formulation of probiotic RI06-95 to facilitate storage
and delivery in a hatchery setting. Three types of formulations (granulated, lyophilized
and spray dried) of RI06-95 were developed. Cell viability of all formulations remained
above 105 colony forming units (CFU) per mL for up to 8 weeks of storage. The
granulated and spray-dried formulation had no adverse impacts on larval oyster survival
and provided protection against challenge with the bacterial pathogen Vibrio
coralliilyticus RE22 (Relative Percent Survival, RPS, as compared to probiotic
untreated control: 69 ± 1 % and 52 ± 35 % respectively). However, treatment of larval
oysters with the lyophilized formulation led to a significant decrease in survival
compared to non-treated controls and afforded no protection. Daily treatment of oyster
larvae with the spray dried formulation in pilot-scale hatchery trials provided significant
protection against laboratory challenge with RE22 (RPS 43 ± 4 %). These results
demonstrate that a sprayed-dried formulation for probiotic RI06-95 can be safely and
effectively used for disease prevention in shellfish hatcheries.
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Introduction
The bivalve shellfish (oysters, clams, scallops, and mussels) industry is an
important and rapidly expanding area of aquaculture production. The total landings for
oysters, clams and scallops in United States alone valued at $859 million (NMFS 2016).
A primary requisite for the aquaculture of most bivalve shellfish species is an abundant,
reliable, and inexpensive supply of seed/small juveniles (Helm et al. 2004). Shellfish
larvae, however, are prone to infectious diseases, which can result in a rapid and high
rate of larval mortality in commercial hatcheries (Elston 1998), leading to substantial
economic losses. For instance, pathogenic strains from several Vibrio spp. including V.
alginolyticus, V. anguillarum, V. coralliilyticus, V. ordalii, V. splendidus, V. tubiashii,
and others, cause bacillary necrosis of larval bivalve shellfish. Clinical signs of vibriosis
in bivalves include necrosis of mantle epithelium, clumping of the cilia, and rapid
mortality (Tubiash et al. 1965; Berthe 2004; Gomez-Leon et al. 2005; KesarcodiWatson et al. 2009).
Given the absence of an adaptive immune system in bivalves allowing for the
use of vaccines as disease prevention tools, the use of probiotics is one of the most
promising management strategies for shellfish disease prevention and control (Elston
1998; Verschuere et al. 2000; Prado et al. 2010). Probiotics are defined as live, nonpathogenic microorganisms which, when administered in adequate amounts, confer a
health benefit to the host (Food and Agricultural Organization of the United States
2006). The most widely used probiotics in human and animal health belong to Bacillus
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spp., Bifidobacterium spp., and lactic-acid bacteria such as Lactobacillus spp. (Hong et
al. 2005, Cutting S 2011). In particular, Bacillus spp. are attractive for commercial
products because they are aerobic, spore-forming bacteria. Spores are capable of
surviving extreme conditions such as the high temperatures and pressure conditions
sometimes used for formulating a commercial probiotic product. Formulations of
Bacillus spp. are stable for long periods without significant loss in viability because
spores enable survival in harsh conditions until germination and proliferation occur in
more favorable environments (Lalloo et al. 2010; Cutting 2011; Azevedo de & Tavares
Brag 2012; Sorokulova 2013; Edna et al. 2014).
We previously reported that marine Bacillus pumilus RI06-95, a producer of the
antibiotic amicoumacin (Socha 2008), antagonized growth of the shellfish pathogen V.
coralliilyticus RE22 in vitro and protected eastern oyster Crassostrea virginica and bay
scallop Argopecten irradians larvae against experimental challenge with V.
coralliilyticus RE22 (Karim et al. 2013b; Sohn et al. 2016a). It was also shown that
daily treatment of larval rearing tanks in a hatchery with RI06-95 led to a decline in the
levels of Vibrio spp. on tank surfaces and an increase in the survival of larval oysters
when challenged with a pathogen (Sohn et al. 2016a). Bacillus spp., have shown
promise as probiotic bacteria to improve host survival, growth, and development in
aquaculture (Queiroz & Boyd 1998; Luis-Villaseñor et al. 2011; Martínez Cruz et al.
2012; Li et al. 2014). Additionally, some bacilli exhibit antagonistic effects against
pathogenic Vibrio spp. (Decamp & Moriarty 2006; Vaseeharan & Ramasamy 2003).
Whole genome analysis of RI06-95 reveals that it is most closely related to B. pumilus
SAFR-32 (Hamblin et al. 2015), a strain isolated as a contaminant in spacecraft
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assembly facilities (Gioia et al. 2007). B. pumilus strains have been isolated from a wide
range of habitats, from aquatic and terrestrial hosts (Hill et al. 2009) to desert basalt
(Benardini et al. 2003), and have been suggested as probiotics for plants, humans,
crustaceans, and finfish (Duc et al. 2004; Hill et al. 2009; Sun et al. 2010; Murugappan
et al. 2013).
Although many studies have shown promising results for the use of probiotics
in shellfish aquaculture, no commercial products are available with demonstrated safety
and efficacy in bivalve larviculture. Probiotics typically are available in several types of
commercial formulations, including dry materials (such as wettable powders, dusts, and
granules) and liquid products (such as cell suspensions in water, oils, and emulsions)
(Austin et al. 1995; Schisler et al. 2004; Salinas et al. 2006; Savini et al. 2010; Dagá et
al. 2013). An appropriate formulation should offer several advantages in addition to
host protection, including: the stabilization of microorganisms during distribution and
storage; ease in handling and delivery of the product; protection of the microbes from
adverse environmental factors; and safety to the aquaculture species. Therefore, the
successful development of an appropriate probiotic formulation requires testing for
efficacy, safety, and stability, especially in bivalve hatchery facilities.
Here, we evaluate three novel formulations of the candidate shellfish probiotic
B. pumilus RI06-95. We determine storage and usage potential, and test each
formulation along with fresh cultures of the same probiotic bacterium for safety and
host protection in both laboratory and in semi-commercial scale hatchery experiments.
While all three formulations resulted in stable products with suitable shelf lives, only a
spray-dried formula provided a high level of safety and efficacy desired for a
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commercially viable product. Our results demonstrate a safe, stable, and easy-to-use
formulation for C. virginica larval aquaculture production.

Methods
Oyster larvae
Laboratory challenge experiments: For the bacterial challenge experiments,
eastern oysters, C. virginica, (4 - 6 day old) were obtained from the Blount Shellfish
Hatchery at Roger Williams University (Bristol, RI, USA) or Virginia Institute of
Marine Science (VIMS) (Wachapreague, VA, USA). Oyster larvae were transported to
the laboratory at the University of Rhode Island (Kingston, RI, USA) and acclimated at
room temperature (~20°C) for at least 24 h before treatment. The larvae were fed instant
algae Shellfish Diet 1800TM (Reed Mariculture Inc., San Jose, CA. USA) during the
experiments.
Hatchery trials: Adult eastern oysters were spawned at the Blount Shellfish
Hatchery for Trials I, II, III and V and at the VIMS Shellfish Hatchery at the
Aquaculture Genetics & Breeding Technology Center (ABC), VIMS for Trial IV.
Larval oysters were distributed into 100-120 L conical tanks at the Blount Shellfish
Hatchery 2 days after fertilization and fed live microalgae, a mix of Tisochrysis lutea
(CCMP1324; formerly Isochrysis sp., Tahitian strain) and Pavlova lutheri
(CCMP1325), daily. Larvae were distributed into 60 L tanks at the VIMS Shellfish
hatchery, and fed Pavlova sp. days 1 - 4 and a mix of Pavlova sp. and Chaetocerus
gracilis from day 5 on.
Pathogen and probiotic strains

27

V. coralliilyticus RE22 was supplied by H. Hasegawa, Department of
Biomedical Sciences, Oregon State University (USA). The freshly cultured B. pumilus
RI06-95 for comparison with formulated versions was cultured in the laboratory. Both
bacteria were maintained as stocks in 50% glycerol at -80 °C until use. They were
cultured on yeast peptone with 3% NaCl (YP30) media (5 g L-1 of peptone, 1 g/L of
yeast extract, 30 g/L of ocean salt (Red Sea Salt, Ohio, USA)) at 28 °C with shaking at
175 rpm as described in Karim et al. 2013a.
Formulation process
Granulated Product Formulation (RI-G)
Probiotic B. pumilus RI06-95 was incubated in 2.25% NaCl (YP22.5) broth
(yeast extract 1 g/L, peptone 5 g/L, 22.5 g/L ocean salt, Instant Ocean) at 25 °C and 175
rpm. An initial culture was incubated for 2 d, then transferred to fresh YP22.5 and
incubated for 4 d. The culture was partitioned into 50 mL sterile centrifuge tubes and
centrifuged for 10 min at 2,350 × g. After centrifugation, cell pellets were transferred
into a sterile petri dish (100 × 15 mm), and dishes were swirled with 2-3 mL culture
media to ensure that the surfaces were completely covered in cells. The dishes were then
covered with single ply, light duty paper (Kimwipes®) and placed in a convection oven
to dry at 30 °C with constant airflow for 24-48 h, depending on initial volume. The dry
cell mass was extruded through three particle size (40s, 80s, and 325s) USA Standard
Sieve stainless steel screens (Cole Palmer, Illinois, USA), yielding products with
average particle sizes of 43, 177, and 420 µm, respectively. The resulting granulated
products were transferred into sterile glass vials and stored at 4 °C. For hatchery trials
the granulated formulations were scaled up following the same formulation procedure
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as above except bacterial cultures were centrifuged at 9,300 × g for 10 min and the final
cell pellet was dried at room temperature (22 ± 3 °C) for approximately 2 days.
Lyophilized Product Formulation (RI-L)
Probiotic B. pumilus RI06-95 was cultured from frozen stocks and then
centrifuged as above. After discarding the liquid supernatant, 25 mL of Sugar Salt
Solution (SSS) (2.5 g/L Instant Ocean, 200 mM sucrose, filtered deionized (DI) water
(pre-filtered through a 0.2 µm filter)) was added to each tube, and the cell pellet was resuspended using a vortex. The re-suspended cells were frozen at -20 °C for 12 h, and
then lyophilized for 48 h (Labconco FreeZone 4.5 lyophilizer, Kansas City, MO, USA).
The tubes were stored at 4 °C until use. 100 mM sucrose was used as a cryoprotectant
during the lyophilization process. For hatchery trials, individual tubes with a single dose
of formulation for a target dose of 5 × 104 CFU/mL for 100 L were prepared.
Spray-dried formulations (RI-SD)
Spray-dried formulations were prepared by Envera LLC (West Chester, PA)
using a proprietary formula. Computer controlled fermentation vessels were used to
grow the probiotic and pasteurized to make 100% spore-based product. After
pasteurization, the probiotic was centrifuged and spray dried into a fine powder that can
be easily hydrated with seawater. The final concentration of the probiotic in the
formulation was 8.6 × 1011 CFU/mg of powder. For the hatchery trial, tubes of the
appropriate amount of formulation for a target dose of 5 × 104 CFU/mL in each 100 L
tank were prepared. At the hatchery seawater was added to the tubes and mixed
thoroughly. The mixed formulation was then added to the tanks daily during feeding.
Fresh culture controls (RI)
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In order to determine the influence of the formulation process itself on the
effectiveness of the probiotic in vivo, we tested simultaneous treatments of freshly
cultured B. pumilus RI06-95 (cultures prepared as described in Sohn et al. 2016b)
alongside formulated treatments in all lab and hatchery trials.
Viability and stability of formulated products
Viability and stability of each formulation was measured by counting colony
forming units (CFU) on 2.5% yeast peptone agar plates using serial dilutions. Preformulation cell concentrations in CFU/mL were measured from culture aliquots
directly before centrifugation. The RI-L product was re-suspended in 50 mL filtered
sterile seawater (FSSW). The RI-G was suspended at 5 mg/mL in FSSW for 10 min and
then vortexed for 1 min. The RI-SD was suspended using 0.1 g into 50 mL FSSW,
followed by 10-fold serial dilutions. The percent cell viability in the formulations was
calculated as follows: % Viability = [(sample formulation CFU/mL) / (pre-formulation
CFU/mL)] × 100%
RI-L was stored at 4 °C, while samples of RI-G were stored at either room
temperature or 4 °C and RI-SD stored at room temperature. The stability of the
formulated probiotics was measured immediately after formulation (t = 0) and 1, 2, 5,
and 8 weeks after formulation, except RI-SD. Each assay was performed in triplicate.
Laboratory pathogen challenge experiments
Laboratory challenge assays were conducted following protocols outlined in
(Karim et al. 2013a). Briefly, larval oysters were placed into six-well plates with 5 mL
of filtered sterile sea water (FSSW, 28 psu). Probiotic treatments were added to the
larvae at a concentration of 104 CFU/mL and incubated at room temperature with gentle
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shaking. After 24 h, the larvae were placed onto a 42 µm nylon mesh and washed gently
using FSSW, then placed back into the original wells. Finally, V. coralliilyticus RE22
was added to each well, with the exception of the non-challenged controls, at a final
concentration of 105 CFU/mL. Larval survival was quantified ~ 24 h after the pathogen
was added using the neutral red technique (Gómez-León et al. 2008). Survival was
calculated by using the formula: Survival (%) = 100 × (number of live larvae/total
number of larvae).
The relative percent survival (RPS) of probiotic pretreatment compared to the
challenged control was calculated using the formula: RPS (%) = [1 - (% survival
challenged control treatment / % survival challenged treatment)] × 100 as described in
Karim et al., 2013.
Hatchery trials
Hatchery experiments were conducted at Roger William University (RWU),
Bristol, RI or the Aquaculture Breeding Center at the Virginia Institute of Marine
Sciences (ABC), following standard operating procedures at each hatchery. For each
trial, twelve 60 L (ABC) or 100 L (RWU) conical larval rearing tanks were used. We
performed four independent trials at RWU between January 2014 and July 2016, and
one trial at VIMS in June 2015 (Trial IV), testing each of the formulations at least once.
Each trial was initiated by adding 8 -10 larvae/mL (800,000 to 1,000,000 initial larvae)
per tank 1-2 d post-fertilization to the conical tanks. Tanks were randomly assigned to
treatments and probiotic formulations were added daily at the time of feeding mixed
with the algal food. Larvae were kept in static conditions and tanks were drained-down
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every other day, cleaned, and re-stocked with fresh water. Treatments, number of tanks
per treatment, and trial duration for each trial is shown in Table 1.
Larval survival and growth during hatchery trial
Data was collected at the time of selected drain-down events. Oyster larvae were
passed through different sized mesh screens (35, 55, 75, and/or 105 µm for Trials I, II,
and III; 35, 48, or 63 µm for Trial IV; 35 or 75 µm for Trial V) depending on the age
and size of the larvae. Oyster larvae retained in each of the screens were collected in a
container, seawater was adjusted to a fixed volume (1 – 5 L depending on the amount
of larvae), and aliquot samples (1 mL each) were placed in Sedgewick Rafter counting
chambers (Graticules ® S50). Larvae were fixed with Lugol’s iodine (Trials I-III) or
temporarily immobilized with a 2:1 mixture of freshwater: 70% isopropyl alcohol
(Trials IV, V). Larvae were counted under a microscope and the presence of live and
dead larvae were recorded. After counting, 50 larvae from each tank (25 from top
screen, 25 from bottom screen) from Trial I and 25 larvae from each tank from Trials
II, III, and V were randomly selected from the slides and photographed with an Olympus
BX51 microscope (Olympus) and measured using an Olympus DP25 camera and
CellSens Standard 1.6 image software (Olympus). During Trial IV, 5 larvae from each
tank were randomly selected and measured on a Nikon E200 microscope. A random
sample from each culture was photographed using a Nikon DS-Fi2 camera and DS-L3
camera control unit. Interval survival rate was determined by dividing the number of
live larvae at each time point by the number of live larvae returned to the tank on the
previous time point.
Laboratory pathogen challenge of probiotic-treated larvae from hatchery
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An aliquot of larvae from each tank collected at selected drain-down events was
transported to the laboratory at University of Rhode Island. Oysters (about 40 – 50
larvae) were placed in six-well plates and then challenged with V. coralliilyticus RE22
at a final concentration of 105 CFU/mL following the methods described in the
laboratory challenge section. Oyster larvae from Trial IV could not be challenged since
very low number of oyster larvae were left in the probiotic treated groups at the
hatchery.
Determination of levels of Vibrio spp in the hatchery
Total number of Vibrio spp. was evaluated using a plate count method on
thiosulfate-citrate-bile salts-sucrose medium (TCBS, Difco) (Sohn et al. 2016a).
Samples were collected from water in the rearing tank (3 x 10 mL), tank surfaces (by
swabbing), and oysters (about 1,000) when the tanks were drained. Swab samples (3 per
tank) of tank surfaces (about 48 cm in length in total) were collected from each tank for
all except Trial V. Each cotton swab was placed into a sterile Falcon tube containing 1
ml of FSSW and then mixed vigorously. Oyster larvae were rinsed with FSSW,
homogenized using a sterile pestle, and suspended in FSSW. Ten-fold serial dilutions
of each sample were prepared in triplicate, and then triplicate 10 µL of each dilution
were plated on TCBS agar plates. After a ten-fold serial dilution, 10 µL samples of each
of the dilutions were spotted evenly onto TCBS agar plates in triplicate for all except
trial 5. The inoculated plates were incubated for 16 - 20 h at 28 ˚C and the colony
forming units (CFU) were calculated. Results are expressed as CFU/mL, where 1 mL
corresponds to 1 mL of water in the tank, 1 mL of swab suspension, or 1 mL of water
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contacting about 1,000 larvae. Determination of Vibrio spp. levels could not be
performed on larvae from trial IV due to very low numbers of surviving larvae.

Statistical Analysis
Larval oyster survival data were subjected to arcsine square root transformation prior to
statistical analysis. The one-way analysis of variance (ANOVA) was used to determine
significance between treatments within each time point. The two-way ANOVA was also
used to determine significance between groups with time and treatment as factors. The
Tukey’s or Sidak’s multiple comparison tests were used for post-hoc pairwise
comparisons. A p-value < 0.05 was considered to be statistically significant.
Formulation cell viability data were analyzed by two-way ANOVA followed by
Tukey’s Test for each temperature and each time point. All statistical analyses were
performed using Graphpad Prism, version 6.0 (Graphpad Software, Inc.). Differences
were considered to be significant at values of p < 0.05.

Results
Viability and stability of formulated products
The stability of the three formulated products was assessed after storage for 8 weeks
(RI-G and RI-L) (Figure 1) or 16 weeks (RI-SD) at ambient temperature. The three
formulated products varied in their final CFU/ml following storage. RI-L and RI-G had
similar pre-formulation concentrations of 1 × 108 CFU/mL and 1.27 × 108 CFU/mL,
respectively. We observed a loss in viability immediately after the RI-G formulation
process (data for RI-SD not available), and then again one week after storage at both 4
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and 27 °C. However, we note strong stability after this initial loss. The spray dried
formulation had a concentration ~200-250-fold higher at 2.65 × 1010 CFU/mL 16 weeks
post formulation.

Effectiveness of B. pumilus RI06-95 formulations at promoting survival after a
pathogen challenge
Laboratory challenge experiments: Pretreatment with fresh or formulated probiotic
had no adverse impact on larval survival (i.e. in the absence of pathogens) over a 48h
period aside from a single instance (L, Fig. 2B), where the formulation reduced larval
survival by 46% compared to the unchallenged control. In the same trial, treatment of
sucrose alone also showed significant reduction in larval survival (L, Fig. 2B). The
ability of formulations to protect oyster larvae from exposure to the pathogen V.
coralliilyticus RE22 was either higher or equal to that of fresh cultures in all experiments
conducted, except in the one instance where sucrose alone was shown to reduce larval
survival (Table 2, L, Fig. 2B). Larval survival was significantly greater in both fresh
and formulated treatments versus controls for one of the three L treatments (Fig.2D),
the G treatment (Fig.2A), and both SD treatments (Fig. 2E, F) (Table 2). In only two
instances was there a significantly higher protection by formulation against the pathogen
challenge than the fresh culture (Table 2, L III and SD II, Fig. 2D and 2F respectively).

Hatchery Trials:
Effect of daily treatment with probiotics in the hatchery on larval growth and survival
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Based on successful protection from pathogen challenges in laboratory trials, all three
formulations were tested in a hatchery. Treatments included in each hatchery trial and
the length of treatment is described in Table 1. The formulations did not have an effect
on the larval growth as shown by larval size measurements compared to control except
for Trial IV with RI-L (Figure 3). None of the formulations had a significant detrimental
impact on survival in the hatchery (Figure 4) except Trial I (RI-G) that showed a
significant negative effect of the probiotic additions. None of the trials showed a
significantly positive effect on larval survival due to probiotic addition (Figure 4). Of
the three formulations, the spray-dried product had the smallest impact on larval
survival. Thus, the SD-formulation is safe for use with oyster larvae in the hatchery.
Effect of daily treatment with probiotics in the hatchery on larval survival to bacterial
challenge
Larvae from the hatchery experiments were tested for improved survival following
challenge with V. coralliilyticus RE22. Since pathogens could not be introduced into
the hatchery, larvae were collected and subjected to laboratory challenges as described
in methods section. Larvae exposed to the granulated or lyophilized probiotics in the
hatchery did not show significantly higher survival to a 24 h bacterial (V. coralliilyticus
RE22) challenge as compared to non-treated challenged larvae (One-way ANOVA; p >
0.05) (Figure 5). A fresh culture of RI06-95 offered some protection on day 12 in Trial
II (One-way ANOVA; p < 0.05; Figure 5 D). Relative percent survival (RPS) provided
by the fresh culture of RI06-95 in this trial was 36 ± 6 % on day 12 (Table 3). On the
other hand, trial V showed significantly improved survival both with RI-SD and fresh
culture of RI06-95 as compared to controls (One-way ANOVA; p < 0.05; Figure 5 G).
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The relative percent survival (RPS) with fresh culture was 28 ± 6% and RI-SD was
43±4% (Table3).

Effect of daily treatment with probiotics in the hatchery on levels of total Vibrio spp.
In general, daily treatment of tanks with either formulation of B. pumilus RI06-95 did
not lead to a significant decrease in the levels of total Vibrio spp. in water, tank surfaces,
or oyster larvae as compared to control groups at each of the time points (Figure 6 and
Figure 7). High levels of variability were observed between tanks and trials within
treatments. Interestingly, levels of Vibrios in the water were lower than 103 CFU/mL in
Trial I (Figure 6A) and none were detected on the tank surfaces during this trial (Figure
6D). Trial I was performed in January, a month in which lower levels of Vibrios are
present in coastal waters in the region (and therefore in water being pumped into the
hatchery) (Duan & Su 2005, Parveen et al. 2008). Similarly, very low levels of Vibrios
were found in Trial V in the water (Fig 6G). Levels of Vibrios on tank surfaces and
larvae were not measured during Trial V. Overall the results show that certain days
probiotic treated tanks (formulated or fresh) show reduced level of Vibrios spp. as
compared to control but there is no significant trend to specifically ascertain that effect.

Discussion
We outline three formulation protocols, a granulation process (G), a lyophilization
process (L), and a commercial spray-dried process (SD). Variation in terms of success
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was achieved for each of the formulations, with the spray-dried formulation showing
overall the best performance.
Granulation process: A traditional approach for formulating microorganisms is airconvective drying, which is a cost-effective process for the dehydration of
microorganisms (Fu & Chen 2011, Guergoletto et al. 2012). Granulation after an airconvective drying is necessary to prevent segregation of the constituents of the powder
and to provide consistent particulate sizes. The loss of viability of probiotic bacteria
during granulation is associated with granulation operating conditions such as
temperature, mechanical and moisture stress, and the characteristics of the selected
microorganisms (Hiolle et al. 2010). This process did cause an immediate loss in
viability from fresh cultures over the short term, as dehydration of bacterial cells poses
serious physiological challenges to the survival of cells, such as conformational and
chemical changes in structural proteins and membrane lipids (Ananta 2005,
Santivarangkna et al. 2008, Ohtake & Wang 2011). However, after these initial shortterm losses the cell count stabilized and remained consistent over 8 weeks. Storage
conditions such as temperature and humidity have also been shown to affect the stability
of granulated probiotic product (Ananta 2005). Mortality of probiotic bacteria during
storage is associated with various stress factors such as temperature, oxygen/air, light,
moisture/humidity, and package material, a combination of which tends to damage or
destroy cells (Wang et al. 2004, Ananta 2005, Chávez & Ledeboer 2007). Our results,
however, suggest that beyond an initial decrease in viability, the granulated product of
RI06-95 could be stored at either 4 °C or room temperature and maintain viability for
up to for 8 weeks. The stability of the granulated product during storage may be due to
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the adaptation of Bacillus spp. to extreme environmental stress by spore-formation
characteristics (Desmond et al. 2002, Driks 2002, Hong et al. 2005, Cutting 2011).
RI-G showed protection in laboratory experiments and did not show any
detrimental effect on the larvae in any of the laboratory assays. However, in the hatchery
trial formulation treated larvae showed reduced survival as compared to control and
freshly grown probiotic. It demonstrated protection from pathogen challenge in
laboratory trials but was unsuccessful in doing so in the hatchery trial. Despite the
favorable results from viability and storage of the granulation protocol, research on the
granulated product was discontinued in this study due to a negative influence on survival
of larval oysters in hatchery settings.

Lyophilization: The lyophilized formulation (L) did not significantly impact cell
viability after the formulation process. Lyophilization has previously been investigated
as a way of preserving and formulating Bacillus spp. as probiotic products (Henn et al.
2015). To ensure sufficient viability after freeze-drying, a disaccharide cryoprotectant
such as sucrose or trehalose is typically added to provide structural support to cell
membranes and proteins (Leslie et al. 1995). We successfully used sucrose at a
concentration of 100 mM that provided stability and viability over time.
RI-L led to variable results in larval survival in hatchery trials. It failed to
provide protection from pathogen challenge in the 2 out of 3 laboratory experiments and
the hatchery trial. It produced no observable negative effect on water quality. Our results
suggest that the addition of sucrose may be responsible for the negative impact on larval
survival, as sucrose alone (without B. pumilus RI06-96) lowered larval survival in 2 of
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4 trials where it was investigated. Because a wide range of bacterial taxa can readily use
sucrose, we suggest that its addition to the formulated product may encourage
antagonistic bacterial growth, and presents greater risks than advantages.

Spray drying: Of the three formulations tested, the commercially prepared spray dried
formulation was found to maintain the highest concentration at room temperature over
time while also showing no negative impact on larval oysters in the laboratory or in the
hatchery trials. After 16 weeks at room temperature, the SD-product still contained
>2.65 × 1010 CFU/g. Previous research has shown that probiotic concentrations of
Bacillus products at around 1 × 104 CFU/ml provide optimal performance (Karim et al.
2013a; Sohn et al. 2016a), meaning to reach a final target concentration of 1×104
CFU/ml in a 1,000 L commercial tank, only ~0.4 g of RI-695 would need to be added.
This would be extremely cost effective for use at a larger scale. Another added benefit
of the formulation is its ease of use. The powder quickly suspends in seawater and is
added to the tank very easily.
The spray-dried formulation was also shown to perform as well or better than
freshly prepared B. pumilus RI06-95 in both laboratory experiments and hatchery trials.
In hatchery experiments, RI-SD showed no significant reduction in larval survival,
water quality or larval growth. In fact, it increased survival compared to freshly prepared
culture in the hatchery trial by day 12. RI-SD also performed well in pathogen challenge
experiments, increasing survival of larvae after the challenge at the same rate or greater
as compared to freshly prepared culture.
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As seen in previous hatchery experiments (Sohn et al. 2016), high levels of
variability were seen between tanks and trials within a treatment. The variation in results
within and/or between experiments in this study could be due to several factors: (1) a
different quality and health status of larvae from each trial; (2) the impact of various
environmental and biological factors such as salinity, pH, temperature/season at the
hatchery; (3) variability in the characteristics of different rearing systems, such as tank,
source or treatment of water, and location of hatchery (Balcazar et al., 2006; Gatesoupe,
1999; Martínez Cruz et al., 2012; Utting and Millican, 1997); and 4) the effect of
variability in the composition of microbial communities and how these communities
may interact with the probiotic. Due to above factors the variability is more pronounced
in hatchery trials than controlled laboratory experiments. Although variability is seen
within and/or between experiments in this study for RI-G and RI-L, it is highly
minimized in the trials using RI-SD. More importantly there is consistency in the goal
of achieving protection from pathogen challenge with use of RI-SD.
The use of probiotics as a disease control mechanism has particular and critical
relevance to shellfish hatcheries, where disease losses are high, vaccination is not
possible and use of antibiotics is not recommended. Our results demonstrate successful
formulation of the candidate probiotic B. pumilus RI06-95 for its use in shellfish
hatcheries using the spray drying method. It also demonstrates the challenge in
formulating the probiotic and the need of thorough testing in both laboratory and
hatchery setting to confirm the effect of formulation. The laboratory and hatchery trials
confirm that the RI-SD formulation is stable over a long term, remains viable and shows
comparable performance to freshly grown cultures of the probiotic. It is suitable for
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storage, transportation and can be easily applied in a hatchery by mixing with sea water.
Although the addition of RI-SD did not show reduction in Vibrio spp. in general, this
might not be a strategy used by the probiotic as its mechanism of action. Probiotics are
known to modulate the immune system of the host (Hardy et al., 2013, Mortha et al.,
2014, Sanchez et al., 2015). This could be one the strategies used by B. pumilus RI0695 to provide protection in the event of vibriosis.
Future research in mechanism of action of the probiotic would help in optimization of
the use formulation in terms of dosage timing and frequency.
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CFU/mg of
formulation

Prior to
Formulation

Figure 1. Impact of formulation processing (granulation or lyophilization) and
temperature storage on the stability of Bacillus pumilus RI06-95. Cell count in the
reconstituted formulation after storage for up to 8 weeks was determined using a plating
method. Data expressed as mean ± SEM of CFU/mg of formulation.

Hatchery
Trial

Treatments

Tanks per
treatment

Treatment
period
(days)

Dates
performed

I

Control, RI-G

6

14

II

Control,
ConwS, RI, RIL

3

12

01/29/15 –
02/10/15

III

Control,
ConwS, RI, RIL

3

12

02/22/15 –
03/06/15

IV

Control, RI-L

4 (control), 3(RI-L)

10

06/24/15 –
07/08/15

V

Control, RI, RISD

3

12

06/06/1606/17/16

01/03/14 –
01/24/14

Table 1: Treatments included in each hatchery trial and the total length of treatment in
days. Abbreviations: controls (no probiotic provided); ConwS = 100 mM sucrose (no
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probiotic, control for lyophilized formulation); RI-G = granulated formulation; RI-L =
lyophilized formulations (in 100 mM sucrose); RI-SD = spray-dried formulation; RI =
RI06-95 freshly cultured in lab.
Relative Percent
Treatment

Survival

Plots

(RPS, % ± SEM)
Granulated

RI-G

69 ± 1

RI

26 ± 5

Lyophilized I

(Figure 2 B)
RI-L

-93 ± 86

RI

22 ± 11

RI-L

25 ± 6

RI

56 ± 4

RI-L

74 ± 1

RI

23 ± 6

RI–SD

21 ± 13

RI

75 ± 5

RI–SD

83 ± 2

Lyophilized II

(Figure 2 C)

Lyophilized III

Spray-dried I

Spray- dried II

(Figure 2 A)

(Figure 2 D)

(Figure 2 E)

(Figure 2 F)

Table 2. Laboratory challenged experiments results: Effect of pre-incubation of oyster
larvae for 24 h with RI06-95 formulated products on survival (RPS, % ± SEM) after
challenge with V. coralliilyticus RE22. Survival was measured 24 h after challenge
and 48 h after addition of the probiotic. Data is expressed as Relative Percent Survival
(RPS, % ± SEM) of challenged oysters exposed to probiotics compared to V.
coralliilyticus RE22 challenged control. Abbreviations: RI-G = granulated
formulation; RI-L = lyophilized formulation (in 100 mM sucrose); RI-SD = spray
dried formulation, RI = fresh; RE22 = V. coralliilyticus RE22.
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E
F

Figure 2. Laboratory challenged experiments results: Effect of pre-incubation of oyster
larvae with Bacillus pumilus RI06-95 formulated products for 24 h on survival (% ±
SEM) after challenge with V. coralliilyticus RE22. Survival was measured 24 h after
challenge and 48 h after addition of the probiotic. (A) Exposure to a granulated product
of Bacillus pumilus RI06-95; (B), (C), and (D) Exposure to lyophilized formulations
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(representative experiments) (E) and (F) Exposure to spray dried formulations.
Abbreviations: C = no probiotic; ConwS = 100 mM sucrose; RI-G = granulated
formulation; RI-L = lyophilized (in 100 mM sucrose) formulation 5; RI = fresh RI0695; RE22 = V. coralliilyticus RE22. Different letters indicate statistically significant
differences between the treatments.

B
250

*

Size (um)

200

Day 12
Day 8

150

Day 5

100
50
0

C

ConwS

RI-L

RI

Treatment

E

Figure 3. Effect of daily treatment with different formulations of Bacillus pumilus
RI06-95 of larval eastern oysters (Crassostrea virginica) in the hatchery on mean larval
size (µm ± SEM) at selected time points. (A) Trial I; (B) Trial II; (C) Trial III; (D) Trial
IV and (E) Trial V. Abbreviations: C = no probiotic; ConwS = 100 mM sucrose; RI-G
= granulated formulation; RI-L = lyophilized (in 100 mM sucrose) formulation; RI-SD
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= formulation RI = fresh RI06-95; RE22 = V. coralliilyticus RE22. An asterisk (*)
indicates statistical significances compared to controls.

E

Figure 4. Effect of daily treatment with probiotics in the hatchery on interval survival
(% ± SEM) of oyster larvae between selected time points. (A) Trial I; (B) Trial II; (C)
Trial III; (D) Trial IV and (E) Trial V. Abbreviations: C = no probiotic; ConwS = 100
mM sucrose; RI-G = granulated formulation; RI-L = lyophilized (in 100 mM sucrose)
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formulation; RI-SD = spray dried formulation; RI = fresh RI06-95. An asterisk (*)
indicates statistical significances between treatments.
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G

Figure 5. Effect of daily probiotic treatment in the hatchery on larval survival to a
laboratory challenge with the pathogen Vibrio coralliilyticus RE22. Larvae were
brought to the laboratory and survival was measured 24 h after challenge with RE22.
(A) Larvae collected on Day 3 after fertilization in Trial I; (B) Day 7 in Trial I; (C) Day
5 in Trial II; D) Day 12 in Trial II; E) Day 5 in Trial III; F) Day 12 in Trial III. (G) Day
8 in Trial V. Abbreviations: C = no probiotic; ConwS = 100 mM sucrose; RI-G =
granulated formulation; RI-L = lyophilized (in 100 mM sucrose) formulation; RI-SD =
spray-dried formulation; RI = fresh RI06-95; RE22 = V. coralliilyticus RE22. A
different letter indicates a significant difference between treatments (One-way
ANOVA; p < 0.05).

Trial

I

II

Treatments

Relative Percent Survival (RPS, % ± SEM)
Day 3

Day 7

-10 ± 2

-78 ± 88

Day 5

Day 12

RI+RE22

36 ± 9

36 ± 6

RI-L+RE22

46 ± 3

2±5

RI-G+RE22
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III
IV

RI+RE22

2 ± 13

16 ± 3

RI-L+RE22

- 36 ± 28

26 ± 1

No challenge data due to low survival of larvae
Day 8
RI + RE22

28 ± 6

RI-SD + RE22

43 ± 4

V

Table 3. Effect of daily exposure to formulations of B. pumilus RI06-95 in the hatchery
on larval oyster survival (%) 24 h after challenge with Vibrio coralliilyticus RE22. Data
is expressed as Relative Percent Survival (RPS, % ± SEM) of challenged oysters
exposed to probiotics compared to V. coralliilyticus RE22 challenged control.
Abbreviations: C = no probiotic; ConwS = 100 mM sucrose; RI-G = granulated
formulation; RI-L = lyophilized (in 100 mM sucrose) formulation; RI-SD = spray dried
formulation, RI = fresh RI06-95; RE22 = V. coralliilyticus RE22
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G

Figure 6. Effect of daily treatment with probiotics on total vibrio levels
(Log10(CFU/mL) ± SEM) in water (A, B, C, G) and tank surfaces (D, E, F) in a hatchery.
(A and D) Trial I (no bacteria were detected in tank surfaces in Trail I); (B and E) Trial
II; and (C and F) Trial III. (G) Trial V. Abbreviations: C = no probiotic; ConwS = 100
mM sucrose; RI-G = granulated formulation; RI-L = lyophilized (in 100 mM sucrose)
formulation;RI-SD = spray-dried formulation; RI = fresh RI06-95; RE22 = V.
coralliilyticus RE22. An asterisk (*) indicates significant differences between
treatments (mean ± SEM, p < 0.05; Two-way ANOVA).
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Figure 7. Effect of daily treatment with probiotics on total vibrio levels
(Log10(CFU/mL) ± SEM) on oyster larvae in the hatchery. (A) Trial I; (B) Trial II; and
(C) Trial III. Abbreviations: C = no probiotic; ConwS = 100 mM sucrose; RI-G =
granulated formulation; RI-L = lyophilized (in 100 mM sucrose) formulation; RI = fresh
RI06-95; RE22 = V. coralliilyticus RE22. An asterisk (*) indicates significant
differences between treatments (mean ± SEM, p < 0.05; Two-way ANOVA).
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Abstract

Vibrio spp. are ubiquitous in marine environments and, in the case of pathogenic
species, responsible for causing disease in several marine organisms. Vibrio
coralliilyticus has emerged as a pathogen affecting a variety of invertebrate species. In
corals, certain strains cause bleaching, while V. coralliilyticus RE22 causes massive and
rapid mortality of eastern oysters (Crassostrea virginica) larvae. Such mortality events
in hatcheries where oyster larvae are reared, lead to heavy losses and subsequent
shortage of oyster seed for the grow-out industry. A better knowledge of oysterpathogen interactions and the mechanisms involved in RE22 pathogenicity may aid the
development of effective management strategies. This study aims to characterize the
larval immune response to experimental challenge by V. coralliilyticus RE22. Six to
ten-day old C. virginica larvae were exposed to V. coralliilyticus RE22 for 6 hours to
understand the host response in the early stages of the disease. Transcriptomes were
obtained by high throughput sequencing of cDNA from three replicate experiments.
Comparison of RE22 treated larval transcriptomes to untreated control larvae yielded
1,534 differentially expressed transcripts (p £ 0.05). Overall, transcriptomic data
showed evidence of suppression of key immune signaling pathways but possibly
activated antiviral pathways. The larval response to RE22 lacked production of protease
inhibitors, hypothesized to be involved in providing protection against the proteases that
are a key virulence factor of RE22. In addition, transcriptomic data suggests modulation
of mucus and cytoskeletal components. The transcriptomic response was also
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characterized by differential expression of metabolic genes, suggesting high metabolic
demand and oxidative stress contributing to larval mortality. This study fills a major gap
in our knowledge on the immune responses in larval stages of this economically and
ecologically important species. This information could aid in developing solutions to
control disease and design better management practices for hatcheries.
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1. Introduction
Vibrio spp. are common pathogens causing disease in a wide variety of aquatic species,
including several species of mollusks. Strains of V. coralliilyticus also cause disease in
corals, leading to bleaching (Ben-Haim et al., 2003, Wilson et al., 2013). V.
coralliilyticus RE22, previously known as V. tubiashii RE22, causes vibriosis in bivalve
larvae (Richards et al., 2015). The disease resulted in heavy mortalities that severely
affected oyster seed production of shellfish hatcheries (Elston et al., 2008).

Infection by vibrios in bivalve larvae is dramatically rapid in progression and
characterized with signs of bacillary necrosis, reduced feeding, and swarming of
bacteria around the moribund larvae (Tubiash et al., 1965). An investigation of the
colonization and infection process in Manila clam (Ruditapes philippinarum) larvae
using a GFP-tagged Vibrio sp. showed pathogen entry through ingestion, with infection
quickly spreading to other organs and followed by colonization and proliferation in the
entire body (Dubert et al., 2016). The genome of V. coralliilyticus RE22 shows that it
encodes several extracellular metalloproteases, serine proteases, hemolysins and type
secretion systems as virulence factors (Hasegawa et al., 2008, Hasegawa et al., 2009,
Spinard et al., 2015). Experimental infection of C. virginica larvae and juveniles with
V. coralliilyticus RE22 showed differences in susceptibility based on the age and genetic
background of the oysters (Gómez-León et al., 2008).

V. coralliilyticus YB1 specifically infects coral Pocillopora damicornis causing coral
tissue lysis at higher seawater temperatures (26-29°C) and its virulence factors include
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a potent extracellular protease (Ben-Haim and Rosenberg, 2002, Ben-Haim et al.,
2003a) whose production is also temperature regulated (Ben-Haim et al., 2003b). V.
coralliilyticus P1 genome and mutant studies demonstrated presence of 17
metalloproteases, serine protease, hemolysin-related protein RbmC, chitinase and
effector genes including vgrG, hlyA and hcp (Santos et al., 2011). Transcriptomic
studies investigating the responses of coral Pocillopora damicornis to V. coralliilyticus
YB1 reported immunosuppression of the host as a pathogenesis strategy of YB1 (VidalDupiol., et al., 2014) including repression of the antimicrobial damicornin (VidalDupiol et al., 2011a). Innate immunity related genes involved in P. damicornis
responses to V. coralliilyticus YB1 include lectins, cystatin B, ferretin, and seleniumbinding protein (Vidal-Dupiol et al., 2011b).
Several studies have characterized changes in gene expression patterns in larval stages
of bivalves during development including Pinctada fucata (Li et al., 2016), C. angulata
(Qin et al., 2012) and in response to vibrio infection in Crassostrea gigas (Hasegawa et
al., 2008) and C. virginica (Genard et al., 2012). This study aims to enhance knowledge
on bivalve-vibrio interactions by analyzing the transcriptomic response of larval eastern
oysters, an economically and ecologically important species, to infection with V.
coralliilyticus RE22, a bacterial pathogen capable of causing rapid and high levels of
mortality in bivalve hatcheries. The goals of this study are to (1) characterize the
response of C. virginica larvae to experimental challenge with V. coralliilyticus RE22;
and (2) provide hypotheses on possible strategies used by V. coralliilyticus RE22 to
overcome larval immune defenses. This information will aid in developing solutions to
control disease and design better management practices for hatcheries.
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2. Materials and methods
2.1 Vibrio coralliilyticus RE22 culture:
The pathogen (supplied by H. Hasegawa, Department of Biomedical Sciences, Oregon
State University) was maintained and stored in 50 % glycerol stocks at -80°C until use.
Inocula from freezer stocks were plated on yeast peptone with 3%NaCl (YP30; 5 g L-1
of peptone, 1 g L-1 of yeast extract, 30 g L-1 of ocean salt, Instant Ocean) agar plates
for 2 d, then transferred to 5 mL of YP3 broth incubated at 25°C on a shaker (134 rpm)
for 1 d. Cultures were washed using Artificial Filtered Sterile Seawater (AFSW, 28-30
psu salinity) twice by centrifugation at 23,000 rpm for 10 min. The OD at 550 nm was
measured and the stock was diluted such as to obtain a sub lethal concentration of 5 ×
104 CFU mL-1 for transcriptome analysis and a lethal concentration (Karim et al., 2013)
of 5 × 105 CFU mL-1 for disease progression analysis.

2.2 Oyster larvae:
C. virginica larvae were obtained from shellfish hatcheries on the east coast of United
States. Larvae 6-10 days old were collected at the hatchery and shipped overnight to the
lab at the University of Rhode Island on a wet filter. Upon arrival to the laboratory,
larvae were washed with AFSW on top of a 40 µm nylon mesh and placed in stock
containers containing AFSW. Larvae were acclimatized to the laboratory environment
(room temperature) for 24 h prior to the experiments.

2.3 Effect of V. coralliilyticus RE22 on mortality of C. virginica larvae
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In order to understand the rate of progression of disease, C. virginica larvae were
experimentally challenged with 5 x 105 CFU mL-1 V. coralliilyticus RE22 (Karim et al.,
2013). Larval density (larvae/mL) of the stock was determined using a Nikon E200
microscope. Larvae (~100) were distributed in wells of a 6-well plate with 5 mL AFSW
and maintained at 22 - 23 °C with gentle rocking. Two treatments (control and
challenge) were each conducted in triplicate. Larval mortality was recorded at 6, 9, 14,
18 and 20h post addition of V. coralliilyticus RE22 by evaluation of active swimming
and/or gut and cilia movement using a Nikon E200 microscope.

2.4 Effect of pathogen exposure on larval gene expression

2.4.1 Experimental set up
For biological replicates, the complete set up as explained below was performed using
larvae from three different hatcheries (n = 3 experiments, operationally designated as
K, M, and V). Larvae from the stocks were distributed into tissue culture flasks (~10,000
per flask) in 500 mL AFSW and kept on a shaker with gentle shaking at ~50 rpm at
room temperature. Larvae were acclimatized to the experimental set up for an additional
24h prior to challenge. Each treatment (control and challenge) was conducted in
duplicate to serve as technical replicates. Larvae were fed with 1 mL of instant algae
Shellfish Diet 1800TM (20,000 cells/mL; Reed Mariculture Inc., San Jose, CA. USA)
immediately prior to treatment in order to promote pathogen ingestion. Challenge with
V. coralliilyticus RE22 was performed with a sub lethal concentration of 5 × 104 CFU
mL-1 for 6h.
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2.4.2 Larval Collection post treatments
Control larvae were collected at 0h and RE22 treatments were collected 6h post
challenge. Larvae were aspirated gently from the flasks using a 100mL serological
pipette, and filtered through a 40 µm sterile filter for collection. Since dead larvae settle
to the bottom, the last 25 mL of each flask was not collected to avoid bias in
transcriptomic response. Larvae were washed with 2mL of AFSW on a 40µm filter,
followed by a wash using 2mL of RNAlater™, aspirated from the filter using a pipette,
placed in labeled 2 ml RNase free microfuge tubes, and held at 4°C for 24h in
RNAlater™ followed by storage at -20°C.

2.4.3 RNA extraction, cDNA prep and sequencing
Tri-reagentä (Sigma-Aldrich) was used for extracting total RNA from all the samples
following manufacturer’s instructions (TRI Reagentä Protocol, Sigma-Aldrich). RNA
extracts were DNase treated using the DNA-freeä DNA removal kit from Ambion and
purity and concentration of RNA was assessed using a Nanodrop 8000
spectrophotometer (Thermo Scientific). RNA from technical replicates was pooled at
equimolar concentration. The quality and quantity of the pools were assessed using
Agilent 2100 Bioanalyzer and High Sensitivity D1000 ScreenTape®. RNA samples
were selectively enriched for poly-A containing mRNA and cDNA libraries were
prepared using the PrepX RNAseq library Prep Kit (Takara Bio USA, inc). Samples
were sequenced on Illumina HiSeq platform with 2x125 reads at a targeted sequencing
71

coverage of 20-30M per sample at the Harvard University, FAS Center for Systems
Biology, MA.

2.4.4 Assembly, annotation and analysis
Raw reads obtained from sequencing were filtered, trimmed and adapters were removed
using bbduk program in BBTools suite from Joint Genome Institute and viewed in
FASTQC (Andrews, 2010). Processed reads were aligned to C. virginica reference
genome (version 3.0) via HISAT2 2.1.0 (Kim et al., 2015) and assembly was performed
using Stringtie (Pertea et al., 2016) using default parameters. To compare the depth of
sequencing across all samples preseq package was used (Daley and Smith., 2013).
Differential gene expression analysis was performed by comparing transcript counts
between RE22 6 h treatment (replicates K, M, V) vs control 0 h (replicates K, M, V)
using DESeq2 (Love et al., 2014). Transcripts with Benjamini-Hochberg adjusted p
value £ 0.05 and log fold change of ≥ 2 or ≤ -2 were considered significantly
differentially expressed. This analysis design only allowed for the most conservative
estimates and only showed differentially expressed genes representing all the biological
replicates. Annotation for differentially expressed genes (DEGs) was performed by
mapping to NCBI protein non-redundant (NR) database using BLASTx (Altschul et al.,
1997) with an e-value cutoff of 1e-3 and hit number threshold of 20. Mapping DEGs to
GO terms was conducted using BLAST2GO v4.1.9 (Conesa et al., 2005) and functional
enrichment was done using topGO (Alexa et al., 2006) with default parameters. ReviGO
(Supek et al., 2011) was used to plot and visualize results obtained from topGO with
default parameters (allowed similarity was set to medium). Significantly enriched GO
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terms were obtained by using Fishers exact test (p £ 0.01). Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathway annotations were also obtained using the KEGG
Automatic Annotation Server (KAAS).
3. Results
3.1 Effect of V. coralliilyticus RE22 on mortality of C. virginica larvae
Mortality in larval oysters exposed to 5´105 CFUmL of V. coralliilyticus RE22 was
initially seen at 14h after challenge, increasing exponentially after that (Figure 1a). The
larvae appeared normal at 6h, but 9h after challenge many showed reduced motility and
feeding (Figure1b).

3.2 Transcriptome alignment
Depth of sequencing for all the transcriptomes ranged from 16,617,375 – 39,681,499
paired end reads. Sequencing saturation curves for all transcriptomes were close to full
saturation, indicating that all but the rarest transcripts would be represented in the
transcriptome (Figure 2). The alignment rate to the Crassostrea virginica reference
genome using HISAT2 ranged from 85 – 89 % (Table 1).

3.3 Differential expression Analysis
Comparison of transcriptomes obtained from RE22 treated (6h) larvae to control (0h)
larvae using DESeq yielded 1,534 differentially expressed transcripts (p ≤ 0.05,
upregulation: log fold change ≥ 2, downregulation: log fold change ≤ -2). Refer to
supplementary data tables in appendix for descriptions and log fold change values.
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3.4 GO and KEGG annotation
A Gene Ontology (GO) term enrichment analysis was performed on all the differentially
expressed transcripts in response to RE22 challenge. There were 22 biological processes
significantly enriched (p<0.05) that mainly belonged to metabolism and signaling, but
none related to immunity (Table 2, Figure 3); 17 metabolic functions significantly
enriched (p<0.05) including “receptor activity” (Figure 4) and membrane related terms
significantly enriched in the cellular component (CC). The highest number of DEGs
mapped to KEGG annotations belonged to signal transduction (Table 3).

3.6 Differentially expressed immune genes in response to RE22
3.6.1 Immune related genes
Described below are some of the important immune-related genes showing differential
expression in RE22 exposed larvae (6h) as compared to control (0h) (Table 4).
Transcripts corresponding to immune receptors upregulated in response to RE22
included TLR receptors (TLR4, TLR13 and TLR Tollo isoform X2), lectin and
fucolectin, and leucine-rich repeats (LRRs). Transcripts identified as scavenger
receptor, complement C1q-like protein 2 and 4, LRR9, and fibronectin type III domaincontaining protein 2 were downregulated.
Transcripts related to the TLR signaling pathway, including myeloid differentiation
primary response protein MyD88-like (MyD88), TNF receptor-associated factor 4-like
(TRAF4), mitogen-activated protein kinase kinase kinase 7-like (TAK1) and tollinteracting protein-like (TOLLIP), showed downregulation in response to RE22
exposure. Important members of the NF-kB pathway that were downregulated included
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NF-kappa-B-activating protein-like (NKAP) and IkB-alpha. An essential component of
the MAP kinase signal transduction pathway, dual specificity mitogen-activated protein
kinase kinase 7-like (MKK7), was upregulated. Surprisingly, transcripts related to
antiviral pathways including stimulator of interferon genes protein-like (STING) and
ubiquitin carboxyl-terminal hydrolase 25-like isoform X3 (USP25) and some members
of the JAK-STAT pathway were upregulated in response to RE22.
In terms of immune effectors, some mucin transcripts were differentially expressed in
response to RE22, showing a mixed response (both up and downregulation).
In addition, cytoskeleton related transcripts including cytoplasmic actin and septin-11like were downregulated, but dynamin-1-like transcripts showed high levels of
upregulation.

3.6.2 Cell death
Transcripts corresponding to autophagy related gene ATG9A were highly upregulated
in response to RE22. Several transcripts that belong to the apoptosis pathway were
differentially expressed in response to RE22 including transcripts identified as death
domain-containing protein CRADD-like, caspases (1, 2, 6, 7-like) and IAP3 were
upregulated while caspase 3 and IAP2 were downregulated (Table 4).

3.6.3 Metabolism and oxidative stress
Transcripts involved in metabolism that were differentially expressed included Cyt
p450 and Cyt c subunits I and III. Heat shock proteins HSP12A and HSP12B were
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highly upregulated, while a few limited antioxidant enzymes were upregulated in
response to RE22 (Table 4).

4. Discussion

Both differential expression and functional enrichment analyses of oyster larvae 6h after
challenge with the bacterial pathogen V. coralliilyticus RE22 suggest increased
metabolic demand and activated pattern recognition receptors but repression of immune
signaling pathways, preventing production of immune effectors against RE22. This
pattern of gene expression is in line with the rapid disease progression observed, with
clinical signs evident 14h after challenge, and heavy mortality by 24h. This acute pattern
of infection allows for a very short window to activate immune responses. Therefore,
the host likely relies on a strong constitutive response and a rapid induction of immune
effectors to combat infection. Such rapid progression of disease in larvae is
characteristic of Vibrio spp. (Tubiash et al., 1965, Dubert et al., 2016). These results are
in accordance with immunosuppressive response to V. coralliilyticus YB1 as seen in
coral Pocillopora damicornis (Vidal-Dupiol et al., 2011a, Vidal-Dupiol et al., 2014) as
well as those seen in C. gigas in response to virulent Vibrio spp (Decker and Saulnier,
2011).
4.1 Differentially expressed immune genes in response to RE22
Highlights of the immunological response of C. virginica larvae to V. coralliilyticus
RE22 at 6h of exposure include pathogen detection via activated pathogen recognition
receptors. However, along with an increased expression of immune receptors, an overall
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suppression of key immune signaling pathways and lack of specific immune effectors
against RE22 was seen, suggesting that the pathogen is able to neutralize the immune
response of the larval host.
Pattern recognition receptors (PRRs) are extremely important to innate immune system
that recognize conserved pathogen-associated molecular patterns (PAMPs) and trigger
signaling pathways that produce a variety of antimicrobials (Akira et al., 2006).
Activation of TLR receptors indicate larvae can detect presence of bacteria especially
via TLR4, which detects LPS (Chow et al., 1999) and hence Gram-negative pathogens
like RE22. Activation of TLRs (Lorgeril et al., 2011, Zhang et al., 2011, Wang et al.,
2016b), lectin (Chen et al., 2011, Genard et al., 2013) and C1q domain containing
proteins (Lv et al., 2018) by several Vibrio spp. and parasitic exposures (Tanguy et al.
2004) have been demonstrated in bivalves. Lectins can activate the complement system
and promote phagocytosis and killing of potential pathogens (Fujita et al., 2004).
However, downregulation of complement C1q-like protein 2 and 4 in response to RE22
suggest suppression of recognition via C1q proteins by RE22.
Consistent with the observed response to V. coralliilyticus YB1 in coral Pocillopora
damicornis (Vidal-Dupiol et al., 2014), key immune signaling pathways in larval
oysters such as TLR, NF-kB, and IL-17 were also downregulated by RE22. Myeloid
differentiation primary response protein 88 (MyD88) is currently the only known
adaptor protein in bivalves (Gerdol et al., 2017) that modulates functioning of TLR
pathway to promote activation of NF-kB pathway (Janssens and Beyaert, 2002).
Downregulation of this fundamental signaling mediator suggests suppression of TLR
pathway. However, MyD88 was upregulated at 24h and TRAF at 48h post challenge
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with V. coralliilyticus LPI 06/210 (104 bacteria/mL in final concentration) in C. gigas
larvae with 13 and 17% mortality rate in challenged larvae as compared to 5 and 7% in
control at 24 and 48h respectively (Genard et al., 2013). It is possible that a later
upregulation of these transcripts upon V. coralliilyticus RE22 exposure may also occur
in eastern oysters, but our analysis was limited to the early time points. Disturbance of
host immune responses leading to downregulation of immune genes was reported in 2yr
old C. gigas post challenge with virulent Vibrio sp, V. splendidus LGP32-GFP and V.
aesturianus 02/041 during first 6h of challenge (Decker and Saulnier, 2011).

4.2 Unexpected differentially expressed immune genes in response to RE22
4.2.1 Conflicting immune gene responses:
Along with the general agreement of suppressed immune recognition and signaling
pathways based on the differentially expressed transcripts, there are some results that
deviate from this observation. Interestingly, toll-interacting protein (TOLLIP), an
important regulator of TLR pathway that represses the TLR pathway (Zhang and
Ghosh., 2002) was downregulated. Zhang et al., (2015) also found downregulation of
TOLLIP at 6h of V. anguillarum infection in Yesso scallop (Patinopecten yessoensis)
but upregulated in the acute phase at 3h. It is possible that our experiment missed the
acute stage of the disease and the very early responses to infection.
TRAFIP2 plays a role similar to MyD88 leading to NF-kB activation through IRAK in
the TLR signaling pathway and it can mediate MAPK pathway via MAPK9 or cJun Nterminal kinase (Rosani et al., 2015). Its upregulation in response to RE22 may suggest
activation of NF-kB pathway and production of pro-inflammatory cytokines (Gu et al.,
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2013). This contradicts the earlier notion of suppressed NF-kB pathway. Upregulation
of MKK7 as seen here can lead to activation of MAPK pathway via stimulation of JNK
followed by c-Jun transcriptional activity (Lu et al.,1997). This is in contrast to abalone
challenge with virulent V. harveyi ORM4 and response of coral P. damicornis to V.
coralliilyticus YB1 where induction of the MAPK pathway was delayed (Travers et al.,
2009, Vidal-Dupiol et al., 2014). Both MAPK and NF-kB activation was seen in
surviving C. gigas post challenge with virulent Vibrio spp., suggesting their importance
in host defense (Lorgeril et al., 2011). Since this transcriptome is obtained from a pool
of larvae perhaps these conflicting signals are derived from the presence of both
susceptible and resistant larvae to RE22 exposure in the pools of oysters used in our
experiments.
4.2.2 Antiviral immune gene responses:
Although, differentially expressed transcripts in response to RE22 indicate majority of
the key immune signaling pathways to be suppressed, antiviral pathways seem to remain
active. STING is a key regulator for sensing intracellular single- or double-stranded
nucleic acids. STING via the cGAS-STING pathway complex with TAK1 and trigger
expression of interferon genes. cGAS is activated whenever foreign DNA (both
bacterial and viral nucleic acids) is detected in the cytoplasm (He et al., 2015, Gerdol,
2017). These results suggest the possibility of an intracellular invasion by RE22 that
could lead to activation of STING or effectors of type secretion systems of RE22 (T6SS
or T1SS) inadvertently leading to activation of these pathways. A special STING
homolog LvSTING was activated in shrimp in response to V. parahaemolyticus
infections that participates in antimicrobial peptide production (Li et al., 2017).
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Similarly, activation of JAK-STAT pathway has been reviewed in bivalves as an
antiviral response (Green et al., 2015) but microbial activation of this pathway has been
shown in Chinese mitten crab Eriocheir sinensis (Li et al., 2013).
4.2.3 Effectors
Extracellular metalloproteases in V. coralliilyticus RE22 are shown to be important in
its pathogenicity to C. gigas larvae (Hasegawa et al., 2008). Therefore, the observation
of lack of serine protease inhibitors in challenged larvae, as well as the lack of
upregulation of other types of protease inhibitors, was unexpected. It is possible that
protease inhibitors are not differentially expressed at the time point tested (6 h) but
might be at a later time point. Expression of metalloprotease of V. tubiashii 07/118 T2
was shown to be downregulated during early infection stage in C. gigas larvae (3 - 6 h)
but significantly upregulated (20 fold) at 16 -18 h post infection with ~60% mortality at
24h post-infection (Mersni-Achour et al., 2015).
Mucus is the first line of defense in oysters besides the closed oyster shell. Mucus was
one of the few immune effectors shown to be upregulated in larval oysters exposed to
V. coralliilyticus RE22. Some pathogenic Vibrio spp. require binding to mucin in the
gut epithelium as a part of their pathogenesis (Bhowmick et al., 2008, Jang et al., 2016),
so it is possible that modulation of host mucus production or composition may allow
RE22 to bind better and breach host defenses in larval oysters.

4.3 Cytoskeletal reorganization
Downregulation of septin-11 associated with the cytoskeleton in response to RE22
suggests possible disruption of cytoskeleton by RE22, but the functional implications
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of this downregulation is not clear. Both actin and septin 8B were shown to be
upregulated by challenge with V. splendidus LGP32 in C. gigas (Duperthuy et al., 2011)
and soft-shell clams, Mya arenaria (Araya et al., 2010) for hemocyte invasion.
Cytoskeletal disruption using upregulation of ß-actin due to V. tapetis challenge in
Ruditapes philippinarum has also been demonstrated (Brulle et al., 2012). We need to
know more about nature of RE22 pathogenesis in cytoskeletal modulation to fully
understand this.

4.4 Cell death
It is difficult to interpret whether apoptosis is inhibited or enhanced in response to RE22
treatment due to modulation of both pro (caspases) and anti-apoptotic (apoptosis
inhibitor) genes. This was also the case in surviving C. gigas on exposure of different
strains of virulent Vibrio spp. (Lorgeril et al., 2011). IAPs were modulated in both
susceptible and resistant C. virginica families in response to A. crassostreae (McDowell
et al., 2014). The mechanisms underlying pathogen-induced modulation of apoptosis in
mollusks are not well understood.

4.5 Metabolism and oxidative stress
Differential expression of heat shock proteins and cytochrome oxidases during RE22
challenge suggests that larvae are experiencing stress and high metabolic demand due
to the inability to rapidly clear RE22 infection. Higher stress levels and lower metabolic
rates have been seen in late responses (24-48h) of V. coralliilyticus LPI 06/210 in C.
gigas (Gernard et al., 2013). Moreover, no increase in expression of antioxidant
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enzymes, necessary to deal with oxidative stress from activated metabolism, was seen
in our study. These results suggest that oyster larvae, which already possess a high
metabolic demand to sustain the processes of rapid growth and development, may not
be able to cope with the additional metabolic demand associated with infection.
Moreover, reduced feeding in infected moribund larvae may not allow replenishment of
energy to mount an expensive immune response (Gernard et al., 2011). It has been
shown for several V. tubiashii strains affecting bivalves that the pathogen enters the host
through ingestion, proliferates in the gut, then spreads to other organs, including the
cilia that are involved in swimming and capturing particles (Tubiash et al., 1965).

5. Conclusion:
The observed absence of induced expression of protease inhibitors, antimicrobial
peptides or other immune effectors able to block RE22 virulence factors, along with
other indications of a suppressed immune system, suggest that larvae are left highly
susceptible to disease and then succumb to infection. Additionally, differential gene
expression analysis indicative of a high metabolic demand and oxidative stress are
consistent with the rapid mortality observed during RE22 infection in oyster larvae.
Further in-depth studies are required to tease out details of the mechanisms used by
RE22 to manipulate the immune system of oyster larvae.
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Figure 1a: Effect of challenge with V. coralliilyticus RE22 on mortality of C. virginica
larvae. Cumulative percent mortality +/- standard error in oyster larvae after 6 – 20 h of
challenge with 5x105 CFU/mL of RE22. Data was averaged over six replicates.
Mortality was first observed at 14 h after challenge, and rapidly increasing thereafter.
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Figure 1b: Effect of Vibrio coralliilyticus RE22 on mortality of C. virginica larvae. (A)
Actively swimming healthy control larvae (B) Active larva with cilia showing signs of
some clumping at 6h (C) Moribund larva with retracted cilia showing reduced
movement at 9h (D) Dead larva with empty shell at 14h
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Figure 2: Sequencing saturation curves for control and challenged larval transcriptomes
showing comparable depth of sequencing for all transcriptomes. Three independent
experiments (K, M, V) with two treatments (Control, C; RE22 treatment, RE22) were
performed.
84

Table 1. Oyster larval transcriptomes in response to a 6h challenge with Vibrio
coralliilyticus RE22 challenge. Number of paired end reads per sample and %
alignment rate to Crassostrea virginica reference genome using HISAT2. Three
independent experiments (K, M, V) with two treatments (Control, C; RE22 treatment,
RE22) were performed in duplicate.
Sample

% Alignment to Crassostrea virginica genome

C_K_0

# paired
reads
22,963,376

C_M_0

16,617,375

87

C_V_0

20,674,506

86

RE_K_6

19,379,823

86

RE_M_6

21,118,821

89

RE_V_6

39,681,499

85

89

Table 2: Gene Ontology (GO) terms of biological functions significantly (p<0.05)
enriched in oyster larvae in response to pathogen challenge (RE22).
GO Term

Significant classicFisher p
number of value
transcripts
mapped
83
0.0074

macromolecule modification
cellular protein modification process

81

0.0098

protein modification process

81

0.0098

cellular protein metabolic process

104

0.0125

biological regulation

201

0.0144

17

0.0202

regulation of biological process

189

0.0204

protein metabolic process

127

0.0221

regulation of cellular process

169

0.0271

regulation of cell communication

29

0.0319

regulation of signaling

29

0.0319

phosphorus metabolic process

86

0.0339

phosphate-containing compound metabolic
process

86

0.0339

cellular macromolecule catabolic process

85

protein catabolic process

14

0.0406

cellular protein catabolic process

14

0.0406

proteolysis involved in cellular protein...

14

0.0406

112

0.0409

39

0.0416

signaling

111

0.0451

single organism signaling

111

0.0451

regulation of signal transduction

27

0.0453

positive regulation of cellular process

27

0.0453

cell communication
protein phosphorylation

Figure 3: Functional enrichment of differentially expressed transcripts using Gene
Ontology terms in Biological Process. The color scale in the legend shows level of
significance, with colder colors indicating higher significance and the size of the bubble
corresponds to the number of significant transcripts mapped to the term.
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Figure 4: Functional enrichment of differentially expressed transcripts using Gene
Ontology terms in Metabolic Function. The color scale in the legend shows level of
significance, with colder colors indicating higher significance and the size of the bubble
corresponds to the number of significant transcripts mapped to the term.
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Table 3: Mapping of differentially expressed transcripts to biological pathways in the
Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Numbers indicate
number of transcripts mapped to each category.
RE22(6h)
Metabolism
Carbohydrate metabolism

29

Energy metabolism

5

Lipid metabolism

36

Nucleotide metabolism

21

Amino acid metabolism

25

Metabolism of other amino acids

8

Glycan biosynthesis and metabolism

12

Metabolism of cofactors and vitamins

7

Metabolism of terpenoids and polyketids

4

Biosynthesis of other secondary metabolites

4

Xenobiotics and biodegradation metabolism

7

Genetic information processing
Transcription

10

Translation

16

Folding sorting and degradation

13

Replication and repair

3

Environmental processing
Membrane transport

2

Signal transduction

199

Signaling molecules and interaction

10

Cellular processes
Transport and catabolism

41

Cell growth and death

39

Cellular community-eukaryotes

42

Cellular community-prokaryotes

2

Cell motility

6

Organismal systems
Immune system

93

Endocrine system

112

Circulatory system

20
88

Digestive system

37

Excretory system

11

Nervous system

44

Sensory system

23

Development

19

Aging

8

Environmental adaptation

17

Table 4: Comparison of expression of selective differentially expressed genes (DEGs)
as compared to control categorized by immune processes (p ≤ 0.05, upregulation: log
fold change ≥ 2, downregulation: log fold change ≤ -2). Colors denote level of
expression as compared to control. Red: all transcripts upregulated, orange: some
transcripts upregulated while some downregulated and yellow: all transcripts
downregulated. DEGs with * denote highly differentially expressed gene.
Expressio
n as
compared
to control

DEGs

Recognition
TLRs
TLR4
TLR4 isoform X1
TLR13
TLR Tollo isoform X2
TOLLIP (toll-interacting protein-like isoform X3)
protein toll-like
myeloid differentiation primary response protein MyD88-like
Lectins
lectin-like *
fucolectin-like
Scavenger receptors
scavenger receptor class B member 1 isoform B
LRR
leucine-rich repeat transmembrane neuronal protein 3-like isoform
X1
leucine-rich repeat-containing protein 74B-like isoform X2
leucine-rich repeat-containing protein 9-like isoform X2
Fibronectin type III domain
89

fibronectin type III domain-containing protein 2-like isoform X3
Complement
complement C1q-like protein 2
complement C1q-like protein 4
Metabolic Enzymes with New Role of Carbohydrate Binding
hexokinase-2-like isoform X2
B cell receptor
dapp1 dual adaptor for phosphotirosine*
Signaling pathways in Immune response
TLR pathway
myeloid differentiation primary response protein MyD88-like
TNF receptor-associated factor 4-like isoform X5 (TRAF4)
mitogen-activated protein kinase kinase kinase 7-like isoform X3
(TAK1)
JAK-STAT
tyrosine-protein kinase JAK2-like (JAK)
son of sevenless homolog 2-like * (SOS2)
tyrosine-protein phosphatase non-receptor type 4-like isoform X4
(PTPN4)
tyrosine-protein phosphatase non-receptor type 23-like (PTPN23)
NF-kB signaling pathway
NF-kappa-B-activating protein-like (NKAP)
NF-kappa-B inhibitor alpha-like isoform X1 (IkB)
TNFAIP3-interacting protein 1-like * (TNIP1)
adapter protein CIKS-like isoform X4 (TRAF3IP2/Act1/CIKS)
Mitogen-Activated Protein Kinases (MAPK) pathway
dual specificity mitogen-activated protein kinase kinase 7-like
isoform X1 (MKK7)
mitogen-activated protein kinase kinase kinase 7-like isoform X3
(TAK1)
cGAS-STING pathway
stimulator of interferon genes protein-like (STING)

Signal transduction
death domain-containing protein 1-like
death domain-containing protein CRADD-like *
ubiquitin carboxyl-terminal hydrolase 14-like
ubiquitin carboxyl-terminal hydrolase 25-like isoform X3 *
(USP25)
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase
gamma-1-like isoform X4 (PLCG1)
90

Effectors
Signaling mucin HKR1
mucin-12-like *
mucin-2-like
mucin-5B-like
mucin-19-like, partial
septin-11-like isoform X2
Apoptosis
Caspase 1
Caspase 2
Caspase 3
Caspase 6
Caspase 7
Caspase 7 Isoform X1
Caspase 7 Isoform X3
baculoviral IAP repeat-containing protein 2-like
baculoviral IAP repeat-containing protein 3-like isoform X1 *
putative inhibitor of apoptosis*
death domain-containing protein CRADD-like *
XK-related protein 8-like isoform X2 *
XK-related protein 6, partial *
cAMP-dependent protein kinase catalytic subunit
TPA_inf: DeltaNp63gamma
epidermal growth factor receptor-like isoform X2
Autophagy
autophagy-related protein 9A-like isoform X1 *
DNA damage-regulated autophagy modulator protein 1-like*
phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit
delta isoform-like isoform X1*
toll-interacting protein-like isoform X3 (TOLLIP)
next to BRCA1 gene 1 protein-like isoform X1
Phagosome
cation-dependent mannose-6-phosphate receptor-like *
cytoplasmic dynein 2 light intermediate chain 1-like *
Lysosome
cation-dependent mannose-6-phosphate receptor-like *
AP-1 complex subunit gamma-1-like isoform X2
Endocytosis
phosphatidylinositol-binding clathrin assembly protein LAP-like *
91

Peroxisome
D-aspartate oxidase-like isoform X1
peroxisome proliferator-activated receptor delta-like isoform X1*
peroxisome proliferator-activated receptor gamma coactivator 1alpha-like
prostaglandin E2 receptor EP4 subtype-like [Crassostrea virginica]
Antioxidant enzymes
maleylacetoacetate isomerase-like*
gamma-glutamyltranspeptidase 1-like
thioredoxin domain-containing protein 15-like
thioredoxin domain-containing protein 3 homolog isoform X15
thioredoxin-related transmembrane protein 2 homolog
Acute phase proteins
Heat shock 70 kDa protein 12A*
heat shock 70 kDa protein 12A-like
heat shock 70 kDa protein 12A-like isoform X1
heat shock 70 kDa protein 12B-like
heat shock 70 kDa protein 12B-like isoform X4 *
Cholinergic immunomodulation
Glutamate receptor *
glutamate receptor ionotropic
muscarinic acetylcholine receptor M3-like
neuronal acetylcholine receptor subunit alpha-2-like
neuronal acetylcholine receptor subunit alpha-5-like
neuropeptide Y receptor type 2-like*
RYamide receptor-like
acetylcholinesterase-like isoform X1*
Cytosletal reorganization
septin-11-like isoform X2
dynamin-1-like isoform X6
PI3K-Akt signaling pathway
PH domain leucine-rich repeat-containing protein phosphatase 2like isoform X2 *
phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit
delta isoform-like isoform X1*
phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2A-like
isoform X4
RAC-gamma serine/threonine-protein kinase-like isoform X1
Others
multidrug resistance protein 1-like isoform X6
92

glycine receptor subunit alpha-3-like isoform X5
gamma-glutamyltranspeptidase 1-like
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase
gamma-1-like isoform X4
Hemicentin-1
Hemicentin-1 like
Hemicentin-1 like isoform X2
Hemicentin-1 like isoform X21*
Hemicentin-1 like isoform X34*
hemicentin-2-like isoform X2
histamine H2 receptor-like
oxidative stress-induced growth inhibitor 2-like
cytochrome b5 reductase 4-like isoform X3 [Crassostrea virginica]
cytochrome c oxidase subunit I *
cytochrome c oxidase subunit III (mitochondrion) *
cytochrome P450 27C1-like
cytochrome P450 2C28-like isoform X2 *
cytochrome P450 2F5-like *
dual specificity protein phosphatase 18-like [Crassostrea virginica]
dual specificity protein phosphatase 7-like [Crassostrea virginica]
protein phosphatase 1 regulatory subunit 16A-like isoform X3
protein phosphatase 1 regulatory subunit 37-like
Tripartite motif-containing protein 2
tripartite motif-containing protein 2-like
tripartite motif-containing protein 2-like isoform X4
tripartite motif-containing protein 3-like
tripartite motif-containing protein 45-like
cAMP-dependent protein kinase catalytic subunit
PREDICTED: stress protein DDR48-like [Salmo salar]
Biomineralization
perlucin-like isoform X1 *
perlucin-like protein isoform X1*
Chitin synthase 3*
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Abstract
The eastern oyster Crassostrea virginica is an ecologically and economically important
species. Bacterial pathogens like vibrios cause heavy mortalities in oyster larvae in
hatcheries. Probiotics are an inexpensive, practical, and natural method of disease
control. Pretreatment of larval oysters with probiotics Bacillus pumilus RI06-95 and
Phaeobacter inhibens S4 significantly decreases mortality caused by experimental
challenge with the pathogen Vibrio coralliilyticus RE22. The aim of this study was to
understand the oyster larval immune response to probiotics RI06-95 and S4 and the role
it may play in protecting larvae from pathogen challenge. C. virginica larvae were
exposed to each probiotic in two settings: controlled 6 and 24 hours laboratory
exposures and 5 to 16 days exposure in a hatchery. Transcriptomes were sequenced
using high throughput RNA sequencing and aligned to the C. virginica reference
genome. Differential expression analysis compared probiotic treated transcriptomes to
unexposed controls. Key features of the host immune response were shared despite the
length of probiotic exposure, type of probiotic exposure and the type of environment in
which exposures were conducted. Transcriptome analysis showed increased expression
of genes for receptors involved in environmental sensing and detection of pathogens,
immune signaling pathways, and immune effectors including serine protease inhibitor,
mucins and perforin-2. In addition, patterns of differential gene expression suggest that
inhibition of apoptosis, enhanced autophagy, and cytoskeletal reorganization may play
a supplemental role in bacterial clearance. Thus, results from this study suggest that
larval oysters show a robust and effective immune response to probiotic exposure,
contributing to clearance of the probiotic within 24 hours after exposure. Activation of
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antibacterial immune effectors by probiotics, when provided 6 – 24 hours prior to
bacterial challenge, may play an important role in protecting larvae from mortality by
V. coralliilyticus RE22. However, for continued effective protection, probiotics should
be applied repeatedly and for at least 6 hours prior to RE22 challenge. This is the first
time that immune responses of larval stages of C. virginica to bacteria are studied using
a larval transcriptome. This research provides important new insights into host-microbe
interactions in larval oysters that could be applied in the design of improved strategies
for use of probiotic organisms for disease control in hatcheries.

102

1. Introduction

The eastern oyster Crassostrea virginica is an economically and ecologically
important species (Newell 2004, NMFS 2014). Rearing of oyster larvae is a critical step
to ensure a healthy and sufficient supply of seed for aquaculture industry. Bacterial
diseases commonly described in larval stages are associated with high mortalities in
hatcheries (Lauckner et al. 1983, Sinderman et al. 1990). Vibriosis is one such disease
that leads to mortality in oyster larvae and juveniles (Tubiash et al, 1965). Bacteria of
the genus Vibrio are ubiquitous within marine environments and detected in tissues of
many marine organisms including abalones, bivalves, corals, fish, shrimp, sponges,
squid, and zooplankton (Thompson et al. 2004). Vibrio can cause larval mass mortalities
in hatcheries in a short period of time leaving few options for treatment (Helm and
Lovatelli 2006). In order to eliminate Vibrios and sanitize the facility, hatcheries need
to shut down for several days after a disease outbreak before production is resumed
(Helm and Lovatelli 2006).

In particular, V. coralliilyticus RE22 (previously V.

tubiashii RE22) has caused high larval and juvenile mortality in hatcheries (Elston et al.
2008). Vibrios are known to produce potent exotoxins that affects larval motility in
oysters. Incapacitated ciliary movement affects feeding, leading to death due to
starvation (DiSalvo et al., 1978, Brown and Roland, 1984, Kennedy, 1996). The
extracellular metalloprotease secreted by V. coralliilyticus is toxic and induces mortality
in oyster larvae (Hasegawa et al., 2008).
Practices to reduce mortality due to bacterial disease include treatment with antibiotics
and disinfection of seawater. Water treatment, however, is expensive and could be toxic
to the larvae if not properly done, while antibiotic treatment can lead to bacterial
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resistance. Treatment with antibiotics raises environmental and human health concerns
as well (Prado et al. 2009, Akinbowale et al., 2016, Ho et al., 2000). Therefore,
alternative methods need to be developed to manage good larval rearing environment
and to control bacterial diseases in bivalve shellfish hatcheries.
Probiotics are defined as a live microbial food supplement that, when administered in a
sufficient amount, confers a health benefit on the host (Food and Agricultural
Organization of the United States 2006). Probiotics are known to benefit the host by a
variety of means, including production of antimicrobials, improving water quality,
enhancing the immune responses of host, and competing for space with pathogenic
bacteria (Verschuere et al. 2000). There is growing evidence that probiotics show
immunomodulatory effects in fish and shellfish (De et al., 2014, Newaj-Fyzul et al.,
2015).
The benefits of probiotics have already been shown in Pacific oysters, Crassostrea gigas
(Douillet and Langdon 1994) and the eastern oyster C. virginica (Karim et al. 2013).
Pretreatment of larval and juvenile C. virginica with probiotic organisms Phaeobacter
inhibens S4 (isolated from the inner shell of oysters) (referred to as S4) and Bacillus
pumilus RI06-95 (isolated from a marine sponge from the Narrow River in Rhode
Island) (referred to as RI) before exposure to the bacterial pathogens Alliroseovarius
crassostreae and Vibrio coralliilyticus RE22 (referred to as RE22) improves oyster
survival rate (Karim et al., 2013). Additionally, probiotics are not harmful to oysters in
absence of pathogens (Karim et al., 2013).
S4 is a Gram-negative organism and production of the antibiotic tropodithietic acid
(TDA) and biofilm formation are two mechanisms utilized by S4 for protecting oysters
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from infection. Mutants of S4 unable to produce TDA and with decreased ability to
produce biofilms, however, still provide some level of protection (Zhao et al. 2016),
suggesting that other mechanisms are also potentially involved. RI is a Gram-positive
organism and produces the antibiotic amicoumacin, but this antibiotic does not inhibit
the growth of RE22 in an in vitro assay, indicating that other mechanisms of action are
also likely involved in RI’s protection of larvae against bacterial challenge (Karim et
al., 2013). Probiotics are known to act as immunomodulators (Hardy et al., 2013,
Mortha et al., 2014, Sanchez et al., 2015). For example, a strain of B. pumilus has been
shown to improve immune responses of Orange-spotted grouper Epinephelus coioides
(Sun et al., 2010), so immunomodulation may be one of the mechanisms involved in the
probiotic activity of RI.
Transcriptomic analysis of C. virginica larval immune responses to pathogen V.
coralliilyticus RE22 showed evidence of suppression of important immune signaling
pathways and decreased expression of genes for immune effectors such as protease
inhibitors, increased metabolic demand, and modulation of mucins in the early stages
of infection (Modak et al, in prep; Chapter 3 of this dissertation). Immunosuppression
as a pathogenesis strategy was also demonstrated in responses of coral Pocillopora
damicornis to V. coralliilyticus YB1 (Vidal-Dupiol., et al., 2014). Similarly, immune
response of soft-shell clams, Mya arenaria, to V. splendidus strain LGP32 showed an
overall downregulation of immune genes such as ficolin, killer cell lectin-like receptor,
natural resistance-associated macrophage protein 1 (Nramp-1), and mitogen-activated
protein kinases (MAPK) (Araya et al., 2010). Our hypothesis is that pre-treatment of
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oyster larvae with probiotics may cause an activated immune state in larvae that would
serve to counteract the immunosuppressive effects of RE22.
Not much is known about the impact of friendly or beneficial bacteria on the immune
system of oysters. The goal of this study is to determine the immunological response of
C. virginica larvae to exposure to two probiotic bacterial species that differ in Gram
character, in order to understand the potential role of immunomodulation as a potential
mechanism of action of the probiotics in providing protection against V. coralliilyticus
RE22.
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2. Materials and methods

2.1 Probiotic Bacterial strains:
Probiotic isolates S4 and RI were maintained and stored in 50 % glycerol stocks at 80°C until use. Bacteria were cultured by plating out freezer stocks on yeast peptone
with 3% NaCl (YP30) agar plates for 1 d then transferred to 5 mL of YP30 broth (5 g
L-1 of peptone, 1 g L-1 of yeast extract, 30 g L-1 of ocean salt, Instant Ocean) incubated
at 28°C on a shaker (134 rpm) for 2 d. Cultures were washed using Artificial Filtered
Sterile Seawater (AFSW, 28 - 30 psu salinity) twice by centrifugation at 23,000 g for
10 min. The OD at 550 nm was measured and the stock was diluted to obtain a
concentration of 5 × 104 colony forming units (CFU) mL-1 as previously described
(Karim et al., 2013).

2.2 Oyster larvae:
C. virginica larvae were obtained from three shellfish hatcheries on the east coast of
United States including Oyster Seed Holdings, VA, Virginia Institute of Marine
Science, VA and Aeros Cultured Oyster Company, NY that served as three biological
replicates. Larvae 6-10 days old were collected at the hatchery and shipped to the
laboratory at the University of Rhode Island on a wet filter overnight. Upon arrival to
the laboratory, larvae were washed with AFSW on top of a 40 µm pore size nylon filter
to prepare a stock. The stock of larvae from each hatchery was used for probiotic
exposures as described below. The same stock was also used for characterizing immune
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response to pathogen V. coralliilyticus RE22 (Modak et al., in prep, Chapter 3 of this
dissertation).

2.3 Effect of length of probiotic pretreatment on protection against bacterial challenge
Previous research on the effect of probiotics on protection against challenge with the
bacterial pathogen V. coralliilyticus RE22 was performed using a 24 h pre-incubation
period with the probiotics prior to bacterial challenge (Karim et al. 2013). In order to
determine if a shorter pre-incubation period with probiotics would confer protection
against bacterial challenge, ~100 larvae were placed in each well of a 6 well plate in 5
mL of AFSW and incubated with 104 CFU mL-1 of probiotics S4 or RI06-95 for 6 or
24h prior to bacterial challenge with 105 CFU mL-1 of RE22. Larval survival was
determined 24 h after challenge using previously described methods (Karim et al. 2013).
Survival rate was calculated as follows: Survival rate (%) = 100 x (number of live
larvae/total number of larvae). One-way analysis of variance (ANOVA) was used to
determine significance between treatments and Tukey’s multiple comparison tests were
used for post-hoc pairwise comparisons (p < 0.05) (Sohn et al., 2016).

2.4. Effect of short-term exposure to probiotics on larval gene expression

2.4.1 Experimental set up for laboratory-scale experiments: For biological replicates,
three independent experiments were performed using larvae from three different
hatcheries. Larval density (larvae mL-1) of the stock was determined using the Nikon
E200 microscope. Two parallel exposures were performed with each set of larvae: (i)
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a large-scale incubation for collection of larvae for transcriptome analysis, and (ii) a
small-scale experiment in 6 well plates for evaluation of the effect of probiotic exposure
on protection against bacterial challenge.
(i) Set up for transcriptome analysis: Larvae were distributed into tissue culture flasks
(~10,000 per flask) in 500 mL AFSW based on the larval density (larvae/mL) and kept
on a shaker with gentle shaking at ~50 rpm at room temperature. Larvae were
acclimatized to the laboratory environment for 24 h. Each treatment was set up in
duplicate as separate flasks to serve as technical replicates. There were five treatment
groups in total viz. Control(0h), RI09-95(6 h), RI09-95(24 h), S4(6 h) and S4(24 h).
Probiotics were applied at a concentration of 104 CFU mL-1. Larvae were fed with
instant algae Shellfish Diet 1800TM (20,000 cells/mL; Reed Mariculture Inc., San Jose,
CA. USA) just prior to treatment in order to promote probiotic ingestion.
(ii) Set up for verification of protection by probiotics: Oyster larvae (~100) were placed
in each well of a 6 well plate in 5 mL of AFSW and incubated with 104 CFU mL-1 of
probiotics S4 or RI for 6 or 24 h prior to bacterial challenge with 105 CFU mL-1 of RE22,
as described in section 2.3 above.

2.4.2 Larval Collection post treatments:
After incubation with probiotics, larvae from the flask set up for the transcriptome
experiment were aspirated gently using a 100 mL serological pipette and filtered
through a 40 µm sterile filter for collection. Since the dead larvae settle to the bottom,
the last 25 mL of each flask was not collected to avoid bias in transcriptomic response.
Larvae were washed with 2 mL of AFSW followed by 2 mL of RNAlater™. Larvae
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retained on the filter were aspirated with a pipette using 1.5 mL of RNAlater, placed in
labeled 2 mL RNase free microfuge tubes, and held at 4°C for 24 h in RNAlater
followed by storage at -20°C.

2.4.3 RNA extraction, cDNA prep and sequencing:
Tri-reagent™ (Sigma-Aldrich) was used for extracting total RNA from all the samples
following manufacturer’s instructions (TRI Reagent™ Protocol, Sigma-Aldrich). RNA
extracts were DNase treated using the DNA-free™ DNA removal kit from Ambion and
purity and concentration of RNA was checked using a Nanodrop 8000
spectrophotometer (Thermo Scientific). Technical replicates were pooled at equimolar
concentration. The quality and quantity of the pools were assessed using Agilent 2100
Bioanalyzer and High Sensitivity D1000 ScreenTape®. RNA samples were selectively
enriched for poly-A containing mRNA and cDNA libraries were prepared using the
PrepX RNAseq library Prep Kit (Takara Bio USA, inc). Samples were sequenced on
Illumina HiSeq platform with 2×125 reads and sequencing coverage of 20-30M per
sample at the Harvard University, FAS Center for Systems Biology, MA.

2.5 Effect of exposure to probiotics in the hatchery on larval gene expression

2.5.1 Experimental set up of hatchery experiments:
Transcriptomes obtained from treatment of larvae with B. pumilus RI06-95 will be
referred to as HT_RI. Adult eastern oysters were spawned at the Blount Shellfish
Hatchery, Roger Williams University, RI. Each trial was initiated by adding 8-10 larvae
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mL-1 (800,000 to 1,000,000 initial larvae) per tank 1 day post-fertilization. Larval
oysters were distributed into 100 L conical tanks filled with filtered and UV treated
seawater (20 – 24 C and 28 – 30 psu salinity) 1 day after fertilization and fed live
microalgae daily from a microalgae production greenhouse. Water from Narragansett
Bay, RI was filtered and UV treated and used for the larval tanks. Treatments included
control and probiotic RI treated at a concentration of 104 CFU mL-1. Each treatment
was conducted in triplicate. Probiotics were added daily at the time of feeding.

2.5.2 Larval Collection post treatments:
Larvae for transcriptomes were collected at three time points: 5, 12 and 16 days post
fertilization from probiotic-treated and control tanks. Larvae had been treated with
probiotics daily starting 1 day after fertilization, as described in Sohn et al. (2016).
Tanks were drained on a filter with suitable pore size (75 – 150 µm depending on the
age of the larvae) at the time of collection. Using a serological pipette, larvae were
aspirated gently and collected in RNase free microfuge tubes with RNAlater™ and
stored at -80°C.

2.5.3 Verification of protection by probiotics: A subsample of larvae was collected from
each treatment and control tanks on day 8 post-fertilization to determine the effect of
exposure to the probiotics in the hatchery on protection against bacterial challenge.
Levels of protection were determined using the methods described in 2.3. above, with
the following modifications: larvae from each tank were placed in triplicate wells in 6well plates with ~100 larvae per well V. coralliilyticus RE22 at 105 CFU mL-1 dose.
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2.5.4 RNA extraction, cDNA prep and sequencing:
Larvae were processed for RNA extraction as described in 2.4.4 above. cDNA libraries
were generated using random hexamer priming that were sequenced on Illumina HiSeq
platform with 2×150 reads and sequencing coverage of 50-70M per sample at the
McDonnell Genomics Institute, Washington University School of Medicine, MO.

2.6 Assembly, annotation and analysis
Raw reads obtained from sequencing were filtered, trimmed and adapters were removed
using bbduk program in BBTools suite from Joint Genome Institute and viewed in
FASTQC (Andrews, 2010). Processed reads were aligned to C. virginica reference
genome (version 3.0) via HISAT2 2.1.0 (Kim et al., 2015) and assembly was performed
using Stringtie (Pertea et al., 2016) with default parameters. To compare the depth of
sequencing across all samples preseq package was used (Daley and Smith., 2013).
Differential gene expression analysis between probiotic (RI or S4) treatment at each
time point (6 or 24 h) and control (time 0, common to all treatments) was performed
using DESeq2 (Love et al., 2014) and transcripts with Benjamini-Hochberg adjusted
pvalue £ 0.05 and log fold change ≥ 2 or ≤ -2 were considered significantly differentially
expressed. For hatchery transcriptomes, each of the days (5, 12 and 16) were considered
as biological replicates and an overall comparison of treatment vs control was
conducted. Transcript counts for each replicate were used to determine which DEGs are
present in each replicate individually. This analysis design only allowed for the
most conservative estimates and only showed differentially expressed genes
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representing all the biological replicates. Annotation for differentially expressed genes
(DEGs) was performed by mapping to NCBI protein non-redundant (NR) database
using BLASTx (Altschul et al., 1997) with an e-value cutoff of 1e-3 and hit number
threshold of 20. Mapping DEGs to GO terms was conducted using BLAST2GO v4.1.9
(Conesa et al., 2005) and functional enrichment was done using topGO (Alexa et al.,
2006) with default parameters. ReviGO (Supek et al., 2011) was used to plot and
visualize results obtained from topGO with default parameters (allowed similarity
adjusted to medium). Significantly enriched GO terms were obtained by using Fishers
exact test (p £ 0.01). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway
annotations were also obtained using the KEGG Automatic Annotation Server (KAAS).

3. Results
3.1 Effect of length of probiotic pretreatment on protection against bacterial
challenge
A short duration of S4 or RI pretreatment (6 h) showed variable levels of protection
against bacterial challenge between technical replicates within experiments and between
experiments, as reflected in the large standard deviations in the relative percent survival
(RPS; Table 1). One out of three experiments showed no protection from probiotic
treatment. The 24h probiotic pretreatment showed a more consistent level of protection
against RE22 challenge (Table 1). In the hatchery trial, larvae treated daily with
probiotics for 8 days in the hatchery showed an increase of 28 ± 6 % in relative percent
survival as compared to untreated larvae after a laboratory challenge with V.
coralliilyticus RE22.
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3.2 Transcriptome completeness
Depth of sequencing for all the lab transcriptomes was comparable between samples
ranging from 16– 25M paired end reads whereas HT_RI transcriptomes ranged from 50
- 70M reads (Table 2). Sequencing saturation curves for all transcriptomes were close
to full saturation, indicating that all but the rarest (least abundant) transcripts would be
represented (Figures 1a and b). The alignment rate to the Crassostrea virginica
reference genome using HISAT2 ranged from 86 – 89% (Table 2).
3.3 Differential Expression Analysis
Probiotic treated larval transcriptomes (RI or S4) at each time point (6 or 24 h) were
compared to control (0 h) transcriptome for normalization. S4 treated transcriptomes
(both 6 h and 24 h) yielded more differentially expressed transcripts when compared to
control (0 h) larvae than RI treated larval transcriptomes (p ≤ 0.05) (Table 3). Larvae
treated with probiotics for 24 h yielded more differentially expressed transcripts than
larvae treated with probiotics for 6h (Table 3).
Comparison of the number of shared and unique differentially expressed genes across
all treatments (Figure 2a) showed a dynamic response to each of the two probiotics.
Overall, larvae treated with S4 for 6 or 24 h have a higher number of differentially
expressed transcripts than larvae treated with RI at 6h or 24h. The percentage of DEGs
shared between S4 and RI is the same (26%) at 6h or 24h suggesting pronounced effect
of treatment as compared to time. Out of the total number of differentially expressed
transcripts in response to S4 and RI at 6 and 24h, 50% transcripts were unique to S4
treatment and 21% were unique to RI treatment. Comparison of differentially expressed
transcripts in hatchery transcriptomes (HT_RI) (Figure 2b) showed 43% transcripts
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shared between RI treatments with only 8%, 3% and 8% unique transcripts in RI_5d,
RI_12d and RI_16d respectively suggesting more of a treatment effect than time. Refer
to supplementary data tables in appendix for descriptions and log fold change values for
differentially expressed genes for all comparisons.
3.4 GO annotation
A Gene Ontology (GO) term enrichment analysis was performed on all the differentially
expressed transcripts in response to probiotic treatment. S4 treatments at both time
points shared terms related to recognition and signaling (Figure 3a, 3b). S4 treatment at
6h showed enrichment in “cellular response to stimulus” whereas at 24h it showed
enrichment in processes related to activation of receptors and signaling pathways
suggesting a progression of immune response to S4.

Very few GO terms were

significantly enriched among DEGs detected from comparison between the control and
larvae exposed to RI in the laboratory and they were mostly related to larval
development (not shown). The HT_RI transcriptomes shared enrichment of the term
“cytoskeletal organization” (Figures 3c) with the S4 (24h) transcriptomes, but none with
the RI laboratory transcriptomes.
3.5 KEGG annotation
Consistent with the results of the enrichment analysis, most of the KEGG pathways that
were represented by differentially expressed C. virginica larval genes related to signal
transduction, immune systems, and endocrine system (Table 4).
3.6 Differentially expressed immune genes shared between probiotics
An overview of the immune genes differentially expressed upon exposure to the
probiotics is depicted in Figure 4. Transcripts corresponding to the genes for several
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types of PRRs were modulated by probiotic treatment, out of which Toll-like receptors
(TLRs), lectins, recognition protein, peptidoglycan receptor protein (PGRP) and
leucine-rich repeat receptors (LRRs) were upregulated, with TLRs and lectins being
most upregulated, while scavenger receptors, leucine rich repeat and fibronectin type III
domain-containing proteins (LRFN), fibronectin domain containing proteins and C1-q
proteins were downregulated. TLR 4, 6 and 13 were consistently upregulated in
response to both probiotics with the exception of HT_RI transcriptome where TLR 13
is downregulated (Table 5).
Consistent with the observation that probiotic treatment led to differential expression of
several TLR receptors, several transcripts involved in the TLR signaling pathway,
including TNF receptor-associated factor 3-like (TRAF3) and mitogen-activated protein
kinase kinase kinase 7-like (TAK1), were differentially expressed upon probiotic
treatment (Table 6).
Moreover, DEG patterns suggested activation of the NF-kB and MAPK pathways by
probiotic exposure. Activation of the NF-kB pathway was indicated by upregulation of
activator B-cell lymphoma/leukemia 10-like (BCL10) and downregulation of inhibitor
NF-kappa-B inhibitor alpha-like isoform X1 (IkB). Some of the key players of the
MAPK pathway including dual specificity mitogen-activated protein kinase kinase 7like (MAP2K7), TAK1, extracellular signal-regulated kinase 2-like (ERK2) were also
upregulated in probiotic-treated larvae. Transcripts corresponding to a key molecule of
the MAPK pathway, MAP2K7, were uniformly upregulated in almost all probiotic
treatments (Table 6).
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Probiotic treatment unanimously leads to modulation of three types of major effectors:
serine protease inhibitor (SPI), mucin and macrophage-expressed gene 1 protein-like
(Mpeg1/Perforin-2) (Table 7). Serine protease inhibitor Cvspi2 was highly upregulated
in all probiotic treatments including HT_RI samples. Digestive cysteine proteinase 2
was highly upregulated in all treatments except HT_RI. Several different types of mucin
genes were modulated in larvae due to probiotic treatment. Both secreted gel-forming
mucins (MUC2, MUC5A, MUC5B and MUC19) and cell surface mucins (MUC3B,
MUC4 and MUC12) were differentially expressed. MUC12 was highly upregulated in
almost all probiotic treatments. MUC5AC was highly upregulated in probiotic
treatments of 24h and MUC2 was upregulated at 6h. Perforin2 was highly upregulated
in all probiotic treated larvae except in HT_RI samples.
Various molecules associated with cytoskeleton reorganization including actin, tubulin,
integrin, myosin and septins (Table 8) as well as those related to phagosome,
endocytosis, peroxisome and lysosome (Table 10) were differentially expressed in
response to probiotics. Prostaglandin G/H synthase 2-like (PTGS2), important in
inflammation reaction, was highly upregulated in all but S4(24h) treatment.
3.7 Differentially expressed immune genes unique to each probiotic
Transcripts of alpha-1–macroglobulin-like, integrins and antioxidant enzymes were
downregulated in larvae exposed to S4 (Table 9). Transcripts corresponding to Tollo
(TLR8) and E3 ubiquitin-protein ligase LRSAM1 were highly upregulated in RI(6h)
alone. HT_RI transcriptomes showed upregulation of histone H2B-like and GTPase
IMAP family member 7-like (GIMAP7) transcripts that were not seen in any other
probiotic treatments.
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3.8 Transcripts involved in antiviral responses
Surprisingly, several genes that are involved in antiviral pathways were also
differentially expressed due to probiotic treatment. These included upregulation of
recognition receptors (TLR3) for detecting intracellular nucleic acids and transcripts
involved in the JAK-STAT and cGAS-STING pathways (Table 6). Stimulator of
interferon genes protein-like (STING), an important part of the cGAS pathway, was
upregulated in all probiotic treatments except HT_RI. Interferon induced protein 44
gene was upregulated in the HT_RI sample. E3 ubiquitin-protein ligase TRIM56 was
heavily modulated in larvae from both probiotic treatments after a 24h exposure.
3.9 Cell death:
Autophagy related ATG9a was highly upregulated in all probiotic treatments except
HT_RI (Table 9). Both initiator and executioner caspases in the apoptosis pathway were
differentially expressed in probiotic treatments (Table 9). Transcripts for the initiator
caspase 2 were upregulated in 6 h treatments while at least one of the executioner
caspases 1,3,6 were upregulated in all treatments. Interestingly, caspases 1, 2, 7 and 8
were downregulated and only caspase-14 was upregulated in HT_RI. Several types of
baculoviral IAP repeat-containing proteins were differentially expressed in response to
probiotic treatments but the type of modulation and type of IAP differed between
treatments. Inhibitor of apoptosis was highly up in all probiotic treatments except
HT_RI, where GIMAP7 was highly upregulated.

4. Discussion
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Exposure of larvae to probiotics S4 and RI induced the expression of a large variety of
immune genes, suggesting a strong immune response comprising of heightened
pathogen recognition, activation of immune signaling pathways and production of an
arsenal of effectors. This probiotic mechanism of larval immunostimulation is
consistent with previous observations that probiotics are cleared from the larvae within
12 - 24 h after treatment (Karim et al., 2013). These immune effectors activated in larvae
upon probiotic exposure may also serve to provide protection against RE22 infection
especially in light of the opposite effect of suppression of signaling pathways and lack
of crucial effectors seen in response to RE22 challenge (Modak et al., in prep; Ch3 of
this dissertation).
4.1 Mechanisms shared between probiotics
Overall, the immune response of larvae to each of the probiotics shared many features,
including: (a) upregulation of a large variety of pathogen recognition receptors involved
in environmental sensing and pathogen detection, followed by (b) activation of multiple
signaling pathways; which ultimately led to the production of (c) an arsenal of effectors
known to have a role in immune defenses against bacterial pathogens (Figures 4 & 5).
Several probiotics are known to modulate (either activate or suppress) signaling
pathways that benefit the host and protect them from pathogens (reviewed in Llewellyn
et al., 2017). Usually, probiotics show a very strain specific response (Baarlen et al.,
2011, Llewellyn et al., 2017). In this case however, despite the difference in Gram
character between S4 and RI, many immune transcripts, especially effectors, were
expressed in response to both probiotics.
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Overall, differential expression analysis suggests activation of various immune
signaling pathways like TLR, NF-kB and MAPK by both probiotics. The TLR pathway
is crucial for bivalve innate immune systems. It recognizes a variety of damageassociated molecular patterns (DAMPs) and pathogen-associated molecular patterns
(PAMPs) to activate NF-kB and MAPK pathway that protect the host from infection by
producing cytokines, chemokines and other effectors (Gerdol et al., 2018). Our findings
showing that TLR3, 4, 6, 8 and 13 were upregulated in response to probiotics are
consistent with the important role of this pathway in bivalve immune responses, and
indicate the potential of probiotics to provide protection against a broad spectrum of
pathogens. Such PRR activation by probiotics due to shared cell envelope components
like lipopolysaccharides, peptidoglycan, and ß-glucans with pathogens is well known
(Pérez- Sánchez et al., 2014). Activation of TLR6 broadens the recognition spectrum
to bacteria, fungi, LPS and peptidoglycan (PGN) (Wang et al., 2018). Subsequent
activation of the MAPK pathway regulates several important cellular processes like cell
proliferation, apoptosis, inflammatory response to pathogens and involved in the innate
immunity of oysters (Wang et al., 2018). Activation of host MAPK and NF-kB and
other signaling pathways by probiotics is seen in human gut associated probiotics
(Thomas & Versalovic et al., 2010, Bermudez-Brito et al., 2012).
This transcriptome analysis also suggests that activation of these pathways leads to
increased transcription of a variety of immune effectors. Larvae already equipped with
effectors as a result of probiotic treatment can carry out expedited clearing of pathogen
upon challenge. Some of these effectors have been shown in previous research to have
the potential to be involved in protection against RE22.
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Protease inhibitors: All probiotic treatments showed highly upregulated serine protease
inhibitor Cvspi2. One of the important virulence factors of RE22 is production of
proteases, most notably metalloproteases (Hasegawa et al., 2008), but also potentially
serine proteases, which are encoded in the genome (Spinard et al., 2015, Richards et al.,
2018). Presence of serine protease inhibitors might neutralize serine protease attack by
RE22 in probiotic pretreated larvae thus playing a significant role in their survival from
RE22 infection. cvSI-1 has been shown to play an important role in host defense against
Perkinsus marinus by inhibiting proliferation of the parasite (LaPeyre et al., 2009, Yu
et al., 2011, Nikapitiya et al., 2014) and is also upregulated in resistant oysters in
response to challenge with the pathogen Aliiroseovarious crassostreae (McDowell et
al., 2014) in C. virginica.
Mucins: Mucus is an important line of defense and plays multiple roles in the hostmicrobe interaction (Allam and Espinosa., 2016). Both secreted gel forming mucins and
cell surface mucins modulated by both probiotics work in concert to clear infection
(Linden et al., 2008). Both Gram negative and Gram-positive bacteria have been shown
to upregulate mucins in humans (Dohrman et al., 1998) which explains how both
probiotics could influence their production. Increased production of mucus could buffer
action of proteases (Yan et al., 2017) used by pathogenic Vibrio spp. to penetrate mucus
and spread infection (Silva et al., 2003). Probiotics modulate the mucus barrier to aid
their adhesion thereby preventing invasion of pathogens (Tuomola et al., 1999, Allam
and Espinosa, 2016). In addition, oysters can also benefit from presence of vast array of
immune recognition and effector proteins in the mucus (Espinosa et al., 2016). Hence,
modulation of mucins can have multiple advantages for probiotic pretreated larvae.
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Perforin-2: Perforin-2/Mpeg1 was highly upregulated in all lab probiotic treated larvae.
Perforin-2 is an important ancient innate immune system effector present in vertebrates
as well as invertebrates that functions by forming pores in intracellular and extracellular
pathogenic bacteria (McCormack and Podack, 2015). In invertebrates, LPS exposure
significantly upregulated a homologue of perforin-2 in a sponge Suberites domuncula
(Wiens et al., 2005) and in disk abalone Haliotis discus discus post V. parahemolyticus
challenge (Bathige et al., 2014). In C. gigas, Cg-Mpeg1 showed significant antibacterial
activity to both Gram-negative and positive bacteria and its transcription level was
significantly up-regulated following infection with V. alginolyticus (He et al., 2011).
Thus, elevated activation of perforin-2 in probiotic pretreated C. virginica larvae might
act as an efficient effector against RE22 upon challenge.
Cytoskeletal organization: In addition, differential expression of actin, septin and
dynamin 1 were shared by both probiotics suggesting a likelihood of their role in
cytoskeletal reorganization (Pagliuso et al., 2016, Sirianni et al., 2016), possibly altering
intracellular pathogenic invasion (Torraca and Mostowy, 2016, Mazon et al., 2017).
Cytoskeletal rearrangements can help in bacterial sensing, compartmentalization of
pathogens (Mostowy & Cossart, 2011), autophagy and apoptosis for host protection
(Mostowy and Shenoy, 2015) as well as phagocytosis (Vicente-Manzanares and
Sánchez-Madrid., 2004). PTGS2, which was upregulated in almost all probiotic
treatments, is a key enzyme producing inflammatory prostaglandins and generation of
inflammatory response activating the immune system in advance.
4.2 Mechanisms unique for each probiotic
Some unique aspects of the probiotic specific response are discussed below:
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Specific response to S4:
In addition to protease inhibition, alpha-1–macroglobulin (which was downregulated
only in S4) is also involved in complement and coagulation cascades (Xiao et al., 2000)
suggesting possible modulation of complement cascades by S4. Integrins (also
downregulated in S4(24h)) have been shown to be used by V. splendidus to enter
hemocytes and evade immunity (Duperthuy, M, et al., 2011). Antioxidant enzymes were
mostly downregulated with S4 treatment, suggesting that S4 treatment does not lead to
oxidative damage, unlike pathogenic exposure (Lorgeril et al., 2008, McDowell et al.,
2014).
Specific response to RI:
Tollo (TLR8, upregulated in response to RI) is related to larval innate immune response
to Gram negative and positive bacteria and shown to regulate antimicrobial production
in Drosophila melanogaster (Akhouayri et al., 2011). E3 ubiquitin-protein ligase
LRSAM1 (highly upregulated in RI (6 h)) is a bacterial recognition protein and ubiquitin
ligase that defends the cytoplasm from invasive pathogens. It is important for ubiquitindependent autophagy against invading intracellular bacterial pathogens (Huett et al.,
2012).
Two unique aspects about HT_RI transcriptome were upregulated transcripts identified
as histone H2B-like and GIMAP7. Histones show antimicrobial action against Gram
negative bacteria like Escherichia coli (Kawasaki et al., 2008) and in C. gigas has been
demonstrated to surround and engulf vibrios (Nikapitiya et al., 2013, Poirier et al.,
2014). GIMAP7 is member of GTPase of the immune-associated proteins family that
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acts an apoptosis regulator (Nitta and Takahama, 2007) and its upregulation suggests
inhibition of apoptosis.
4.3 Unexpected responses to probiotics
Interestingly, multiple members of antiviral pathways were also modulated in response
to probiotics. STING, an important part of the cGAS pathway, was highly upregulated
in all lab probiotic treatments. A special STING homolog LvSTING was activated in
shrimp in response to V. parahaemolyticus infections that participates in antimicrobial
peptide production (Li et al., 2017). Thus, this pathway plays an essential role in host
response to pathogen invasion including bacteria, owing to detection of cytosolic DNA
recognition and type I IFN production (Tao et al., 2016). Activation of these pathway
suggests that probiotic exposure may provide protection against viruses (Thomas et al.
2010, Bermudez-Brito et al., 2012).
4.4 Cell death
ATG9a was highly upregulated by all probiotic treatments suggesting activation of
autophagy (He and Klionsky, 2009) consistently by both probiotics. Autophagy and
septins together restrict cytosolic bacterial replication (Torraca and Mostowy, 2016) and
maybe an additional mechanism of action against RE22 invasion.
Various apoptosis inhibitors were highly upregulated in response to both probiotic
treatments suggesting overall inhibition of apoptosis in response to probiotics.
However, patterns of expression of apoptotic genes vary across different environmental
stressors in bivalves suggesting it is a very complex pathway that is still not completely
understood (Gerdol et al., 2018). Surviving C. gigas also showed apoptosis inhibition
in response to virulent Vibrio sp. (Lorgeril et al., 2011). One of the virulence factors of
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RE22 is production of hemolysins (Spinard et al., 2015) showing toxic effects on
hemocytes (Gómez-León et al., 2008). Inhibition of apoptosis by probiotic pretreatment
might result in a higher number of hemocytes (Lee et al., 1993) that can potentially
counter the effect of hemolysins secreted by RE22 upon challenge.
4.5 Length of probiotic pretreatment for effective protection from challenge
As seen in the results (Table 1), shorter probiotic pretreatment provides variable
protection whereas longer pretreatment provides consistent protection from challenge.
Comparison of 6h and 24h transcriptomes showed same key effector mechanisms
activated at both time points viz upregulation of serine protease inhibitors, mucins and
perforin-2. There are however subtle differences for example in types of PRRs, mucins
and septins that are upregulated at 6 h compared to those at 24 h. Certain genes involved
in biomineralization and larval development and growth were also upregulated at 24 h.
This supports the observation that longer exposure provides better protection perhaps
due to increased pathogen sensing, additional growth effects and longer time for all
larvae to respond to probiotic pretreatment. Previous studies have also shown chronic
exposure of probiotics work better (Llewellyn et al., 2017).

5. Conclusion
This study indicates that probiotics use immunomodulation as a mechanism of action
that may play a role in the protection conferred against RE22 infection. Although 6 h of
pretreatment with probiotics might suffice for some larvae to protect themselves from
RE22 challenge, a 24 h pretreatment consistently allows majority of them to elicit the
immune responses effective in providing protection. This knowledge might help in
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designing better management strategies to control larval mortality in hatcheries by use
of probiotics as a natural and environmental friendly solution. In the future, it would be
beneficial to use this information to target the functional identification of effectors that
serve in protecting larvae against RE22 infection.
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Table 1: Effect of varying lengths of probiotic pretreatment on larval survival after
experimental challenge with the pathogen V. coralliilyticus RE22. Results are
expressed as the relative increase in percent survival +/- standard deviation (SD) of
larvae pretreated with probiotics as compared to non-treated and challenged larvae. S4
+ RE22: Larvae pretreated with Phaeobacter inhibens S4 and then challenged with
RE22. RI + RE22: Larvae pretreated with Bacillus pumilus RI0-695 and then challenged
with RE22. - Not Tested.

S4 + RE22

RPS (average +/- SD)
6h
24h
8d
37 ± 26
41 ± 2

RI + RE22

30 ± 39

Treatment
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45 ± 5

28 ± 6
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Figure 1a: Sequencing saturation curves for RNA-seq samples obtained in laboratory
for control, RI treated 6h, RI treated 24h, S4 treated 6h, S4 treated 24h larval
transcriptomes. Curves are provided for each experiment (biological replicates; K, M,
V).
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Figure 1b: Sequencing saturation curves for RNA-seq samples obtained in hatchery for
control and B. pumilis RI06-95 treated oyster larval transcriptomes. Larvae were
collected on day 5, 12 and 16 after fertilization, after being treated daily starting 1 day
after fertilization.
Table 2: Oyster larval transcriptomes in response to probiotic treatment. Laboratory
transcriptomes: Oyster larvae were treated with B. pumilus RI0-695 and Phaeobacter
inhibens S4 for 6 or 24 h. Larvae for control (C) transcriptomes were collected at time
0h. Hatchery transcriptomes: Larvae were treated daily in the hatchery with RI06-95
(RI) or not-treated (Con), and collected 5, 12 or 16 d after fertilization. Three
independent laboratory experiments (K, M, V) with two treatments (Control: C; RI
treatment: RI, S4 treatment: S4) were performed in duplicate. Number of paired end
reads per sample and % alignment rates to Crassostrea virginica reference genome
using HISAT2 are shown.
Sample
C_K_0
C_M_0

# paired
% Alignment to Crassostrea virginica
reads
genome
Laboratory transcriptomes
22,963,376
89
16,617,375
88
130

C_V_0
RI_K_24
RI_K_6
RI_M_24
RI_M_6
RI_V_24
RI_V_6
S4_K_24
S4_K_6
S4_M_24
S4_M_6
S4_V_24
S4_V_6
Con_5d
Con_12d
Con_16d
RI_5d
RI_12d
RI_16d

20,674,506
27,507,148
25,325,997
22,339,707
20,649,356
18,412,447
18,720,304
25,285,770
17,536,097
21,950,812
14,570,962
17,840,669
21,556,827
Hatchery transcriptomes
73,690,654
60,768,394
70,771,125
61,710,678
59,865,884
50,226,597

86
86
87
86
86
83
86
87
88
87
86
89
88
53
93
64
94
94
61

Table 3: Number of differentially expressed genes per comparison (p ≤ 0.05,
upregulation: log fold change ≥ 2, downregulation: log fold change ≤ -2).
Comparison

# DEGs

Lab transcriptomes
6h probiotic treatment
RI vs Con
S4 vs Con
24h probiotic treatment
RI vs Con
S4 vs Con
Hatchery transcriptome
5, 12, 16d post fertilization
RI vs Con
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1,550
2,269
2,139
3,459

2,993

Figure 2a: Venn Diagram of shared and unique differentially expressed genes for
each probiotic treatment (B. pumilus RI0-695 and Phaeobacter inhibens S4) at 6 h and
24 h in laboratory samples.
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Figure 2b: Plot comparing number of differentially expressed genes in probiotic
treatments at 5, 12 and 16 days in a hatchery. Numbers above the highlighted bar (boxed
in red) show the number of differentially expressed genes shared in all probiotic
treatments.
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Figure 3a: Functional enrichment of differentially expressed transcripts in S4 (6h) using
Gene Ontology terms in Biological Process. The color scale in the legend shows level
of significance (warmer colors are less significant than cooler colors) and the size of the
bubble corresponds to the number of significant transcripts mapped to the term.
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Figure 3b: Functional enrichment of differentially expressed transcripts in S4 (24h)
using Gene Ontology terms in Biological Process. The color scale in the legend shows
level of significance (warmer colors are less significant than cooler colors) and the size
of the bubble corresponds to the number of significant transcripts mapped to the term.
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Figure 3c: Functional enrichment of differentially expressed transcripts in hatchery RI
transcriptomes using Gene Ontology terms in Biological Process. The color scale in the
legend shows level of significance (warmer colors are less significant than cooler colors)
and the size of the bubble corresponds to the number of significant transcripts mapped
to the term.
Table 4: KEGG annotation of differentially expressed genes
RI(6h)
Metabolism
Carbohydrate metabolism
Energy metabolism
Lipid metabolism
Nucleotide metabolism
Amino acid metabolism
Metabolism of other amino acids
Glycan biosynthesis and
metabolism
Metabolism of cofactors and
vitamins
Metabolism of terpenoids and
polyketids

S4(6h)

RI(24h)

S4(24h)

27
4
25
10
13
6

36
10
29
20
37
9

37
13
40
16
26
19

68
17
48
29
51
19

7

19

20

31

6

17

14

16

3

3

4

5
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Biosynthesis of other secondary
metabolites
Xenobiotics and biodegradation
metabolism
Genetic information processing
Transcription
Translation
Folding sorting and degradation
Replication and repair
Environmental processing
Membrane transport
Signal transduction
Signaling molecules and
interaction
Cellular processes
Transport and catabolism
Cell growth and death
Cellular community-eukaryotes
Cellular community-prokaryotes
Cell motility
Organismal systems
Immune system
Endocrine system
Circulatory system
Digestive system
Excretory system
Nervous system
Sensory system
Development
Aging
Environmental adaptation

2

8

5

4

9

8

11

13

11
16
16
1

20
25
23
5

13
23
25
8

17
44
43
15

1
200

3
261

2
294

5
387

8

10

17

23

45
38
48
1
8

58
51
59
2
9

64
64
52
0
12

87
106
70
1
17

124
133
18
33
11
61
20
22
20
30

112
114
16
34
12
50
16
22
20
30

113
171
29
41
14
75
24
23
19
31

137
210
36
63
23
101
31
31
22
34
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Figure 4: Overview of the immune responses induced in oyster larvae in response to
treatment with probiotics S4 and RI, as measured through high-throughput analysis of
differential gene expression. Overall, PRRs including TLRs, lectins, PGRPs and LRRs
were upregulated while others were downregulated. Signaling pathways including TLR,
NF-kB, MAPK and antiviral pathways including JAK-STAT, cGAS-STING were
activated. Immune effectors were activated including mucins, protease inhibitor and
perforin-2. Autophagy was activated and apoptosis was inhibited. Antioxidant enzymes
were downregulated. Cytoskeleton related molecules including septins were modulated
by both probiotics.
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Figure 5: Hypothesized role of selected effectors of immunity whose expression was
found to be upregulated in larval oysters in response to probiotic treatment on
providing protection against challenge to V. coralliilyticus RE22. Mucin and protease
inhibitors provide protection outside the oyster body and perforin-2 providing
protection once the pathogen is within oyster tissues.
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Table 5: Patterns of differential gene expression of immune receptors in oyster larvae in response to probiotic treatment (p ≤ 0.05,
upregulation: log fold change ≥ 2, downregulation: log fold change ≤ -2). Yellow denotes downregulation, orange denotes up and
downregulation of transcripts mapped to the same gene, red denotes upregulation. HT-RI: larvae treated daily with probiotic Bacillus
pumilus RI0695 (RI) for 5, 12 or 16 days; RI_6h: Larvae exposed to RI for 6h; RI_24h: Larvae exposed to RI for 24h; S4_6h: Larvae
exposed to S4 for 6h; S4_24h: Larvae exposed to S4 for 24h.
Probiotics
HT_RI
Receptors
TLRs
toll-like receptor 1
TLR3 isoform X1
TLR4
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TLR4 isoform X1
toll-like receptor 6
TLR6 isoform X1
TLR13
TLR13 isoform X1
TLR Tollo isoform X2
protein toll-like
Lectins
C-type lectin domain family 4 member E-like
C-type lectin domain family 3 member A-like
lectin-like *
lectin BRA-3-like
plectin-like isoform X4

RI_6h

RI_24h

S4_6h

S4_24h

hepatic lectin like
galactose-specific lectin nattectin-like
fucolectin-like
Scavenger receptors
scavenger receptor class F member 2-like
scavenger receptor class B member 1 isoform B
scavenger receptor class B member 1-like isoform X1
Scavenger receptor cysteine-rich type 1 protein M130
scavenger receptor cysteine-rich type 1 protein M130-like isoform X1
somatomedin-B and thrombospondin type-1 domain-containing protein-like
proteoglycan 4-like isoform X4
PGRP
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peptidoglycan-recognition protein SC2-like *
LRFN
leucine-rich repeat and fibronectin type III domain-containing protein 1-like protein
leucine-rich repeat and fibronectin type-III domain-containing protein 5-like
LRR
leucine-rich repeat transmembrane neuronal protein 3-like isoform X1
leucine-rich repeat transmembrane protein FLRT1-like
leucine-rich repeat transmembrane protein FLRT3-like
leucine-rich repeat-containing protein 24-like
leucine-rich repeat-containing protein 27-like
leucine-rich repeat-containing protein 28-like isoform X3
leucine-rich repeat-containing protein 34-like isoform X2
leucine-rich repeat-containing protein 40

leucine-rich repeat-containing protein 45-like
Leucine-rich repeat-containing protein 49
leucine-rich repeat-containing protein 4C-like isoform X1
leucine-rich repeat-containing protein 70-like
leucine-rich repeat-containing protein 71-like isoform X21
leucine-rich repeat-containing protein 71-like isoform X22
leucine-rich repeat-containing protein 74A-like
leucine-rich repeat-containing protein 74A-like isoform X2
leucine-rich repeat-containing protein 74B-like
leucine-rich repeat-containing protein 74B-like isoform X2
leucine-rich repeat-containing protein 74B-like isoform X3
leucine-rich repeat-containing protein 74B-like isoform X6
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leucine-rich repeat-containing protein 9-like isoform X2
leucine-rich repeat and IQ domain-containing protein 1
leucine zipper putative tumor suppressor 2 homolog
Fibronectin type III domain
fibronectin type III domain-containing protein 1-like
fibronectin type III domain-containing protein 2-like isoform X3
fibronectin type-III domain-containing protein 3A-like isoform X4
ankyrin repeat and fibronectin type-III domain-containing protein 1-like
C1q proteins
C1q-related factor-like *
complement C1q-like protein 2
complement C1q tumor necrosis factor-related protein 2-like
complement C1q tumor necrosis factor-related protein 4-like

complement C1q tumor necrosis factor-related protein 4-like isoform X3
alpha-1-macroglobulin-like
alpha-1-macroglobulin-like isoform X2
Macrophage mannose receptor 1
Macrophage mannose receptor 1-like isoform X1*
Metabolic Enzymes with New Role of Carbohydrate Binding
Phosphoenolpyruvate carboxykinase
hexokinase-2-like isoform X2
B cell receptor
dapp1 dual adaptor for phosphotirosine*
Cholinergic immunomodulation
Glutamate receptor *
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glutamate receptor 2-like
glutamate receptor ionotropic
dopamine receptor 2-like
muscarinic acetylcholine receptor M1-like
neuronal acetylcholine receptor subunit alpha-6-like
neuronal acetylcholine receptor subunit alpha-9-like
choline transporter-like protein 2
apoptogenic protein 1
anti-apoptotic protein NR13-like
neuropeptide FF receptor 2-like
neuropeptide SIFamide receptor-like
neuropeptide Y receptor type 1-like
neuropeptide Y receptor type 2-like*

pro-neuropeptide Y-like isoform X1*
metabotropic glutamate receptor 8-like isoform X1
acetylcholinesterase-like isoform X1*
acetylcholinesterase-like

Table 6: Patterns of differential gene expression of immune signaling pathways in oyster larvae in response to probiotic treatment (p ≤
0.05, upregulation: log fold change ≥ 2, downregulation: log fold change ≤ -2). Yellow denotes downregulation, orange denotes up
and downregulation of transcripts mapped to the same gene, red denotes upregulation. HT-RI: larvae treated daily with probiotic
Bacillus pumilus RI0695 (RI) for 5, 12 or 16 days; RI_6h: Larvae exposed to RI for 6h; RI_24h: Larvae exposed to RI for 24h; S4_6h:
Larvae exposed to S4 for 6h; S4_24h: Larvae exposed to S4 for 24h.
Probiotics
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HT_RI
Signaling pathways in Immune response
TLR pathway
TNF receptor-associated factor 3-like isoform X3 (TRAF3)
tumor necrosis factor receptor superfamily member 1B-like isoform X1
tumor necrosis factor receptor superfamily member
mitogen-activated protein kinase kinase kinase 7-like isoform X3 (TAK1)
JAK-STAT
tyrosine-protein kinase JAK2-like (JAK)
signal transducer and activator of transcription 3-like isoform X6 (STAT3)
Suppressor of cytokine signaling 7 (SOCS)
son of sevenless homolog 2-like * (SOS2)
epidermal growth factor receptor-like (EGFR)

RI_6h

RI_24h

S4_6h

S4_24h

epidermal growth factor receptor-like isoform X2
epidermal growth factor receptor-like isoform X4
tyrosine-protein phosphatase non-receptor type 11 isoform X3 (SHP2)
tyrosine-protein phosphatase non-receptor type 4-like isoform X4 (PTPN4)
tyrosine-protein phosphatase non-receptor type 9-like isoform X2 (PTPN9)
tyrosine-protein phosphatase non-receptor type 23-like (PTPN23)
NF-kB signaling pathway
NF-kappa-B-activating protein-like (NKAP)
NF-kappa-B inhibitor alpha-like isoform X1 (IkB)
smad nuclear interacting protein 1-like (SNIP1)
TNFAIP3-interacting protein 1-like * (TNIP1)
B-cell lymphoma/leukemia 10-like (BCL10)
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ELKS/Rab6-interacting/CAST family member 1-like
ELKS/Rab6-interacting/CAST family member 1-like isoform X3
ELKS/Rab6-interacting/CAST family member 1-like isoform X5*
TRAF-type zinc finger domain-containing protein 1-like *
adapter protein CIKS-like isoform X4 (TRAF3IP2/Act1/CIKS)
NF-kappa-B inhibitor-interacting Ras-like protein 1 isoform X8
nuclear factor NF-kappa-B p105 subunit-like isoform X2
lipopolysaccharide-induced tumor necrosis factor-alpha factor homolog
Mitogen-Activated Protein Kinases (MAPK) pathway
dual specificity mitogen-activated protein kinase kinase 1-like isoform X1
mitogen-activated protein kinase-binding protein 1-like isoform X4 (MEKK1)
mitogen-activated protein kinase kinase kinase kinase 3-like (MKK3)
Mitogen-activated protein kinase kinase kinase 7 (MKK7)

dual specificity mitogen-activated protein kinase kinase 7-like isoform X1 (MKK7)
mitogen-activated protein kinase kinase kinase 7-like isoform X3 (TAK1)
mitogen-activated protein kinase 11-like (MAPK11)
mitogen-activated protein kinase kinase kinase 13-like isoform X2 (MAPK13)
mitogen-activated protein kinase 14A-like (P38)
transforming growth factor-beta, partial
C-Jun-amino-terminal kinase-interacting protein 4-like *
extracellular signal-regulated kinase 2-like isoform X4
stress-activated protein kinase JNK-like isoform X1 (JNK)
Regulator of G-protein signaling 3
cGAS-STING pathway
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stimulator of interferon genes protein-like (STING)
RIG-1 pathway related
interferon regulatory factor 2-binding protein-like
Signal transduction
death domain-containing protein 1-like
death domain-containing protein CRADD-like *
integrin alpha-2-like isoform X5 *
integrin alpha-4-like isoform X1 *
integrin beta-3-like [Crassostrea virginica]
ubiquitin carboxyl-terminal hydrolase 14-like
ubiquitin carboxyl-terminal hydrolase 20-like isoform X2
ubiquitin carboxyl-terminal hydrolase 22-like *
ubiquitin carboxyl-terminal hydrolase 25-like isoform X3 * (USP25)
cellular retinoic acid-binding protein 2-like

1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1-like isoform X4
(PLCG1)
epidermal growth factor receptor-like
epidermal growth factor receptor-like isoform X2
epidermal growth factor receptor-like isoform X4
tyrosine-protein phosphatase non-receptor type 11 isoform X3
basic leucine zipper transcriptional factor ATF-like 3
nuclear factor of activated T-cells 5-like isoform X2
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Table 7: Patterns of differential gene expression of immune effectors in response to probiotic treatment (p ≤ 0.05, upregulation: log fold
change ≥ 2, downregulation: log fold change ≤ -2). Yellow denotes downregulation, orange denotes up and downregulation of transcripts
mapped to the same gene, red denotes upregulation. HT-RI: larvae treated daily with probiotic Bacillus pumilus RI0695 (RI) for 5, 12
or 16 days; RI_6h: Larvae exposed to RI for 6h; RI_24h: Larvae exposed to RI for 24h; S4_6h: Larvae exposed to S4 for 6h; S4_24h:
Larvae exposed to S4 for 24h.
Probiotics
HT_R
I
Effectors
serine protease inhibitor Cvsi-2-like *
serine protease inhibitor dipetalogastin-like *
kunitz-type serine protease inhibitor conotoxin Cal9.1b-like
digestive cysteine proteinase 2-like*
serine protease 44-like
interferon-induced protein 44-like isoform X2
interleukin-17 receptor D-like

RI_6h

RI_24h

S4_6h

S4_24h

Signaling mucin HKR1
integumentary mucin C.1-like
integumentary mucin C.1-like isoform X1
integumentary mucin C.1-like isoform X3
mucin-12-like *
mucin-17-like isoform X2
mucin-2-like
mucin-2-like isoform X2
mucin-3B-like isoform X4
mucin-4 isoform X3
mucin-4-like isoform X7
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mucin-4-like isoform X8
mucin-5AC-like *
mucin-5AC-like isoform X5
mucin-5B-like
mucin-19-like, partial
mucin-19 isoform X2
PREDICTED: mucin-19 isoform X7
IgGFc-binding protein*
septin-2-like
septin-2-like isoform X1
septin-2-like isoform X8
septin-7 isoform X3
septin-11-like isoform X2
macrophage-expressed gene 1 protein-like * (Perforin-2/Mpeg1)

antistasin-like
SH3-domain binding protein 2
alpha-1-macroglobulin-like
alpha-1-macroglobulin-like isoform X2
cystatin-A-like

Table 8: Patterns of differential gene expression that are part of cytoskeletal reorganization in oyster larvae in response to probiotic
treatment (p ≤ 0.05, upregulation: log fold change ≥ 2, downregulation: log fold change ≤ -2). Yellow denotes downregulation, orange
denotes up and downregulation of transcripts mapped to the same gene, red denotes upregulation. HT-RI: larvae treated daily with
probiotic Bacillus pumilus RI0695 (RI) for 5, 12 or 16 days; RI_6h: Larvae exposed to RI for 6h; RI_24h: Larvae exposed to RI for 24h;
S4_6h: Larvae exposed to S4 for 6h; S4_24h: Larvae exposed to S4 for 24h.
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Probiotics
HT_RI
Cytosletal reorganization
Actin, cytoplasmic
actin-like
actin-3-like isoform X1
septin-2-like
septin-2-like isoform X1
septin-2-like isoform X8
septin-7 isoform X3
septin-11-like isoform X2
dynamin-1-like isoform X6

RI_6h

RI_24h

S4_6h

S4_24h

Table 9: Patterns of differential gene expression that are part of apoptosis and autophagy in oyster larvae in response to probiotic
treatment (p ≤ 0.05, upregulation: log fold change ≥ 2, downregulation: log fold change ≤ -2). Yellow denotes downregulation, orange
denotes up and downregulation of transcripts mapped to the same gene, red denotes upregulation. HT-RI: larvae treated daily with
probiotic Bacillus pumilus RI0695 (RI) for 5, 12 or 16 days; RI_6h: Larvae exposed to RI for 6h; RI_24h: Larvae exposed to RI for
24h; S4_6h: Larvae exposed to S4 for 6h; S4_24h: Larvae exposed to S4 for 24h.
Probiotics
HT_RI
Apoptosis
Caspase 1
Caspase 2
Caspase 3
caspase-3-like isoform X2
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Caspase 6
Caspase 6 Isoform X2
Caspase 7
Caspase 7 Isoform X1
Caspase 7 Isoform X3
Caspase-8
caspase-14-like isoform X2
caspase recruitment domain-containing protein 14-like isoform X5
baculoviral IAP repeat-containing protein 2-like
baculoviral IAP repeat-containing protein 2-like isoform X2
baculoviral IAP repeat-containing protein 2-like isoform X1
baculoviral IAP repeat-containing protein 3-like
baculoviral IAP repeat-containing protein 3-like isoform X1 *

RI_6h

RI_24h

S4_6h

S4_24h

baculoviral IAP repeat-containing protein 6-like isoform X5
baculoviral IAP repeat-containing protein 7A-like isoform X2
baculoviral IAP repeat-containing protein 7-like isoform X3
putative inhibitor of apoptosis*
Apoptosis inhibitor IAP
bifunctional apoptosis regulator-like isoform X1
apoptogenic protein 1
apoptosis-inducing factor 3-like
protein kinase C iota type-like isoform X4
multiple epidermal growth factor-like domains protein 10 isoform X2
multiple epidermal growth factor-like domains protein 10 isoform X4
multiple epidermal growth factor-like domains protein 6
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multiple epidermal growth factor-like domains protein 6 isoform X1
death domain-containing protein CRADD-like *
apoptotic chromatin condensation inducer in the nucleus-like
cathepsin L-like isoform X2
cathepsin L1-like
cathepsin O-like
programmed cell death protein 2-like isoform X1
programmed cell death protein 6-like isoform X2
programmed cell death 6-interacting protein-like isoform X3
XK-related protein 8-like isoform X2 *
XK-related protein 6, partial *
XK-related protein 4
cell death protein 3-like

cell death abnormality protein 1-like
cell death-inducing p53-target protein 1-like isoform X5
cell death specification protein 2
FAS-associated factor 1-like
serine/threonine-protein kinase/endoribonuclease IRE1-like
inositol 1,4,5-trisphosphate receptor type 1-like isoform X10*
cAMP-dependent protein kinase catalytic subunit
Actin, cytoplasmic
actin-like
actin-3-like isoform X1
poly [ADP-ribose] polymerase 2-like isoform X2
poly [ADP-ribose] polymerase 3-like

152

epidermal growth factor receptor-like isoform X2
epidermal growth factor receptor-like isoform X4
basic immunoglobulin-like variable motif-containing protein isoform X5
Oxidoreductase HTATIP2
ATP-dependent zinc metalloprotease YME1L1-like
GIMAP
tax1-binding protein 1 homolog isoform X3*
Autophagy
autophagy-related protein 9A-like isoform X1 *
transcription factor SPT20 homolog isoform X1
vacuole membrane protein 1-like
protein kinase C delta type
DNA damage-regulated autophagy modulator protein 2-like

DNA damage-regulated autophagy modulator protein 1-like*
run domain Beclin-1-interacting and cysteine-rich domain-containing protein-like isoform X3
phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform-like isoform X1*
TOLLIP (toll-interacting protein-like isoform X3)
serine/threonine-protein kinase/endoribonuclease IRE1-like
ubiquitin-like protein ATG12 isoform X1
ubiquitin-like-conjugating enzyme ATG10 isoform X3
inositol 1,4,5-trisphosphate receptor type 1-like isoform X10*
protein kinase C delta type*
insulin receptor substrate 1-B-like isoform X2 *
Homeobox protein HD1*
inositol 1,4,5-trisphosphate receptor type 1-like isoform X10*
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alpha-soluble NSF attachment protein-like
endophilin-B1-like
ras-related protein rab7
hamartin-like isoform X2*
ras-related protein M-Ras-like
RAC-gamma serine/threonine-protein kinase-like isoform X1
UV radiation resistance-associated gene protein-like
next to BRCA1 gene 1 protein-like isoform X1

Table 10: Patterns of differential gene expression that are part of phagosome, endosome, peroxisome, lysosome, antioxidant enzymes
and acute phase proteins in oyster larvae in response to probiotic treatment (p ≤ 0.05, upregulation: log fold change ≥ 2,
downregulation: log fold change ≤ -2). Yellow denotes downregulation, orange denotes up and downregulation of transcripts mapped
to the same gene, red denotes upregulation. HT-RI: larvae treated daily with probiotic Bacillus pumilus RI0695 (RI) for 5, 12 or 16

days; RI_6h: Larvae exposed to RI for 6h; RI_24h: Larvae exposed to RI for 24h; S4_6h: Larvae exposed to S4 for 6h; S4_24h:
Larvae exposed to S4 for 24h.
Probiotics
HT_RI
Phagosome
Actin, cytoplasmic
actin-like
cathepsin L-like isoform X2
cathepsin O-like
cation-dependent mannose-6-phosphate receptor-like *
Coagulation factor V *
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cytoplasmic dynein 1 heavy chain 1-like isoform X1 *
cytoplasmic dynein 2 heavy chain 1-like isoform X4
cytoplasmic dynein 1 light intermediate chain 2-like isoform X11 *
cytoplasmic dynein 2 light intermediate chain 1-like *
ras-related protein Rab-5B-like isoform X1
macrophage mannose receptor 1-like isoform X1
nitric oxide synthase brain-like isoform X2
digestive cysteine proteinase 2-like*
Lysosome
lysosomal acid lipase/cholesteryl ester hydrolase-like
lysosomal acid lipase/cholesteryl ester hydrolase-like isoform X2
cation-dependent mannose-6-phosphate receptor-like *
sulfatase-modifying factor 1-like

RI_6h

RI_24h

S4_6h

S4_24h

lysosomal-associated transmembrane protein 4A-like
ADP-ribosylation factor-binding protein GGA1-like *
ADP-ribosylation factor-binding protein GGA1-like *
AP-1 complex subunit gamma-1-like isoform X2
AP-1 complex subunit sigma-2 isoform X4 *
clathrin heavy chain 2 isoform X2
lysosomal-trafficking regulator-like isoform X4
lysosomal alpha-glucosidase-like isoform X1
Endocytosis
AP-2 complex subunit mu-1
clathrin heavy chain 2 isoform X2
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tumor susceptibility gene 101 protein-like
hepatocyte growth factor-regulated tyrosine kinase substrate-like
syntaxin-7-like isoform X3
phosphatidylinositol-binding clathrin assembly protein LAP-like *
Peroxisome
probable peroxisomal membrane protein PEX13
D-aspartate oxidase-like *
D-aspartate oxidase-like isoform X1
phytanoyl-CoA dioxygenase, peroxisomal-like
enoyl-CoA delta isomerase 2, mitochondrial-like isoform X2
peroxisomal acyl-coenzyme A oxidase 1-like
peroxisomal acyl-coenzyme A oxidase 1-like isoform X2
peroxisome proliferator-activated receptor delta-like isoform X1*
peroxisome proliferator-activated receptor gamma coactivator 1-alpha-like

prostaglandin E synthase 2-like [Crassostrea virginica]
prostaglandin E2 receptor EP4 subtype-like [Crassostrea virginica]
prostaglandin G/H synthase 2-like isoform X2 [Crassostrea virginica] *
prostaglandin reductase 1-like isoform X2 *
peroxisomal carnitine O-octanoyltransferase-like
Antioxidant enzymes
glutathione peroxidase 7-like [Crassostrea virginica]
glutathione S-transferase C-terminal domain-containing protein-like isoform X1 [Crassostrea
virginica]
glutathione S-transferase kappa 1-like [Crassostrea virginica]
glutathione S-transferase omega-1-like
glutathione S-transferase P 2-like
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glutathione S-transferase 3-like
glutathione-independent glyoxalase HSP31-like
glutathione S-transferase P 2-like
maleylacetoacetate isomerase-like*
gamma-glutamyltranspeptidase 1-like
Superoxide dismutase [Cu-Zn]
thioredoxin domain-containing protein 15-like
thioredoxin domain-containing protein 3 homolog isoform X15
thioredoxin domain-containing protein 5-like
thioredoxin-like
thioredoxin-like protein 1
thioredoxin-related transmembrane protein 1-like isoform X1
thioredoxin-related transmembrane protein 2 homolog

Acute phase proteins
heat shock 70 kDa protein 4*
Heat shock 70 kDa protein 12A*
heat shock 70 kDa protein 12A-like
heat shock 70 kDa protein 12A-like isoform X1
heat shock 70 kDa protein 12A-like isoform X3
heat shock 70 kDa protein 12B-like
heat shock 70 kDa protein 12B-like isoform X4 *
heat shock factor protein-like
heat shock protein 30C-like
heat shock protein HSP 90-beta-like

157

Stress response protein NhaX

Table 11: Patterns of differential gene expression that are part of metabolism, biomineralization and other processes in oyster larvae in
response to probiotic treatment (p ≤ 0.05, upregulation: log fold change ≥ 2, downregulation: log fold change ≤ -2). Yellow denotes
downregulation, orange denotes up and downregulation of transcripts mapped to the same gene, red denotes upregulation. HT-RI:
larvae treated daily with probiotic Bacillus pumilus RI0695 (RI) for 5, 12 or 16 days; RI_6h: Larvae exposed to RI for 6h; RI_24h:
Larvae exposed to RI for 24h; S4_6h: Larvae exposed to S4 for 6h; S4_24h: Larvae exposed to S4 for 24h.

Probiotics
HT_RI
Others
furin-like protease kpc-1 isoform X1
multidrug resistance protein 1-like isoform X1
multidrug resistance-associated protein 1-like isoform X3*
multidrug resistance protein 1-like isoform X6
multidrug resistance-associated protein 4-like
multidrug resistance-associated protein 5-like
multidrug resistance-associated protein 5-like isoform X2
multidrug resistance-associated protein 7-like
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laccase-3-like
laccase-like
laccase-5-like
peptidoglycan-recognition protein SC2-like
glycine receptor subunit alpha-3-like isoform X5
gamma-glutamyltranspeptidase 1-like
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1-like isoform X4
cysteine proteinase inhibitor 8-like
Hemicentin-1
Hemicentin-1 like
Hemicentin-1 like isoform X2
Hemicentin-1 like isoform X3
Hemicentin-1 like isoform X5

RI_6h

RI_24h

S4_6h

S4_24h

Hemicentin-1 like isoform X6
Hemicentin-1 like isoform X9
Hemicentin-1 like isoform X21*
Hemicentin-1 like isoform X34*
Hemicentin-1 like isoform X40
hemicentin-2-like isoform X2
histamine H2 receptor-like
oxidative stress-induced growth inhibitor 2-like
cytochrome b [Crassostrea virginica]
cytochrome b5 reductase 4-like isoform X3 [Crassostrea virginica]
cytochrome c oxidase subunit I *
cytochrome c oxidase subunit III (mitochondrion) *
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cytochrome P450 2C8
cytochrome P450 2C42-like
cytochrome P450 27C1-like
cytochrome P450 2C28-like isoform X2 *
cytochrome P450 2C42-like
Cytochrome P450 2D14
cytochrome P450 2F5-like *
cytochrome P450 4F22-like
cytochrome P450 2J5-like isoform X2*
cytochrome P450 3A6-like
Cytochrome P450 3A11
cytochrome P450 3A24-like isoform X1
cytochrome P450 3A29-like

cytochrome P450 4A25-like
cytochrome P450 4V2-like isoform X1
cytochrome P450 4F22-like *
dual specificity protein phosphatase 1-A-like [Crassostrea virginica]
dual specificity protein phosphatase 14-like isoform X1 [Crassostrea virginica]
dual specificity protein phosphatase 18-like [Crassostrea virginica]
dual specificity protein phosphatase 19-like [Crassostrea virginica]
dual specificity protein phosphatase 7-like [Crassostrea virginica]
dual specificity tyrosine-phosphorylation-regulated kinase 4-like isoform X14 [Crassostrea virginica]
protein phosphatase 1 regulatory subunit 12A-like isoform X2
protein phosphatase 1 regulatory subunit 12A-like isoform X4
protein phosphatase 1 regulatory subunit 16A-like isoform X3
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protein phosphatase 1 regulatory subunit 36-like isoform X1
protein phosphatase 1 regulatory subunit 37-like
protein phosphatase 1 regulatory subunit 42-like isoform X1
Tripartite motif-containing protein 2
tripartite motif-containing protein 2-like
tripartite motif-containing protein 5-like
tripartite motif-containing protein 5-like isoform X2
tripartite motif-containing protein 2-like isoform X2
tripartite motif-containing protein 2-like isoform X4
tripartite motif-containing protein 2-like isoform X1
tripartite motif-containing protein 3-like
tripartite motif-containing protein 3-like isoform X1
tripartite motif-containing protein 45-like

tripartite motif-containing protein 55-like
universal stress protein A-like protein isoform X5
epididymal secretory protein E1-like *
perilipin-2-like isoform X3*
nitric oxide synthase brain-like isoform X2
Ig-like and fibronectin type-III domain-containing protein 2 *
macrophage migration inhibitory factor-like
retinoic acid receptor RXR-gamma isoform X1
NAD-dependent protein deacetylase sirtuin-1-like *
cAMP-dependent protein kinase catalytic subunit
PREDICTED: stress protein DDR48-like [Salmo salar]
B-cell lymphoma 6 protein homolog isoform X3
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1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1-like isoform X12
cell wall integrity and stress response component 3-like isoform X3 [
histone H2B-like
Biomineralization
perlucin-like
perlucin-like isoform X1 *
perlucin-like isoform X2
perlucin-like protein
perlucin-like protein isoform X1*
Chitin synthase 3*
Chitin synthase C
putative carbonic anhydrase-like protein 1
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CHAPTER 5

DISSERTATION SUMMARY: USE OF PROBIOTICS BACILLUS PUMILUS
RI06-95 AND PHAEOBACTER INHIBENS S4 IN LARVICULTURE OF
CRASSOSTREA VIRGINICA TO STIMULATE HOST IMMUNITY AND LIMIT
IMPACT OF VIBRIO CORALLIILYTICUS RE22
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This dissertation research confirms the benefits of use of probiotics B. pumilus
RI06-95 and P. inhibens S4 as a natural and environmentally safe solution in disease
management of C. virginica larviculture (Karim et al., 2013, Zhao et al., 2016, Sohn et
al., 2016).
Use of suitably formulated probiotics can aid vibriosis management in hatchery
larviculture of Crassostrea virginica preventing sudden and massive larval mortalities.
This research demonstrates the successful formulation of a candidate probiotic strain,
Bacillus pumilus RI06-95, that facilitates stable long-term storage and easy delivery in
a hatchery setting. Daily treatment of oyster larvae with the spray dried formulation in
pilot-scale hatchery trials provided significant protection against laboratory challenge
with Vibrio coralliilyticus RE22 (RPS 43 ± 4 %). The results demonstrated that a
sprayed-dried formulation for probiotic RI06-95 is a commercially viable product that
can be safely and effectively used to limit negative impacts of vibriosis in shellfish
hatcheries. Understanding host-microbe interactions between C. virginica larvae and
pathogen or between larvae and probiotics would immensely help in designing protocols
of probiotic use commercially.
This research showed the swift progression of disease both in terms of rapidly
increasing mortality post 14h of exposure as well as impact on host immune system.
Immunological responses of C. virginica larvae to pathogen V. coralliilyticus RE22, as
measured through transcriptome analysis, suggest the ability of vibrio exposure to
suppress immune-related pathway activation and immune effector production. The
research also highlights the need and suitability of preventative measures like probiotics
rather than treatment options to protect larvae from effects of V. coralliilyticus RE22.
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This dissertation research on the immunological responses of C. virginica larvae
to both probiotics B. pumilus RI06-95 and P. inhibens S4 shows that the
immunosuppression by RE22 may be counteracted by probiotics ‘priming’ of the larval
immune response. This research demonstrates the ability of both probiotics to activate
pathogen recognition receptors (PRRs) that could aid in pathogen detection, activation
of immune signaling pathways and production of immune effectors that could
potentially aid in inactivation of RE22 and its virulence factors.
A hypothesized model based on the findings of this dissertation research and
previously published work is proposed here (Fig 1). When C. virginica larvae are
pretreated with probiotics, RI and S4 for 6 to 24 h, most larvae are protected from RE22
challenge (Fig1-1). A more prolonged 24 h pretreatment (versus 6 h) allows for more
consistent elicitation of immune responses, and therefore more consistent levels of
protection against RE22. Immune responses include activation of PRRs, immune
signaling pathways and production of immune effectors like mucins, serine protease
inhibitors and perforn-2 (Fig1-2). Oysters have a high basal rate of apoptosis that
regulate hemocyte number (Sokolova 2009). Transcriptomic data suggests treatment
with probiotics may inhibit hemocyte apoptosis, leading to increase in the number of
hemocytes (Fig1-3). This immunostimulation likely contributes to clearing probiotics
from the system (Karim et al., 2013), but also may contribute to counteracting RE22
virulence. When probiotic pretreated (and hence immunostimulated larvae) are
challenged with RE22, a series of changes brought about by the probiotics in the host
may assist the larvae in blocking RE22 (Fig1-4). Increased mucin production may
enhance the epithelial barrier blocking penetration and prevent adhesion of pathogen.
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Increased production of serine protease inhibitors may help to counter the effect of
serine proteases potentially produced by RE22. This immunomodulation would
complement other mechanisms of action of probiotics. Probiotic biofilm established
during the pretreatment period may reduce colonization sites for RE22 competitively
excluding them from colonizing the gut. Biofilm formation and competition assays
between S4 and RE22 showed pretreatment with S4 excludes RE22 (Zhao et al., 2016).
The draft genome of RI suggested its ability to form biofilms (Hamblin et al., 2015) but
there is no experimental data to support it yet. Antibiotic tropodithietic acid (TDA)
produced by S4 also aids in eliminating RE22 (Karim et al., 2013). S4 also secretes Nacyl homoserine lactones (AHLs) that quorum quench RE22 metalloprotease gene
expression that are a crucial part of its virulence (Zhao et al., 2018). Increased
production of perforin-2 due to probiotic pretreatment may also aid in neutralizing
pathogens both intracellularly and extracellularly within oyster tissues. Increased
number of hemocytes owing to apoptosis inhibition post probiotic treatment may
increase phagocytic pressure on RE22 as well as buffer cytotoxic effects of hemolysins
secreted by RE22 (Fig1-5) that diminish hemocyte survival (Gomez-Leon et al., 2008).
All these effects probably work in concert to allow more probiotic pretreated C.
virginica larvae to survive post RE22 challenge than those without probiotic
pretreatment, by effectively reducing the infective dose of RE22 (Fig1-4) and providing
larvae with mechanisms to further neutralize and kill RE22 within the oyster tissues
(Fig1-5), leading to increased survival (Fig1-6). Due to effective clearing of probiotics
within oysters due to the larval immune response, however, their protective effect
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diminishes over time as also seen in experimental evidence (Karim et al., 2013) unless
probiotics are applied repeatedly.
Immune effectors produced in response to probiotics, specifically highlighted in
this study are highly suitable in blocking virulence factors and pathogenesis of RE22.
However, application of probiotics and their overall immunostimulatory effect may
likely help in protecting larvae from other bacterial and viral infections. Thus, this
research advocates use of probiotic formulations in commercial shellfish aquaculture
for their beneficial effects. In addition, it provides new insights in oyster immunity in
response to non-pathogenic bacteria and the crosstalk between host and probiotics.
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Figure 1: Hypothesized model showing in a series of steps (1-6) how effects of
probiotic pretreatment on host immunity may complement other mechanisms of action
of probiotics in providing protection from V. coralliilyticus RE22 challenge. QQ:
quorum quenching, SPI: serine protease inhibitor, TDA: tropodithietic acid.
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APPENDIX

Table 1. Two-way ANOVA for the levels of Vibrios in water, tank surface, and oyster
on each trial with RI formulations.
ANOVA table

SS

DF

MS

F (DFn, DFd)

P value

Interaction

9.009

2

4.505

F (2, 10) = 2.278

P = 0.1530

Time

1.689

2

0.8446

F (2, 10) = 0.4271

P = 0.6638

Treatment

0.03975 1

0.03975 F (1, 5) = 0.07956

P = 0.7892

Subjects (matching)

2.498

5

0.4996

F (5, 10) = 0.2526

P = 0.9289

Residual

19.78

10

1.978

Interaction

2.834

2

1.417

F (2, 10) = 2.879

P = 0.1029

Time

4.138

2

2.069

F (2, 10) = 4.204

P = 0.0473

Treatment

0.05357 1

0.05357 F (1, 5) = 0.03503

P = 0.8589

Subjects (matching)

7.647

5

1.529

F (5, 10) = 3.107

P = 0.0599

Residual

4.922

10

0.4922

Interaction

4.051

6

0.6752

F (6, 16) = 1.467

P = 0.2512

Time

46.39

2

23.19

F (2, 16) = 50.39

P < 0.0001

Treatment

8.178

3

2.726

F (3, 8) = 4.766

P = 0.0344

Subjects (matching)

4.576

8

0.572

F (8, 16) = 1.243

P = 0.3372

Residual

7.364

16

0.4603

Interaction

5.513

6

0.9188

F (6, 16) = 0.4252

P = 0.8515

Time

58.79

2

29.39

F (2, 16) = 13.60

P = 0.0004

Treatment

20.56

3

6.854

F (3, 8) = 4.529

P = 0.0389

Subjects (matching)

12.11

8

1.513

F (8, 16) = 0.7004

P = 0.6872

Residual

34.57

16

2.161

Trial I: oyster

Trial I: water

Trial II: oyster

Trial II: tank surface
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Table 2: Differentially expressed genes with log fold change for probiotic or pathogen treatments when compared to control (Con 0 h)
in laboratory transcriptomes (p ≤ 0.05, upregulation: log fold change ≥ 2, downregulation: log fold change ≤ -2). RI_6h: Larvae
exposed to RI for 6h; RI_24h: Larvae exposed to RI for 24h; S4_6h: Larvae exposed to S4 for 6h; S4_24h: Larvae exposed to S4 for
24h; RE22_6h: Larvae exposed to RE22 for 6h.

Log2FoldChange Hit_def

Treatment

Recognition
178

TLRs
23.05478838

toll-like receptor 13 [Crassostrea virginica]

S4_6h

-22.74173118

toll-like receptor 13 [Crassostrea virginica]

S4_24h

20.83600237

toll-like receptor 13 [Crassostrea virginica]

S4_24h

21.32340853

toll-like receptor 13 [Crassostrea virginica]

RI_24h

22.15592205

toll-like receptor 13 [Crassostrea virginica]

RE22_6h

21.51071325

toll-like receptor 13 isoform X1 [Crassostrea virginica]

S4_24h
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22.42155892

toll-like receptor 13 isoform X1 [Crassostrea virginica]

S4_24h

17.30506755

toll-like receptor 13 isoform X1 [Crassostrea virginica]

RI_24h

21.06459929

toll-like receptor 3 isoform X1 [Crassostrea virginica]

S4_24h

22.49716465

toll-like receptor 3 isoform X1 [Crassostrea virginica]

RI_24h

-22.48957053

toll-like receptor 4 [Crassostrea virginica]

S4_6h

-23.60095447

toll-like receptor 4 [Crassostrea virginica]

RI_24h

21.86007267

toll-like receptor 4 [Crassostrea virginica]

S4_6h

20.06293431

toll-like receptor 4 [Crassostrea virginica]

S4_24h

18.52915288

toll-like receptor 4 [Crassostrea virginica]

RI_6h

20.85337828

toll-like receptor 4 [Crassostrea virginica]

RE22_6h

-27.08359576

toll-like receptor 4 isoform X1 [Crassostrea virginica]

S4_6h

-23.23844181

toll-like receptor 4 isoform X1 [Crassostrea virginica]

S4_24h

-22.60452533

toll-like receptor 4 isoform X1 [Crassostrea virginica]

S4_24h

-21.22164677

toll-like receptor 4 isoform X1 [Crassostrea virginica]

S4_24h
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-3.670100715

toll-like receptor 4 isoform X1 [Crassostrea virginica]

S4_24h

-21.77985815

toll-like receptor 4 isoform X1 [Crassostrea virginica]

RI_6h

-25.3837144

toll-like receptor 4 isoform X1 [Crassostrea virginica]

RE22_6h

-20.33473167

toll-like receptor 4 isoform X1 [Crassostrea virginica]

RE22_6h

-23.85245048

toll-like receptor 6 isoform X1 [Crassostrea virginica]

S4_6h

-24.52152638

toll-like receptor 6 isoform X1 [Crassostrea virginica]

RI_6h

6.948335986

toll-like receptor Tollo isoform X2 [Crassostrea virginica]

RI_24h

6.751339206

toll-like receptor Tollo isoform X2 [Crassostrea virginica]

RE22_6h

-18.59470318

toll-interacting protein-like isoform X3 [Crassostrea virginica]

RE22_6h

20.59470698

lectin BRA-3-like [Crassostrea virginica]

S4_24h

-21.67159

lectin BRA-3-like [Crassostrea virginica]

RI_6h

15.5998376

lectin BRA-3-like [Crassostrea virginica]

RI_24h

-21.98669883

hepatic lectin-like [Crassostrea virginica]

S4_6h

Lectins

-28.16031439

complement C1q tumor necrosis factor-related protein 4-like isoform X3 [Crassostrea

RI_6h

virginica]
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-2.942969529

complement C1q-like protein 2 [Crassostrea virginica]

S4_6h

-2.720935883

complement C1q-like protein 2 [Crassostrea virginica]

RE22_6h

-4.990716982

complement C1q-like protein 4 [Crassostrea virginica]

RE22_6h

5.323119114

fucolectin-like [Crassostrea virginica]

S4_6h

5.500587362

fucolectin-like [Crassostrea virginica]

RI_6h

6.563854383

fucolectin-like [Crassostrea virginica]

RE22_6h

-21.98669883

hepatic lectin-like [Crassostrea virginica]

S4_6h

-24.64487832

scavenger receptor class B member 1 isoform B [Alligator mississippiensis]

RI_6h

-25.10222908

scavenger receptor class B member 1 isoform B [Alligator mississippiensis]

RE22_6h

-5.982694265

scavenger receptor class F member 2-like [Crassostrea virginica]

S4_6h

Scavenger receptors

PGRP

-5.798327381

peptidoglycan-recognition protein SC2-like [Crassostrea virginica]

S4_6h

leucine-rich repeat and fibronectin type III domain-containing protein 1-like protein

S4_24h

LRRs
-5.147401101

[Crassostrea virginica]
-6.212337034

leucine-rich repeat and fibronectin type III domain-containing protein 1-like protein

RI_24h

[Crassostrea virginica]
-21.92443052

leucine-rich repeat and fibronectin type-III domain-containing protein 5-like isoform X1

RI_24h
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[Crassostrea virginica]
9.844842922

leucine-rich repeat transmembrane neuronal protein 3-like isoform X1 [Crassostrea

RI_6h

virginica]
20.97197566

leucine-rich repeat transmembrane neuronal protein 3-like isoform X1 [Crassostrea

RI_6h

virginica]
20.96078701

leucine-rich repeat transmembrane neuronal protein 3-like isoform X1 [Crassostrea
virginica]

RE22_6h
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-23.84553133

leucine-rich repeat transmembrane protein FLRT1-like [Crassostrea virginica]

S4_6h

-23.84658918

leucine-rich repeat transmembrane protein FLRT1-like [Crassostrea virginica]

S4_24h

-23.04060289

leucine-rich repeat-containing protein 24-like [Crassostrea virginica]

S4_24h

-15.08871621

leucine-rich repeat-containing protein 24-like [Crassostrea virginica]

S4_24h

-8.156979152

leucine-rich repeat-containing protein 24-like [Crassostrea virginica]

S4_24h

20.08727174

leucine-rich repeat-containing protein 28-like isoform X3 [Crassostrea virginica]

S4_24h

6.821818096

leucine-rich repeat-containing protein 34-like isoform X2 [Crassostrea virginica]

S4_6h

-23.06503275

leucine-rich repeat-containing protein 45-like [Crassostrea virginica]

S4_24h

-23.72912188

leucine-rich repeat-containing protein 45-like [Crassostrea virginica]

RI_24h

22.71972652

leucine-rich repeat-containing protein 4C-like isoform X1 [Crassostrea virginica]

S4_6h

20.7202629

leucine-rich repeat-containing protein 4C-like isoform X1 [Crassostrea virginica]

RI_6h

22.88621537

leucine-rich repeat-containing protein 4C-like isoform X1 [Crassostrea virginica]

RI_24h

-24.40103127

leucine-rich repeat-containing protein 70-like [Crassostrea virginica]

S4_24h

-25.58565569

leucine-rich repeat-containing protein 71-like isoform X21 [Crassostrea virginica]

S4_24h

184

-11.00397714

leucine-rich repeat-containing protein 74A-like isoform X2 [Crassostrea virginica]

S4_6h

-11.92749456

leucine-rich repeat-containing protein 74A-like isoform X2 [Crassostrea virginica]

S4_6h

-22.72669381

leucine-rich repeat-containing protein 74B-like [Crassostrea virginica]

S4_24h

-23.52071418

leucine-rich repeat-containing protein 74B-like [Crassostrea virginica]

RI_24h

5.554434603

leucine-rich repeat-containing protein 74B-like isoform X6 [Crassostrea virginica]

S4_6h

7.401747777

leucine-rich repeat-containing protein 74B-like isoform X6 [Crassostrea virginica]

S4_24h

-23.01756736

leucine-rich repeat-containing protein 9-like isoform X2 [Crassostrea virginica]

RI_6h

-5.5609716

leucine-rich repeat-containing protein 9-like isoform X2 [Crassostrea virginica]

RI_6h

-5.297693704

leucine-rich repeat-containing protein 9-like isoform X2 [Crassostrea virginica]

RE22_6h

Fibronectin type III domain
-4.785308683

fibronectin type III domain-containing protein 1-like [Crassostrea virginica]

S4_24h

-23.90865588

fibronectin type III domain-containing protein 2-like isoform X3 [Crassostrea virginica]

RI_24h

-22.69764157

fibronectin type III domain-containing protein 2-like isoform X3 [Crassostrea virginica]

RI_24h

-24.13260348

fibronectin type III domain-containing protein 2-like isoform X3 [Crassostrea virginica]

RE22_6h

C1q proteins
-28.16031439

complement C1q tumor necrosis factor-related protein 4-like isoform X3 [Crassostrea

RI_6h

virginica]

185

-2.942969529

complement C1q-like protein 2 [Crassostrea virginica]

S4_6h

-2.720935883

complement C1q-like protein 2 [Crassostrea virginica]

RE22_6h

-4.990716982

complement C1q-like protein 4 [Crassostrea virginica]

RE22_6h

-27.07147054

alpha-1-macroglobulin-like [Crassostrea virginica]

S4_6h

-27.09597681

alpha-1-macroglobulin-like [Crassostrea virginica]

S4_24h

-4.827641592

alpha-1-macroglobulin-like [Crassostrea virginica]

S4_24h

-16.82943987

Macrophage mannose receptor 1 [Crassostrea gigas]

S4_24h

-23.67745527

macrophage mannose receptor 1-like isoform X1 [Crassostrea virginica]

RI_24h

Metabolic Enzymes with New Role of Carbohydrate Binding
-3.019898078

Phosphoenolpyruvate carboxykinase

S4_24h

20.50362782

hexokinase-2-like isoform X2 [Crassostrea virginica]

S4_6h

186

-27.8856754

hexokinase-2-like isoform X2 [Crassostrea virginica]

RI_6h

-24.29212676

hexokinase-2-like isoform X2 [Crassostrea virginica]

RI_6h

10.04796022

hexokinase-2-like isoform X2 [Crassostrea virginica]

RI_6h

20.45474609

hexokinase-2-like isoform X2 [Crassostrea virginica]

RI_6h

-27.93663561

hexokinase-2-like isoform X2 [Crassostrea virginica]

RI_24h

-28.20643409

hexokinase-2-like isoform X2 [Crassostrea virginica]

RE22_6h

-24.71581303

hexokinase-2-like isoform X2 [Crassostrea virginica]

RE22_6h

11.04164794

hexokinase-2-like isoform X2 [Crassostrea virginica]

RE22_6h

21.25153221

hexokinase-2-like isoform X2 [Crassostrea virginica]

RE22_6h

Cholinergic immunomodulation
2.908686031

glutamate receptor 2-like [Crassostrea virginica]

RI_6h

-23.53192783

glutamate receptor ionotropic

S4_24h

-8.851813981

glutamate receptor ionotropic

S4_24h

-26.48442583

glutamate receptor ionotropic

RI_6h

187

-22.22604191

glutamate receptor ionotropic

RE22_6h

20.55673148

glutamate receptor-interacting protein 1-like isoform X4 [Crassostrea virginica]

RI_24h

7.766510402

muscarinic acetylcholine receptor M3-like [Crassostrea virginica]

RE22_6h

-23.96329241

neuronal acetylcholine receptor subunit alpha-2-like [Crassostrea virginica]

RE22_6h

10.39346971

neuronal acetylcholine receptor subunit alpha-5-like isoform X1 [Crassostrea virginica]

RE22_6h

21.77501036

neuronal acetylcholine receptor subunit alpha-9-like [Crassostrea virginica]

S4_24h

21.26581499

neuronal acetylcholine receptor subunit alpha-9-like [Crassostrea virginica]

RI_24h

-23.03542166

neuronal acetylcholine receptor subunit alpha-9-like [Crassostrea virginica]

S4_24h

-4.54262089

neuropeptide SIFamide receptor-like [Crassostrea virginica]

S4_6h

-23.60128855

neuropeptide Y receptor type 2-like [Crassostrea virginica]

RE22_6h

Signaling pathways in Immune response
-11.1762089

TNF receptor-associated factor 3-like isoform X3 [Crassostrea virginica]

S4_6h

-9.894522176

TNF receptor-associated factor 4-like isoform X5 [Crassostrea virginica]

RE22_6h

24.64790366

LOW QUALITY PROTEIN: tyrosine-protein kinase JAK2-like [Crassostrea virginica]

S4_6h

188

-23.39582662

LOW QUALITY PROTEIN: tyrosine-protein kinase JAK2-like [Crassostrea virginica]

S4_24h

-4.478976796

LOW QUALITY PROTEIN: tyrosine-protein kinase JAK2-like [Crassostrea virginica]

S4_24h

-21.85010489

LOW QUALITY PROTEIN: tyrosine-protein kinase JAK2-like [Crassostrea virginica]

RI_6h

25.29177394

LOW QUALITY PROTEIN: tyrosine-protein kinase JAK2-like [Crassostrea virginica]

RI_24h

24.11940272

LOW QUALITY PROTEIN: tyrosine-protein kinase JAK2-like [Crassostrea virginica]

RE22_6h

-7.662488479

signal transducer and activator of transcription 3-like isoform X6 [Crassostrea virginica]

RI_24h

-26.82508167

LOW QUALITY PROTEIN: son of sevenless homolog 2-like [Crassostrea virginica]

RE22_6h

-20.08059767

LOW QUALITY PROTEIN: son of sevenless homolog 2-like [Crassostrea virginica]

S4_24h

-20.7042899

LOW QUALITY PROTEIN: son of sevenless homolog 2-like [Crassostrea virginica]

RI_24h

-21.98909234

epidermal growth factor receptor-like [Crassostrea virginica]

S4_24h

-21.85708608

epidermal growth factor receptor-like isoform X2 [Crassostrea virginica]

S4_6h

-22.21636099

epidermal growth factor receptor-like isoform X2 [Crassostrea virginica]

RI_24h

3.582236878

epidermal growth factor receptor-like isoform X2 [Crassostrea virginica]

S4_6h

-26.61502073

epidermal growth factor receptor-like isoform X4 [Crassostrea virginica]

S4_24h

4.440719006

epidermal growth factor receptor-like isoform X4 [Crassostrea virginica]

S4_24h

4.780146091

PREDICTED: tyrosine-protein phosphatase non-receptor type 11 isoform X3

S4_6h

[Crassostrea gigas]
-24.59389772

tyrosine-protein phosphatase non-receptor type 13-like isoform X3 [Crassostrea

S4_6h

virginica]
-21.79438105

tyrosine-protein phosphatase non-receptor type 13-like isoform X3 [Crassostrea

S4_6h

virginica]
189

-21.90808833

tyrosine-protein phosphatase non-receptor type 13-like isoform X3 [Crassostrea

S4_24h

virginica]
-23.41598784

tyrosine-protein phosphatase non-receptor type 23-like isoform X1 [Crassostrea

S4_6h

virginica]
20.99622685

tyrosine-protein phosphatase non-receptor type 23-like isoform X1 [Crassostrea
virginica]

S4_6h

20.32249114

tyrosine-protein phosphatase non-receptor type 23-like isoform X1 [Crassostrea

S4_24h

virginica]
21.72359644

tyrosine-protein phosphatase non-receptor type 23-like isoform X1 [Crassostrea

RI_6h

virginica]
22.3115501

tyrosine-protein phosphatase non-receptor type 23-like isoform X1 [Crassostrea

RI_24h

virginica]
20.18049393

tyrosine-protein phosphatase non-receptor type 23-like isoform X1 [Crassostrea

RE22_6h

190

virginica]
19.62125156

tyrosine-protein phosphatase non-receptor type 4-like isoform X4 [Crassostrea

S4_6h

virginica]
21.66755905

tyrosine-protein phosphatase non-receptor type 4-like isoform X4 [Crassostrea

S4_24h

virginica]
23.55240592

tyrosine-protein phosphatase non-receptor type 4-like isoform X4 [Crassostrea
virginica]

RI_6h

22.38124103

tyrosine-protein phosphatase non-receptor type 4-like isoform X4 [Crassostrea

RI_24h

virginica]
23.05607193

tyrosine-protein phosphatase non-receptor type 4-like isoform X4 [Crassostrea

RE22_6h

virginica]
-10.65160003

tyrosine-protein phosphatase non-receptor type 4-like isoform X6 [Crassostrea

S4_6h

virginica]
-10.6365949

tyrosine-protein phosphatase non-receptor type 4-like isoform X6 [Crassostrea

S4_24h

191

virginica]
-8.931960108

tyrosine-protein phosphatase non-receptor type 4-like isoform X6 [Crassostrea

RE22_6h

virginica]
-24.13233234

tyrosine-protein phosphatase non-receptor type 9-like isoform X2 [Crassostrea

RI_24h

virginica]
-23.73611409

NF-kappa-B inhibitor alpha-like isoform X1 [Crassostrea virginica]

S4_6h

-9.500032383

NF-kappa-B inhibitor alpha-like isoform X1 [Crassostrea virginica]

RI_6h

192

-9.657932705

NF-kappa-B inhibitor alpha-like isoform X1 [Crassostrea virginica]

RE22_6h

-24.81953437

NF-kappa-B-activating protein-like [Crassostrea virginica]

S4_6h

-24.69597209

NF-kappa-B-activating protein-like [Crassostrea virginica]

S4_24h

-24.42843374

NF-kappa-B-activating protein-like [Crassostrea virginica]

S4_24h

-23.65126954

NF-kappa-B-activating protein-like [Crassostrea virginica]

S4_24h

-24.77085054

NF-kappa-B-activating protein-like [Crassostrea virginica]

RI_6h

-25.40980564

NF-kappa-B-activating protein-like [Crassostrea virginica]

RI_24h

-24.86565855

NF-kappa-B-activating protein-like [Crassostrea virginica]

RI_24h

-25.18633897

NF-kappa-B-activating protein-like [Crassostrea virginica]

RE22_6h

-21.62114724

smad nuclear interacting protein 1-like [Crassostrea virginica]

S4_6h

-22.01002997

smad nuclear interacting protein 1-like [Crassostrea virginica]

RI_6h

22.23806571

TNFAIP3-interacting protein 1-like [Crassostrea virginica]

RI_6h

23.32946941

TNFAIP3-interacting protein 1-like [Crassostrea virginica]

RE22_6h

3.669180885

PREDICTED: B-cell lymphoma/leukemia 10-like [Crassostrea gigas]

S4_6h

193

5.125890801

PREDICTED: B-cell lymphoma/leukemia 10-like [Crassostrea gigas]

S4_24h

-24.48845992

ELKS/Rab6-interacting/CAST family member 1-like isoform X3 [Crassostrea virginica] RI_6h

-24.52498266

ELKS/Rab6-interacting/CAST family member 1-like isoform X3 [Crassostrea virginica] RI_24h

22.90392037

ELKS/Rab6-interacting/CAST family member 1-like isoform X5 [Crassostrea virginica] S4_24h

21.99071309

ELKS/Rab6-interacting/CAST family member 1-like isoform X5 [Crassostrea virginica] RI_24h

21.29621653

adapter protein CIKS-like [Crassostrea virginica]

S4_6h

21.89981234

adapter protein CIKS-like [Crassostrea virginica]

S4_24h

19.10179883

adapter protein CIKS-like [Crassostrea virginica]

RI_6h

21.9145228

adapter protein CIKS-like [Crassostrea virginica]

RI_24h

21.96174137

adapter protein CIKS-like [Crassostrea virginica]

RE22_6h

-21.68449844

adapter protein CIKS-like isoform X4 [Crassostrea virginica]

RI_24h

-5.87337841

PREDICTED: dual specificity mitogen-activated protein kinase kinase 1-like isoform

RI_24h

X1 [Crassostrea gigas]
-25.72060852

MAP kinase-activated protein kinase 2-like isoform X2 [Crassostrea virginica]

RI_24h

-2.470755161

mitogen-activated protein kinase kinase kinase 13-like isoform X2 [Crassostrea

S4_24h

virginica]
-24.25502986

mitogen-activated protein kinase kinase kinase 13-like isoform X2 [Crassostrea

RI_24h

virginica]

194

-7.716909755

Mitogen-activated protein kinase kinase kinase 7 [Crassostrea gigas]

-21.70047837

mitogen-activated protein kinase kinase kinase 7-like isoform X3 [Crassostrea virginica] S4_6h

-2.753446313

mitogen-activated protein kinase kinase kinase 7-like isoform X3 [Crassostrea virginica] S4_6h

22.14143778

mitogen-activated protein kinase kinase kinase 7-like isoform X3 [Crassostrea virginica] S4_6h

-21.62740093

mitogen-activated protein kinase kinase kinase 7-like isoform X3 [Crassostrea virginica] S4_24h

21.84933712

mitogen-activated protein kinase kinase kinase 7-like isoform X3 [Crassostrea virginica] RI_6h

-3.340398882

mitogen-activated protein kinase kinase kinase 7-like isoform X3 [Crassostrea virginica] RI_24h

-22.1261532

mitogen-activated protein kinase kinase kinase 7-like isoform X3 [Crassostrea virginica] RE22_6h

20.30696981

dual specificity mitogen-activated protein kinase kinase 7-like isoform X1 [Crassostrea
virginica]

RI_6h

S4_6h

21.95392224

dual specificity mitogen-activated protein kinase kinase 7-like isoform X1 [Crassostrea

S4_24h

virginica]
21.12567936

dual specificity mitogen-activated protein kinase kinase 7-like isoform X1 [Crassostrea

RI_6h

virginica]
-18.51291804

dual specificity mitogen-activated protein kinase kinase 7-like isoform X1 [Crassostrea

RI_24h

virginica]
22.55409809

dual specificity mitogen-activated protein kinase kinase 7-like isoform X1 [Crassostrea

RE22_6h

195

virginica]
-10.42721287

LOW QUALITY PROTEIN: mitogen-activated protein kinase 14A-like [Crassostrea

RI_6h

virginica]
-22.51874945

LOW QUALITY PROTEIN: mitogen-activated protein kinase kinase kinase kinase 3-

S4_24h

like [Crassostrea virginica]
-23.17120745

LOW QUALITY PROTEIN: mitogen-activated protein kinase kinase kinase kinase 3like [Crassostrea virginica]

RI_24h

7.880002894

transforming growth factor-beta, partial [Crassostrea ariakensis]

RI_24h

6.414756431

transforming growth factor-beta, partial [Crassostrea ariakensis]

S4_24h

-24.5406632

LOW QUALITY PROTEIN: C-Jun-amino-terminal kinase-interacting protein 4-like

S4_24h

[Crassostrea virginica]
-23.28637433

LOW QUALITY PROTEIN: C-Jun-amino-terminal kinase-interacting protein 4-like

S4_24h

[Crassostrea virginica]

196

8.201025972

extracellular signal-regulated kinase 2-like isoform X4 [Crassostrea virginica]

RI_24h

-22.50186319

stimulator of interferon genes protein-like [Crassostrea virginica]

S4_6h

20.17836595

stimulator of interferon genes protein-like [Crassostrea virginica]

S4_6h

-16.95226096

stimulator of interferon genes protein-like [Crassostrea virginica]

S4_24h

-7.478972473

stimulator of interferon genes protein-like [Crassostrea virginica]

RI_6h

17.42282629

stimulator of interferon genes protein-like [Crassostrea virginica]

RI_6h

20.17813132

stimulator of interferon genes protein-like [Crassostrea virginica]

RI_24h

20.42313211

stimulator of interferon genes protein-like [Crassostrea virginica]

RE22_6h

197

-6.713339842

death domain-containing protein 1-like [Crassostrea virginica]

S4_6h

-6.937781661

death domain-containing protein 1-like [Crassostrea virginica]

S4_24h

-4.130539001

death domain-containing protein 1-like [Crassostrea virginica]

RI_6h

-6.57016357

death domain-containing protein 1-like [Crassostrea virginica]

RE22_6h

21.29117555

death domain-containing protein CRADD-like [Crassostrea virginica]

S4_6h

19.33282647

death domain-containing protein CRADD-like [Crassostrea virginica]

RI_6h

21.07018009

death domain-containing protein CRADD-like [Crassostrea virginica]

RE22_6h

19.40341779

integrin alpha-4-like isoform X1 [Crassostrea virginica]

S4_24h

20.6821385

integrin alpha-4-like isoform X1 [Crassostrea virginica]

RI_24h

-2.282127264

integrin beta-3-like [Crassostrea virginica]

S4_24h

11.0047672

ubiquitin carboxyl-terminal hydrolase 14-like [Mizuhopecten yessoensis]

S4_6h

21.44939539

ubiquitin carboxyl-terminal hydrolase 14-like [Mizuhopecten yessoensis]

S4_24h

11.5782336

ubiquitin carboxyl-terminal hydrolase 14-like [Mizuhopecten yessoensis]

RI_6h

21.74942278

ubiquitin carboxyl-terminal hydrolase 14-like [Mizuhopecten yessoensis]

RI_24h

11.12138173

ubiquitin carboxyl-terminal hydrolase 14-like [Mizuhopecten yessoensis]

RE22_6h

-24.21434106

ubiquitin carboxyl-terminal hydrolase 20-like isoform X2 [Crassostrea virginica]

S4_24h

22.53788386

ubiquitin carboxyl-terminal hydrolase 25-like isoform X3 [Crassostrea virginica]

S4_6h

19.53896908

ubiquitin carboxyl-terminal hydrolase 25-like isoform X3 [Crassostrea virginica]

S4_24h

21.61706409

ubiquitin carboxyl-terminal hydrolase 25-like isoform X3 [Crassostrea virginica]

RI_6h

21.55529349

ubiquitin carboxyl-terminal hydrolase 25-like isoform X3 [Crassostrea virginica]

RI_24h

22.99322029

ubiquitin carboxyl-terminal hydrolase 25-like isoform X3 [Crassostrea virginica]

RE22_6h

198

Effectors
-7.636639706

serine protease 44-like [Crassostrea virginica]

S4_24h

21.50670849

serine protease inhibitor Cvsi-2-like [Crassostrea virginica]

S4_6h

12.83482328

serine protease inhibitor Cvsi-2-like [Crassostrea virginica]

S4_24h

21.11968406

serine protease inhibitor Cvsi-2-like [Crassostrea virginica]

RI_6h

20.26304644

serine protease inhibitor Cvsi-2-like [Crassostrea virginica]

RI_24h

28.4447526

serine protease inhibitor dipetalogastin-like [Crassostrea virginica]

S4_6h

199

22.31014239

serine protease inhibitor dipetalogastin-like [Crassostrea virginica]

RI_24h

15.3518296

serine protease inhibitor dipetalogastin-like [Crassostrea virginica]

S4_24h

-22.79409461

kunitz-type protease inhibitor 1-like [Crassostrea virginica]

S4_6h

20.0825116

LOW QUALITY PROTEIN: digestive cysteine proteinase 2-like [Crassostrea virginica]

S4_6h

20.26000192

LOW QUALITY PROTEIN: digestive cysteine proteinase 2-like [Crassostrea virginica]

S4_24h

21.99420619

LOW QUALITY PROTEIN: digestive cysteine proteinase 2-like [Crassostrea virginica]

RI_6h

19.1215388

LOW QUALITY PROTEIN: digestive cysteine proteinase 2-like [Crassostrea virginica]

RI_24h

-23.58012026

Signaling mucin HKR1 [Mizuhopecten yessoensis]

S4_6h

-23.80421719

Signaling mucin HKR1 [Mizuhopecten yessoensis]

S4_24h

-9.356963695

Signaling mucin HKR1 [Mizuhopecten yessoensis]

S4_24h

-24.38357841

Signaling mucin HKR1 [Mizuhopecten yessoensis]

RI_6h

-21.90572271

Signaling mucin HKR1 [Mizuhopecten yessoensis]

RI_6h

-16.19910691

Signaling mucin HKR1 [Mizuhopecten yessoensis]

RI_24h

-24.51441136

Signaling mucin HKR1 [Mizuhopecten yessoensis]

RE22_6h

200

-2.369460824

integumentary mucin C.1-like [Crassostrea virginica]

S4_24h

3.541415795

integumentary mucin C.1-like [Crassostrea virginica]

RI_24h

21.31111159

integumentary mucin C.1-like isoform X1 [Crassostrea virginica]

S4_24h

-15.40397187

integumentary mucin C.1-like isoform X1 [Crassostrea virginica]

RI_24h

-23.4017782

integumentary mucin C.1-like isoform X3 [Crassostrea virginica]

S4_24h

-24.11558579

integumentary mucin C.1-like isoform X3 [Crassostrea virginica]

RI_6h

15.84736053

LOW QUALITY PROTEIN: mucin-12-like [Crassostrea virginica]

S4_6h

19.8605114

LOW QUALITY PROTEIN: mucin-12-like [Crassostrea virginica]

S4_24h

21.24020302

LOW QUALITY PROTEIN: mucin-12-like [Crassostrea virginica]

RI_6h

20.3172585

LOW QUALITY PROTEIN: mucin-12-like [Crassostrea virginica]

RI_24h

20.50006596

LOW QUALITY PROTEIN: mucin-12-like [Crassostrea virginica]

RE22_6h

-25.58549501

mucin-17-like isoform X2 [Crassostrea virginica]

S4_6h

-22.60499384

mucin-17-like isoform X2 [Crassostrea virginica]

S4_24h

-23.3302576

mucin-17-like isoform X2 [Crassostrea virginica]

RI_24h

201

-12.40357314

mucin-2-like [Crassostrea virginica]

RE22_6h

3.74775207

mucin-3B-like isoform X4 [Crassostrea virginica]

S4_6h

4.020665081

mucin-3B-like isoform X4 [Crassostrea virginica]

S4_6h

-22.20357216

mucin-3B-like isoform X4 [Crassostrea virginica]

S4_24h

3.986726111

mucin-3B-like isoform X4 [Crassostrea virginica]

RI_6h

4.460044136

mucin-3B-like isoform X4 [Crassostrea virginica]

RI_24h

-10.73484035

mucin-3B-like isoform X4 [Crassostrea virginica]

S4_24h

-23.44462362

mucin-4-like isoform X7 [Crassostrea virginica]

S4_24h

-6.728200181

mucin-4-like isoform X8 [Crassostrea virginica]

RI_6h

19.8087086

mucin-5AC-like [Crassostrea virginica]

S4_24h

24.20835013

mucin-5AC-like [Crassostrea virginica]

RI_24h

-23.63449535

mucin-5AC-like isoform X2 [Crassostrea virginica]

S4_24h

-25.71724187

mucin-5AC-like isoform X5 [Crassostrea virginica]

S4_24h

-25.5565658

mucin-5AC-like isoform X5 [Crassostrea virginica]

S4_24h

202

-25.02710707

mucin-5AC-like isoform X5 [Crassostrea virginica]

S4_24h

-24.9869002

mucin-5AC-like isoform X5 [Crassostrea virginica]

S4_24h

-24.55559512

mucin-5AC-like isoform X5 [Crassostrea virginica]

S4_24h

20.15216503

macrophage-expressed gene 1 protein-like [Crassostrea virginica]

S4_6h

-23.12210565

macrophage-expressed gene 1 protein-like [Crassostrea virginica]

S4_24h

21.2588995

macrophage-expressed gene 1 protein-like [Crassostrea virginica]

S4_24h

21.13829677

macrophage-expressed gene 1 protein-like [Crassostrea virginica]

RI_6h

19.19639966

macrophage-expressed gene 1 protein-like [Crassostrea virginica]

RI_24h

-25.14528973

antistasin-like [Crassostrea virginica]

RI_6h

-25.22546326

antistasin-like [Crassostrea virginica]

RI_24h

-8.191296146

cystatin-A-like [Crassostrea virginica]

RI_24h

Apoptosis
-6.21042132

caspase-1-like [Crassostrea virginica]

S4_24h

20.95052586

caspase-1-like [Crassostrea virginica]

S4_6h
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20.96735265

caspase-1-like [Crassostrea virginica]

S4_24h

21.36960577

caspase-1-like [Crassostrea virginica]

RI_6h

21.94629746

caspase-1-like [Crassostrea virginica]

RI_24h

20.13240973

caspase-1-like [Crassostrea virginica]

RE22_6h

8.059692737

caspase-3-like isoform X2 [Crassostrea virginica]

S4_6h

-22.07884074

caspase-3-like isoform X2 [Crassostrea virginica]

S4_24h

19.83057052

caspase-3-like isoform X2 [Crassostrea virginica]

S4_24h

-8.724115052

caspase-3-like isoform X2 [Crassostrea virginica]

RI_24h

18.89735984

caspase-3-like isoform X2 [Crassostrea virginica]

RI_24h

5.865260258

caspase-6-like [Crassostrea virginica]

RI_6h

6.332228555

caspase-6-like [Crassostrea virginica]

RE22_6h

-11.6773146

caspase-6-like isoform X2 [Crassostrea virginica]

S4_24h

-8.871803044

caspase-6-like isoform X2 [Crassostrea virginica]

S4_24h

3.340083172

caspase-6-like isoform X2 [Crassostrea virginica]

S4_24h
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-12.17173082

caspase-6-like isoform X2 [Crassostrea virginica]

RI_24h

-8.404424419

caspase-6-like isoform X2 [Crassostrea virginica]

RI_24h

3.27853441

caspase-6-like isoform X2 [Crassostrea virginica]

RI_24h

18.19169296

caspase-7-like [Crassostrea virginica]

S4_6h

19.24463486

caspase-7-like [Crassostrea virginica]

RI_6h

19.8989936

caspase-7-like [Crassostrea virginica]

RE22_6h

-7.554426297

caspase-7-like isoform X1 [Crassostrea virginica]

S4_6h

-6.02479199

caspase-7-like isoform X1 [Crassostrea virginica]

S4_24h

-6.826149987

caspase-7-like isoform X1 [Crassostrea virginica]

RI_24h

-6.880726858

caspase-7-like isoform X1 [Crassostrea virginica]

RE22_6h

-21.01107236

caspase-7-like isoform X3 [Crassostrea virginica]

RI_24h

-21.23808674

caspase-7-like isoform X3 [Crassostrea virginica]

RE22_6h

-25.94532375

baculoviral IAP repeat-containing protein 2-like [Crassostrea virginica]

S4_24h

-26.32635634

baculoviral IAP repeat-containing protein 2-like [Crassostrea virginica]

RE22_6h
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-24.35012269

baculoviral IAP repeat-containing protein 3-like [Crassostrea virginica]

S4_24h

19.47455056

baculoviral IAP repeat-containing protein 3-like isoform X1 [Crassostrea virginica]

S4_6h

19.10971772

baculoviral IAP repeat-containing protein 3-like isoform X1 [Crassostrea virginica]

RI_6h

21.20706554

baculoviral IAP repeat-containing protein 3-like isoform X1 [Crassostrea virginica]

RE22_6h

-11.87771995

baculoviral IAP repeat-containing protein 6-like isoform X5 [Crassostrea virginica]

S4_6h

-6.7526098

baculoviral IAP repeat-containing protein 6-like isoform X5 [Crassostrea virginica]

S4_6h

-23.00355415

baculoviral IAP repeat-containing protein 7-A-like isoform X2 [Crassostrea virginica]

RI_24h

-23.45580618

baculoviral IAP repeat-containing protein 7-A-like isoform X2 [Crassostrea virginica]

RI_24h

18.88003432

putative inhibitor of apoptosis [Crassostrea virginica]

RE22_6h

20.38877928

putative inhibitor of apoptosis [Crassostrea virginica]

RI_6h

20.544862

putative inhibitor of apoptosis [Crassostrea virginica]

S4_6h

20.82027693

putative inhibitor of apoptosis [Crassostrea virginica]

RI_24h

21.23594337

putative inhibitor of apoptosis [Crassostrea virginica]

S4_24h

-21.79877969

bifunctional apoptosis regulator-like isoform X1 [Crassostrea virginica]

S4_6h
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-21.84056799

bifunctional apoptosis regulator-like isoform X1 [Crassostrea virginica]

S4_24h

-4.862913449

apoptogenic protein 1

RI_6h

-22.71920742

cathepsin L-like isoform X2 [Crassostrea virginica]

S4_24h

-25.24123094

cathepsin L-like isoform X2 [Crassostrea virginica]

RI_6h

-22.92152325

cathepsin O-like [Crassostrea virginica]

S4_6h

-24.09391392

programmed cell death 6-interacting protein-like isoform X3 [Crassostrea virginica]

S4_24h

-7.976483879

programmed cell death protein 6-like isoform X2 [Crassostrea virginica]

S4_6h

23.29208898

XK-related protein 6-like [Crassostrea virginica]

RI_6h

24.85645254

XK-related protein 6, partial [Stegodyphus mimosarum]

RE22_6h

8.288290515

XK-related protein 6, partial [Stegodyphus mimosarum]

RI_6h

20.4704348

XK-related protein 6, partial [Stegodyphus mimosarum]

S4_6h

24.25694523

XK-related protein 6, partial [Stegodyphus mimosarum]

RI_24h

23.1394026

XK-related protein 6, partial [Stegodyphus mimosarum]

S4_24h

19.26657006

XK-related protein 8-like isoform X2 [Crassostrea virginica]

RE22_6h

20.93957528

XK-related protein 8-like isoform X2 [Crassostrea virginica]

RI_6h

19.66346021

XK-related protein 8-like isoform X2 [Crassostrea virginica]

S4_6h

4.704739877

cell death-inducing p53-target protein 1-like isoform X5 [Crassostrea virginica]

S4_6h

7.038385691

cell death-inducing p53-target protein 1-like isoform X5 [Crassostrea virginica]

S4_24h

Autophagy
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19.68063935

autophagy-related protein 9A-like isoform X1 [Crassostrea virginica]

S4_6h

22.23975139

autophagy-related protein 9A-like isoform X1 [Crassostrea virginica]

S4_6h

19.00211451

autophagy-related protein 9A-like isoform X1 [Crassostrea virginica]

S4_24h

20.33463466

autophagy-related protein 9A-like isoform X1 [Crassostrea virginica]

S4_24h

20.2328524

autophagy-related protein 9A-like isoform X1 [Crassostrea virginica]

RI_6h

22.04434718

autophagy-related protein 9A-like isoform X1 [Crassostrea virginica]

RI_6h

17.69258697

autophagy-related protein 9A-like isoform X1 [Crassostrea virginica]

RI_24h

19.97079557

autophagy-related protein 9A-like isoform X1 [Crassostrea virginica]

RI_24h

17.464467

autophagy-related protein 9A-like isoform X1 [Crassostrea virginica]

RE22_6h
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20.11113826

autophagy-related protein 9A-like isoform X1 [Crassostrea virginica]

RE22_6h

-22.38835903

transcription factor SPT20 homolog isoform X1 [Crassostrea virginica]

S4_6h

-22.81940536

transcription factor SPT20 homolog isoform X1 [Crassostrea virginica]

RI_6h

-23.79270551

vacuole membrane protein 1-like [Crassostrea virginica]

S4_6h

-24.49304386

vacuole membrane protein 1-like [Crassostrea virginica]

RI_6h

-22.8200889

PREDICTED: protein kinase C delta type [Crassostrea gigas]

S4_24h

-23.97489076

PREDICTED: protein kinase C delta type [Crassostrea gigas]

RI_24h

20.26349909

DNA damage-regulated autophagy modulator protein 1-like [Crassostrea virginica]

S4_6h

20.91174474

DNA damage-regulated autophagy modulator protein 1-like [Crassostrea virginica]

S4_24h

20.84051785

DNA damage-regulated autophagy modulator protein 1-like [Crassostrea virginica]

RE22_6h

-6.547974505

run domain Beclin-1-interacting and cysteine-rich domain-containing protein-like

S4_24h

isoform X3 [Crassostrea virginica]
20.7845565

phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform-like
isoform X1 [Crassostrea virginica]

S4_6h

21.39532399

phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform-like

S4_24h

isoform X1 [Crassostrea virginica]
22.58624048

phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform-like

RI_6h

isoform X1 [Crassostrea virginica]
21.22674556

phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform-like

RI_24h

isoform X1 [Crassostrea virginica]
22.60384771

phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform-like

RE22_6h
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isoform X1 [Crassostrea virginica]
Phagosome
-11.04839433

Actin, cytoplasmic [Crassostrea gigas]

S4_6h

-22.15040686

actin-3-like isoform X1 [Crassostrea virginica]

S4_6h

-23.28807439

actin-3-like isoform X1 [Crassostrea virginica]

RI_6h

-2.009714808

actin-like [Crassostrea virginica]

S4_24h

-25.67615427

cytoplasmic dynein 1 heavy chain 1-like isoform X1 [Crassostrea virginica]

S4_6h

-24.78846969

cytoplasmic dynein 1 heavy chain 1-like isoform X1 [Crassostrea virginica]

S4_24h

-18.35355926

cytoplasmic dynein 1 light intermediate chain 2-like isoform X11 [Crassostrea

S4_6h

virginica]
-23.99337051

cytoplasmic dynein 1 light intermediate chain 2-like isoform X11 [Crassostrea

S4_24h

virginica]
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20.46400243

cytoplasmic dynein 2 light intermediate chain 1-like [Crassostrea virginica]

S4_6h

19.94858466

cytoplasmic dynein 2 light intermediate chain 1-like [Crassostrea virginica]

S4_24h

19.68213706

cytoplasmic dynein 2 light intermediate chain 1-like [Crassostrea virginica]

RI_6h

20.2666716

cytoplasmic dynein 2 light intermediate chain 1-like [Crassostrea virginica]

RI_24h

19.56136995

cytoplasmic dynein 2 light intermediate chain 1-like [Crassostrea virginica]

RE22_6h

22.04398056

cation-dependent mannose-6-phosphate receptor-like [Crassostrea virginica]

S4_6h

-6.510608147

cation-dependent mannose-6-phosphate receptor-like [Crassostrea virginica]

RI_6h

22.65257645

cation-dependent mannose-6-phosphate receptor-like [Crassostrea virginica]

RI_6h

22.2320337

cation-dependent mannose-6-phosphate receptor-like [Crassostrea virginica]

RI_24h

21.24015816

cation-dependent mannose-6-phosphate receptor-like [Crassostrea virginica]

RE22_6h

-26.35735397

lysosomal-associated transmembrane protein 4A-like [Crassostrea virginica]

S4_6h

-27.83132813

lysosomal-associated transmembrane protein 4A-like [Crassostrea virginica]

RI_24h

-5.595601397

lysosomal acid lipase/cholesteryl ester hydrolase-like [Crassostrea virginica]

RI_6h

Lysosome

Endocytosis & Peroxisome
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7.204505845

AP-2 complex subunit mu-1 [Crassostrea gigas]

RI_24h

8.234098827

probable peroxisomal membrane protein PEX13 [Crassostrea virginica]

S4_6h

7.151949067

probable peroxisomal membrane protein PEX13 [Crassostrea virginica]

S4_24h

-24.32891036

peroxisomal acyl-coenzyme A oxidase 1-like [Crassostrea virginica]

RI_24h

-23.1387346

peroxisomal acyl-coenzyme A oxidase 1-like [Crassostrea virginica]

S4_24h

-23.64616222

peroxisomal acyl-coenzyme A oxidase 1-like [Crassostrea virginica]

RI_24h

-6.184641444

peroxisomal acyl-coenzyme A oxidase 1-like isoform X2 [Crassostrea virginica]

S4_24h

Antioxidant enzymes

-3.86662093

glutathione peroxidase 7-like [Crassostrea virginica]

S4_24h

-21.14341297

glutathione S-transferase C-terminal domain-containing protein-like isoform X1

S4_24h

[Crassostrea virginica]
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4.340577781

glutathione S-transferase kappa 1-like [Crassostrea virginica]

RI_6h

-21.74743898

maleylacetoacetate isomerase-like [Crassostrea virginica]

S4_6h

-22.28036183

maleylacetoacetate isomerase-like [Crassostrea virginica]

RI_24h

-22.57607848

maleylacetoacetate isomerase-like [Crassostrea virginica]

RE22_6h

-9.092994732

Superoxide dismutase [Cu-Zn] [Crassostrea gigas]

S4_24h

24.656834

thioredoxin domain-containing protein 15-like [Crassostrea virginica]

S4_6h

22.08653805

thioredoxin domain-containing protein 15-like [Crassostrea virginica]

RE22_6h

-22.17861058

thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica]

S4_6h

-5.275085802

thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica]

S4_6h

-24.08250505

thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica]

S4_24h

-22.68468309

thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica]

S4_24h
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-15.3248519

thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica]

S4_24h

9.959973369

thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica]

S4_24h

19.68049721

thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica]

S4_24h

-22.94170493

thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica]

RI_6h

-24.96201578

thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica]

RI_24h

-24.87983434

thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica]

RI_24h

-22.95218203

thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica]

RI_24h

7.365024046

thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica]

RI_24h

18.02755971

thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica]

RI_24h

23.85507502

thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica]

RI_24h

-23.27838106

thioredoxin domain-containing protein 3 homolog isoform X15 [Crassostrea virginica]

RE22_6h

-2.096359322

thioredoxin domain-containing protein 5-like [Crassostrea virginica]

S4_24h

-25.88062202

thioredoxin-like [Crassostrea virginica]

S4_24h

-10.64240601

thioredoxin-like [Crassostrea virginica]

RI_6h

-26.51486203

thioredoxin-like [Crassostrea virginica]

RI_24h

-3.729163339

thioredoxin-like protein 1 [Crassostrea virginica]

RI_24h

3.293281563

thioredoxin-related transmembrane protein 1-like isoform X1 [Crassostrea virginica]

RI_6h

3.156411653

thioredoxin-related transmembrane protein 1-like isoform X1 [Crassostrea virginica]

RI_24h

-24.70491532

thioredoxin-related transmembrane protein 2 homolog [Crassostrea virginica]

RI_24h

-24.9360089

thioredoxin-related transmembrane protein 2 homolog [Crassostrea virginica]

RE22_6h

Acute phase proteins
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-9.723127722

Heat shock 70 kDa protein 12A [Crassostrea gigas]

S4_24h

5.535364462

heat shock 70 kDa protein 12A-like [Crassostrea virginica]

S4_24h

5.686282343

heat shock 70 kDa protein 12A-like [Crassostrea virginica]

RI_24h

-22.26223254

heat shock 70 kDa protein 12A-like [Crassostrea virginica]

RE22_6h

-23.79702313

heat shock 70 kDa protein 12A-like isoform X1 [Crassostrea virginica]

S4_6h

6.658680636

heat shock 70 kDa protein 12A-like isoform X1 [Crassostrea virginica]

S4_6h

5.254504823

heat shock 70 kDa protein 12A-like isoform X1 [Crassostrea virginica]

RI_6h
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5.250678277

heat shock 70 kDa protein 12A-like isoform X1 [Crassostrea virginica]

RE22_6h

-4.162351016

heat shock 70 kDa protein 12B-like [Crassostrea virginica]

RE22_6h

-23.06134796

heat shock 70 kDa protein 12B-like [Crassostrea virginica]

S4_24h

19.64075977

heat shock 70 kDa protein 12B-like isoform X4 [Crassostrea virginica]

S4_6h

19.49655284

heat shock 70 kDa protein 12B-like isoform X4 [Crassostrea virginica]

RI_6h

18.54456763

heat shock 70 kDa protein 12B-like isoform X4 [Crassostrea virginica]

RE22_6h

-22.43374437

heat shock factor protein-like [Crassostrea virginica]

RI_24h

-18.35638131

heat shock protein 30C-like [Crassostrea virginica]

S4_24h

3.254119893

heat shock protein HSP 90-beta-like [Crassostrea virginica]

S4_6h

Cytoskeletal organization
-24.67660059

PREDICTED: dynamin-1 isoform X2 [Crassostrea gigas]

S4_6h

-11.01417755

dynamin-1-like isoform X6 [Crassostrea virginica]

S4_6h

23.58398582

dynamin-1-like isoform X6 [Crassostrea virginica]

S4_6h

-21.25056055

dynamin-1-like isoform X6 [Crassostrea virginica]

S4_24h
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-23.67694566

dynamin-1-like isoform X6 [Crassostrea virginica]

RI_6h

23.2104963

dynamin-1-like isoform X6 [Crassostrea virginica]

RI_6h

-13.1405264

dynamin-1-like isoform X6 [Crassostrea virginica]

RI_24h

18.62495089

dynamin-1-like isoform X6 [Crassostrea virginica]

RE22_6h

9.249110026

PREDICTED: septin-7 isoform X3 [Crassostrea gigas]

S4_6h

9.161299284

PREDICTED: septin-7 isoform X3 [Crassostrea gigas]

RI_6h

-21.6896377

septin-11-like isoform X2 [Crassostrea virginica]

RE22_6h

-22.00129053

septin-2-like isoform X1 [Crassostrea virginica]

S4_6h

7.044855946

septin-2-like isoform X1 [Crassostrea virginica]

S4_6h

-21.88584245

septin-2-like isoform X1 [Crassostrea virginica]

S4_24h

-22.73608544

septin-2-like isoform X1 [Crassostrea virginica]

RI_24h

-23.27740458

septin-2-like isoform X1 [Crassostrea virginica]

S4_24h

-10.38732509

septin-2-like isoform X8 [Crassostrea virginica]

RI_6h

-7.952386425

septin-2-like isoform X8 [Crassostrea virginica]

RI_6h

Others
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-23.59339061

multidrug resistance protein 1-like isoform X1 [Crassostrea virginica]

S4_6h

-14.96548899

multidrug resistance protein 1-like isoform X6 [Crassostrea virginica]

S4_24h

21.14757041

multidrug resistance protein 1-like isoform X6 [Crassostrea virginica]

RI_6h

22.22331368

multidrug resistance protein 1-like isoform X6 [Crassostrea virginica]

RI_24h

21.3339868

multidrug resistance protein 1-like isoform X6 [Crassostrea virginica]

RE22_6h

-25.28253245

multidrug resistance-associated protein 4-like [Crassostrea virginica]

S4_6h

-11.35931265

multidrug resistance-associated protein 4-like [Crassostrea virginica]

S4_24h

-2.996574031

multidrug resistance-associated protein 5-like isoform X2 [Crassostrea virginica]

S4_24h

-22.29106079

multidrug resistance-associated protein 7-like [Crassostrea virginica]

S4_24h

-2.512272237

laccase-3-like [Crassostrea virginica]

RI_24h

-4.990554678

laccase-like [Crassostrea virginica]

RI_6h

-23.49586873

Hemicentin-1, partial [Crassostrea gigas]

S4_6h

-21.69620493

Hemicentin-1

S4_6h
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-8.779619013

Hemicentin-1

S4_6h

-26.12075367

Hemicentin-1

S4_24h

-22.82446184

Hemicentin-1

RE22_6h

4.970041769

hemicentin-1-like [Crassostrea virginica]

S4_6h

-23.57120259

hemicentin-1-like [Crassostrea virginica]

S4_6h

7.211995212

hemicentin-1-like [Crassostrea virginica]

S4_6h

-24.43651737

hemicentin-1-like [Crassostrea virginica]

RE22_6h

-22.74745907

hemicentin-1-like isoform X2 [Crassostrea virginica]

S4_24h

-22.04213544

hemicentin-1-like isoform X2 [Crassostrea virginica]

S4_24h

-23.91446285

hemicentin-1-like isoform X2 [Crassostrea virginica]

RE22_6h

-6.483050928

hemicentin-1-like isoform X2 [Crassostrea virginica]

RI_6h

-20.92100668

hemicentin-1-like isoform X21 [Crassostrea virginica]

S4_6h

-21.90630905

hemicentin-1-like isoform X21 [Crassostrea virginica]

RI_6h

-21.71429592

hemicentin-1-like isoform X21 [Crassostrea virginica]

RI_24h
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-22.25262628

hemicentin-1-like isoform X21 [Crassostrea virginica]

RE22_6h

-21.95606244

hemicentin-1-like isoform X21 [Crassostrea virginica]

RE22_6h

-25.24784795

hemicentin-1-like isoform X3 [Crassostrea virginica]

S4_24h

15.22210309

hemicentin-1-like isoform X34 [Crassostrea virginica]

S4_6h

19.54287658

hemicentin-1-like isoform X34 [Crassostrea virginica]

S4_24h

19.38940516

hemicentin-1-like isoform X34 [Crassostrea virginica]

RI_6h

19.36636019

hemicentin-1-like isoform X34 [Crassostrea virginica]

RI_24h

19.77553284

hemicentin-1-like isoform X34 [Crassostrea virginica]

RE22_6h

-21.26298714

hemicentin-1-like isoform X40 [Crassostrea virginica]

S4_6h

-22.32330998

hemicentin-1-like isoform X40 [Crassostrea virginica]

S4_24h

7.289148836

hemicentin-1-like isoform X5 [Crassostrea virginica]

S4_6h

17.82784086

hemicentin-1-like isoform X5 [Crassostrea virginica]

S4_24h

20.84952352

hemicentin-1-like isoform X5 [Crassostrea virginica]

RI_24h

-24.07441428

hemicentin-1-like isoform X6 [Crassostrea virginica]

S4_6h

220

-22.70945451

hemicentin-1-like isoform X9 [Crassostrea virginica]

S4_24h

-25.40188462

hemicentin-1-like isoform X9 [Crassostrea virginica]

RI_6h

-29.99115794

hemicentin-1-like isoform X9 [Crassostrea virginica]

RI_24h

9.38130971

hemicentin-2-like isoform X2 [Crassostrea virginica]

S4_6h

20.95642279

hemicentin-2-like isoform X2 [Crassostrea virginica]

S4_24h

9.373853638

hemicentin-2-like isoform X2 [Crassostrea virginica]

RI_6h

20.55310454

hemicentin-2-like isoform X2 [Crassostrea virginica]

RI_24h

9.777286784

hemicentin-2-like isoform X2 [Crassostrea virginica]

RE22_6h

-8.922154094

histamine H2 receptor-like [Crassostrea virginica]

S4_24h

-22.19114574

histamine H2 receptor-like [Crassostrea virginica]

S4_24h

-22.75801453

histamine H2 receptor-like [Crassostrea virginica]

RI_24h

-22.90867354

histamine H2 receptor-like [Crassostrea virginica]

RE22_6h

-5.471576144

oxidative stress-induced growth inhibitor 2-like [Crassostrea virginica]

S4_6h

-9.718337318

oxidative stress-induced growth inhibitor 2-like [Crassostrea virginica]

RI_6h

221

-6.452016421

oxidative stress-induced growth inhibitor 2-like [Crassostrea virginica]

RE22_6h

-2.071397009

cytochrome b [Crassostrea virginica]

RI_6h

20.23697806

cytochrome b5 reductase 4-like isoform X3 [Crassostrea virginica]

S4_24h

22.07024714

cytochrome b5 reductase 4-like isoform X3 [Crassostrea virginica]

RI_6h

17.91802039

cytochrome b5 reductase 4-like isoform X3 [Crassostrea virginica]

RI_24h

21.0441541

cytochrome b5 reductase 4-like isoform X3 [Crassostrea virginica]

RE22_6h

-30

cytochrome c oxidase subunit I [Crassostrea virginica]

S4_6h

-12.21152488

cytochrome c oxidase subunit I [Crassostrea virginica]

S4_6h

13.83136184

cytochrome c oxidase subunit I [Crassostrea virginica]

S4_6h

-12.7345641

cytochrome c oxidase subunit I [Crassostrea virginica]

S4_24h

23.04305396

cytochrome c oxidase subunit I [Crassostrea virginica]

S4_24h

27.42296011

cytochrome c oxidase subunit I [Crassostrea virginica]

S4_24h

29.20729823

cytochrome c oxidase subunit I [Crassostrea virginica]

S4_24h

-24.69050988

cytochrome c oxidase subunit I [Crassostrea virginica]

RI_6h

222

-24.66864706

cytochrome c oxidase subunit I [Crassostrea virginica]

RI_6h

29.16889206

cytochrome c oxidase subunit I [Crassostrea virginica]

RI_6h

-30

cytochrome c oxidase subunit I [Crassostrea virginica]

RI_24h

-13.01827661

cytochrome c oxidase subunit I [Crassostrea virginica]

RI_24h

20.69401443

cytochrome c oxidase subunit I [Crassostrea virginica]

RI_24h

30

cytochrome c oxidase subunit I [Crassostrea virginica]

RI_24h

-30

cytochrome c oxidase subunit I [Crassostrea virginica]

RE22_6h

-11.365341

cytochrome c oxidase subunit I [Crassostrea virginica]

RE22_6h

-10.31599264

cytochrome c oxidase subunit I [Crassostrea virginica]

RE22_6h

30

cytochrome c oxidase subunit I [Crassostrea virginica]

RE22_6h

-12.33130181

cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]

S4_24h

-26.50197006

cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]

RI_6h

-17.04367675

cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]

RI_24h

11.0050444

cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]

S4_6h

223

15.84125515

cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]

S4_6h

26.82143733

cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]

S4_6h

28.26611263

cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]

S4_6h

10.86124348

cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]

S4_24h

11.67321719

cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]

S4_24h

30

cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]

S4_24h

30

cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]

S4_24h

12.78997263

cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]

RI_6h

30

cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]

RI_6h

30

cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]

RI_6h

14.9301273

cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]

RI_24h

25.83550682

cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]

RI_24h

27.94606978

cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]

RI_24h

15.68484216

cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]

RE22_6h

224

29.89148054

cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]

RE22_6h

7.51088163

cytochrome P450 27C1-like [Crassostrea virginica]

S4_6h

8.171393189

cytochrome P450 27C1-like [Crassostrea virginica]

S4_24h

-24.81197395

cytochrome P450 27C1-like [Crassostrea virginica]

RI_6h

9.022848188

cytochrome P450 27C1-like [Crassostrea virginica]

RI_6h

7.477144414

cytochrome P450 27C1-like [Crassostrea virginica]

RI_24h

6.794994273

cytochrome P450 27C1-like [Crassostrea virginica]

RE22_6h

21.27504686

cytochrome P450 2C28-like isoform X2 [Crassostrea virginica]

S4_6h

18.70986303

cytochrome P450 2C28-like isoform X2 [Crassostrea virginica]

S4_24h

-22.33591302

cytochrome P450 2C28-like isoform X2 [Crassostrea virginica]

RI_6h

20.28813849

cytochrome P450 2C28-like isoform X2 [Crassostrea virginica]

RI_24h

20.46500703

cytochrome P450 2C28-like isoform X2 [Crassostrea virginica]

RE22_6h

6.238313253

Cytochrome P450 2D14 [Crassostrea gigas]

RI_6h

-21.35382089

cytochrome P450 2F5-like [Crassostrea virginica]

S4_6h

225

-21.63670878

cytochrome P450 2F5-like [Crassostrea virginica]

S4_24h

-22.27759983

cytochrome P450 2F5-like [Crassostrea virginica]

RI_24h

-22.65584492

cytochrome P450 2F5-like [Crassostrea virginica]

RE22_6h

-21.3071929

cytochrome P450 2J5-like isoform X2 [Crassostrea virginica]

S4_24h

-22.51502577

cytochrome P450 3A6-like [Crassostrea virginica]

S4_24h

-9.01112453

cytochrome P450 4A25-like [Crassostrea virginica]

S4_6h

-10.01277913

cytochrome P450 4V2-like isoform X1 [Crassostrea virginica]

S4_6h

-20.02751343

cytochrome P450 4V2-like isoform X1 [Crassostrea virginica]

RI_24h

-8.791304071

dual specificity protein phosphatase 1-A-like [Crassostrea virginica]

RI_24h

4.381729845

dual specificity protein phosphatase 14-like isoform X1 [Crassostrea virginica]

RI_24h

-23.83873688

dual specificity protein phosphatase 18-like [Crassostrea virginica]

RI_24h

-24.07000154

dual specificity protein phosphatase 18-like [Crassostrea virginica]

RE22_6h

9.288349328

dual specificity protein phosphatase 19-like [Crassostrea virginica]

S4_24h

8.034347824

dual specificity protein phosphatase 19-like [Crassostrea virginica]

RI_24h

226

-24.95777889

dual specificity protein phosphatase 7-like [Crassostrea virginica]

RI_6h

8.541240553

dual specificity protein phosphatase 7-like [Crassostrea virginica]

RI_24h

-25.38312764

dual specificity protein phosphatase 7-like [Crassostrea virginica]

RE22_6h

-8.245775085

protein phosphatase 1 regulatory subunit 12A-like isoform X4 [Crassostrea virginica]

S4_24h

-24.53980697

protein phosphatase 1 regulatory subunit 16A-like isoform X3 [Crassostrea virginica]

S4_6h

10.20776883

protein phosphatase 1 regulatory subunit 16A-like isoform X3 [Crassostrea virginica]

S4_6h

9.225134929

protein phosphatase 1 regulatory subunit 16A-like isoform X3 [Crassostrea virginica]

S4_24h

9.587762441

protein phosphatase 1 regulatory subunit 16A-like isoform X3 [Crassostrea virginica]

RI_6h

8.067829643

protein phosphatase 1 regulatory subunit 16A-like isoform X3 [Crassostrea virginica]

RI_24h

8.666364977

protein phosphatase 1 regulatory subunit 16A-like isoform X3 [Crassostrea virginica]

RE22_6h

8.659545152

protein phosphatase 1 regulatory subunit 36-like isoform X1 [Crassostrea virginica]

RI_6h

-7.364558291

protein phosphatase 1 regulatory subunit 37-like [Crassostrea virginica]

S4_6h

-7.980896037

protein phosphatase 1 regulatory subunit 37-like [Crassostrea virginica]

RE22_6h

7.015542075

protein phosphatase 1 regulatory subunit 42-like isoform X1 [Crassostrea virginica]

RI_24h

227

-24.30599943

protein phosphatase 1 regulatory subunit 42-like isoform X5 [Crassostrea virginica]

S4_24h

20.18059945

Tripartite motif-containing protein 2 [Crassostrea gigas]

S4_6h

23.03367057

Tripartite motif-containing protein 2 [Crassostrea gigas]

S4_6h

-7.262763056

Tripartite motif-containing protein 2 [Crassostrea gigas]

S4_24h

21.37325729

Tripartite motif-containing protein 2 [Crassostrea gigas]

S4_24h

-22.62992934

Tripartite motif-containing protein 2 [Crassostrea gigas]

RI_6h

-11.07407202

Tripartite motif-containing protein 2 [Crassostrea gigas]

RI_6h

20.48455649

Tripartite motif-containing protein 2 [Crassostrea gigas]

RI_6h

20.56883143

Tripartite motif-containing protein 2 [Crassostrea gigas]

RI_6h

-22.63181448

Tripartite motif-containing protein 2 [Crassostrea gigas]

RI_24h

21.63871709

Tripartite motif-containing protein 2 [Crassostrea gigas]

RI_24h

19.01092158

Tripartite motif-containing protein 2 [Crassostrea gigas]

RE22_6h

21.96955011

Tripartite motif-containing protein 2 [Crassostrea gigas]

RE22_6h

-9.107874381

Tripartite motif-containing protein 2 [Crassostrea gigas]

S4_24h

228

-24.94189095

tripartite motif-containing protein 2-like [Crassostrea virginica]

S4_6h

-21.21518109

tripartite motif-containing protein 2-like [Crassostrea virginica]

S4_6h

-24.99785172

tripartite motif-containing protein 2-like [Crassostrea virginica]

S4_24h

-22.97055523

tripartite motif-containing protein 2-like [Crassostrea virginica]

S4_24h

-22.56316651

tripartite motif-containing protein 2-like [Crassostrea virginica]

S4_24h

-21.63143212

tripartite motif-containing protein 2-like [Crassostrea virginica]

S4_24h

-21.555795

tripartite motif-containing protein 2-like [Crassostrea virginica]

S4_24h

-21.48502657

tripartite motif-containing protein 2-like [Crassostrea virginica]

S4_24h

2.440722296

tripartite motif-containing protein 2-like [Crassostrea virginica]

S4_24h

-23.52232576

tripartite motif-containing protein 2-like [Crassostrea virginica]

RI_24h

-22.27754888

tripartite motif-containing protein 2-like [Crassostrea virginica]

RI_24h

-6.664288475

tripartite motif-containing protein 2-like [Crassostrea virginica]

RI_24h

-23.67795281

tripartite motif-containing protein 2-like [Crassostrea virginica]

RE22_6h

-22.94845541

tripartite motif-containing protein 2-like [Crassostrea virginica]

RE22_6h

229

20.60131168

tripartite motif-containing protein 2-like [Crassostrea virginica]

S4_6h

20.75582702

tripartite motif-containing protein 2-like [Crassostrea virginica]

S4_24h

20.51645227

tripartite motif-containing protein 2-like [Crassostrea virginica]

RI_6h

-23.97927626

tripartite motif-containing protein 2-like [Crassostrea virginica]

RI_24h

20.6240354

tripartite motif-containing protein 2-like [Crassostrea virginica]

RI_24h

20.61455877

tripartite motif-containing protein 2-like [Crassostrea virginica]

RE22_6h

-21.16657646

tripartite motif-containing protein 2-like isoform X2 [Crassostrea virginica]

S4_6h

9.572758843

tripartite motif-containing protein 2-like isoform X2 [Crassostrea virginica]

S4_6h

-21.69698695

tripartite motif-containing protein 2-like isoform X2 [Crassostrea virginica]

RI_6h

7.793596061

tripartite motif-containing protein 2-like isoform X2 [Crassostrea virginica]

RI_6h

22.30459712

tripartite motif-containing protein 2-like isoform X4 [Crassostrea virginica]

S4_6h

21.31432232

tripartite motif-containing protein 2-like isoform X4 [Crassostrea virginica]

RE22_6h

-24.62951513

tripartite motif-containing protein 3-like [Crassostrea virginica]

S4_24h

-25.52121202

tripartite motif-containing protein 3-like [Crassostrea virginica]

RI_24h

-25.70706555

tripartite motif-containing protein 3-like [Crassostrea virginica]

RE22_6h

-6.057275712

tripartite motif-containing protein 3-like [Crassostrea virginica]

RE22_6h

-24.1355023

tripartite motif-containing protein 45-like [Crassostrea virginica]

RE22_6h

-21.78539178

tripartite motif-containing protein 5-like isoform X2 [Crassostrea virginica]

RI_24h

-21.98439629

perlucin-like [Crassostrea virginica]

S4_6h

-23.38363804

perlucin-like [Crassostrea virginica]

S4_24h

-21.96732063

perlucin-like [Crassostrea virginica]

S4_24h

-8.094282488

perlucin-like [Crassostrea virginica]

S4_24h

-23.03677587

perlucin-like isoform X1 [Crassostrea virginica]

S4_24h

-22.45971194

perlucin-like isoform X1 [Crassostrea virginica]

RE22_6h

18.507209

perlucin-like isoform X2 [Crassostrea virginica]

S4_24h

15.20165795

perlucin-like isoform X2 [Crassostrea virginica]

RI_24h

-23.43817576

perlucin-like protein [Crassostrea virginica]

S4_24h

Biomineralization

230

-6.765931252

perlucin-like protein [Crassostrea virginica]

RI_24h

21.94929471

perlucin-like protein isoform X1 [Crassostrea virginica]

S4_6h

21.68188164

perlucin-like protein isoform X1 [Crassostrea virginica]

RE22_6h

25.09518802

Chitin synthase 3 [Crassostrea gigas]

RE22_6h

24.46274385

Chitin synthase 3 [Crassostrea gigas]

RI_6h

21.58959401

Chitin synthase 3 [Crassostrea gigas]

S4_6h

-7.045235918

Chitin synthase C [Crassostrea gigas]

S4_24h

231
Table 3: Differentially expressed genes with log fold change for probiotic treatment when compared to control in hatchery
transcriptomes (p ≤ 0.05, upregulation: log fold change ≥ 2, downregulation: log fold change ≤ -2). HT-RI: larvae treated daily with
probiotic Bacillus pumilus RI0695 (RI) for 5, 12 or 16 days

Log2FoldChange Hit_def

Treatment

Recognition
TLRs

232

-6.333302299

toll-like receptor 1 [Crassostrea virginica]

HT_RI

-5.117571098

toll-like receptor 6 [Crassostrea virginica]

HT_RI

10.50152784

toll-like receptor 6 [Crassostrea virginica]

HT_RI

-7.016997176

toll-like receptor 4 isoform X1 [Crassostrea virginica]

HT_RI

5.181661209

toll-like receptor 4 isoform X1 [Crassostrea virginica]

HT_RI

-13.50652647

toll-like receptor 4 isoform X1 [Crassostrea virginica]

HT_RI

-28.195436

toll-like receptor 4 isoform X1 [Crassostrea virginica]

HT_RI

-10.52830632

toll-like receptor 13 [Crassostrea virginica]

HT_RI

-7.548517655

C-type lectin domain family 4 member E-like [Crassostrea virginica]

HT_RI

-9.313083618

C-type lectin domain family 3 member A-like [Crassostrea virginica]

HT_RI

Lectin

Scavenger receptors

-8.035179262

scavenger receptor class B member 1-like isoform X1 [Crassostrea virginica]

HT_RI

-8.089778373

scavenger receptor class B member 1-like isoform X1 [Crassostrea virginica]

HT_RI

-3.505324316

scavenger receptor cysteine-rich type 1 protein M130-like isoform X1

HT_RI

[Crassostrea virginica]
-5.113872743

scavenger receptor cysteine-rich type 1 protein M130-like isoform X1

HT_RI

[Crassostrea virginica]
LRFN
233

-7.614151619

leucine-rich repeat and fibronectin type III domain-containing protein 1-like

HT_RI

protein [Crassostrea virginica]
-10.54947853

leucine-rich repeat and fibronectin type-III domain-containing protein 5-like

HT_RI

[Crassostrea virginica]
LRRs
7.538001578

leucine-rich repeat and IQ domain-containing protein 1-like [Crassostrea
virginica]

HT_RI

7.603603801

leucine-rich repeat neuronal protein 3-like [Crassostrea virginica]

HT_RI

-7.290369986

leucine-rich repeat neuronal protein 3-like [Crassostrea virginica]

HT_RI

-3.910728944

leucine-rich repeat transmembrane protein FLRT3-like [Crassostrea virginica]

HT_RI

8.884936086

leucine-rich repeat-containing G-protein coupled receptor 4-like [Crassostrea

HT_RI

virginica]
-5.222764772

leucine-rich repeat-containing G-protein coupled receptor 4-like [Crassostrea

HT_RI

virginica]
234

6.417892215

leucine-rich repeat-containing protein 24-like [Crassostrea virginica]

HT_RI

-5.851688629

leucine-rich repeat-containing protein 24-like [Crassostrea virginica]

HT_RI

-6.888253251

leucine-rich repeat-containing protein 24-like [Crassostrea virginica]

HT_RI

-10.67681921

leucine-rich repeat-containing protein 71-like isoform X21 [Crassostrea

HT_RI

virginica]
11.13843633

leucine-rich repeat-containing protein 71-like isoform X22 [Crassostrea
virginica]

HT_RI

-12.72995479

leucine-rich repeat-containing protein 74A-like isoform X2 [Crassostrea

HT_RI

virginica]
-9.675716266

leucine-rich repeat-containing protein 74B-like isoform X3 [Crassostrea

HT_RI

virginica]
Fibronectin domain containing
3.471877714

fibronectin type-III domain-containing protein 3A-like isoform X4 [Crassostrea

HT_RI

virginica]
235

-7.597144145

fibronectin type-III domain-containing protein 3A-like isoform X4 [Crassostrea

HT_RI

virginica]
C1q proteins
7.068747239

complement C1q tumor necrosis factor-related protein 2-like [Crassostrea

HT_RI

virginica]
-8.687727906

complement C1q tumor necrosis factor-related protein 4-like isoform X3
[Crassostrea virginica]

HT_RI

Others
-5.683456288

Macrophage mannose receptor 1 [Crassostrea gigas]

HT_RI

-9.358422983

macrophage mannose receptor 1-like [Crassostrea virginica]

HT_RI

7.683007501

macrophage migration inhibitory factor-like [Crassostrea virginica]

HT_RI

Cholinergic immunomodulation

236

-6.155933795

muscarinic acetylcholine receptor M1-like [Crassostrea virginica]

HT_RI

-10.64631968

muscarinic acetylcholine receptor M1-like [Crassostrea virginica]

HT_RI

-10.62270936

glutamate receptor ionotropic

HT_RI

-10.76881678

glutamate receptor ionotropic

HT_RI

-9.746999757

neuronal acetylcholine receptor subunit alpha-10-like isoform X2 [Crassostrea

HT_RI

virginica]
-10.55585177

neuronal acetylcholine receptor subunit alpha-10-like isoform X2 [Crassostrea
virginica]

HT_RI

-10.41167226

neuronal acetylcholine receptor subunit alpha-10-like isoform X3 [Crassostrea

HT_RI

virginica]

237

2.6604451

neuronal acetylcholine receptor subunit alpha-6-like [Crassostrea virginica]

HT_RI

11.8076763

neuronal acetylcholine receptor subunit alpha-9-like [Crassostrea virginica]

HT_RI

-7.276192743

neuronal acetylcholine receptor subunit alpha-9-like [Crassostrea virginica]

HT_RI

-12.41663085

neuronal acetylcholine receptor subunit alpha-9-like [Crassostrea virginica]

HT_RI

10.57507598

neuropeptide FF receptor 2-like [Crassostrea virginica]

HT_RI

19.88309004

neuropeptide Y receptor type 1-like [Crassostrea virginica]

HT_RI

-11.49570393

TNF receptor-associated factor 3-like isoform X3 [Crassostrea virginica]

HT_RI

8.268728895

tumor necrosis factor receptor superfamily member 1B-like isoform X1

HT_RI

Signaling pathways

[Crassostrea virginica]
4.135043574

NF-kappa-B inhibitor-interacting Ras-like protein 1 isoform X8 [Crassostrea
virginica]

HT_RI

3.572468448

NF-kappa-B inhibitor-interacting Ras-like protein 1 isoform X8 [Crassostrea

HT_RI

virginica]

238

-6.180435424

nuclear factor NF-kappa-B p105 subunit-like isoform X2 [Crassostrea virginica]

HT_RI

6.794484856

C-Jun-amino-terminal kinase-interacting protein 4-like [Crassostrea virginica]

HT_RI

11.83894875

stress-activated protein kinase JNK-like isoform X1 [Crassostrea virginica]

HT_RI

11.81769312

stress-activated protein kinase JNK-like isoform X1 [Crassostrea virginica]

HT_RI

5.027413466

stress-activated protein kinase JNK-like isoform X1 [Crassostrea virginica]

HT_RI

-7.126718787

mitogen-activated protein kinase 11-like [Crassostrea virginica]

HT_RI

-9.730631672

mitogen-activated protein kinase 11-like [Crassostrea virginica]

HT_RI

-13.9275785

mitogen-activated protein kinase 11-like [Crassostrea virginica]

HT_RI

-10.23892565

mitogen-activated protein kinase 7-like isoform X2 [Crassostrea virginica]

HT_RI

-11.91394746

interferon regulatory factor 2-binding protein-like [Crassostrea virginica]

HT_RI

-10.43886642

integrin alpha-2-like isoform X10 [Crassostrea virginica]

HT_RI

11.26277301

integrin alpha-2-like isoform X5 [Crassostrea virginica]

HT_RI

12.22522579

integrin beta-like protein C isoform X1 [Crassostrea virginica]

HT_RI

9.093480693

nuclear factor of activated T-cells 5-like isoform X2 [Crassostrea virginica]

HT_RI

3.339268822

nuclear factor of activated T-cells 5-like isoform X2 [Crassostrea virginica]

HT_RI

5.805191913

serine protease inhibitor Cvsi-2-like [Crassostrea virginica]

HT_RI

-2.31732885

kunitz-type serine protease inhibitor conotoxin Cal9.1b-like [Crassostrea

HT_RI

Effectors

virginica]
239

-11.91394746

interferon regulatory factor 2-binding protein-like [Crassostrea virginica]

HT_RI

10.23389419

interferon-induced protein 44-like isoform X2 [Crassostrea virginica]

HT_RI

4.93870882

interferon-induced protein 44-like isoform X2 [Crassostrea virginica]

HT_RI

10.86738137

Signaling mucin HKR1 [Mizuhopecten yessoensis]

HT_RI

-9.926277007

Signaling mucin HKR1 [Mizuhopecten yessoensis]

HT_RI

-11.19554614

Signaling mucin HKR1 [Mizuhopecten yessoensis]

HT_RI

-7.627259354

integumentary mucin C.1-like isoform X3 [Crassostrea virginica]

HT_RI

5.366202536

mucin-17-like isoform X2 [Crassostrea virginica]

HT_RI

-5.772730703

mucin-17-like isoform X2 [Crassostrea virginica]

HT_RI

-13.12905042

mucin-2-like [Crassostrea virginica]

HT_RI

-5.905452651

mucin-5AC-like [Crassostrea virginica]

HT_RI

-8.77598416

mucin-5AC-like isoform X5 [Crassostrea virginica]

HT_RI

-7.924485961

caspase-1-like [Crassostrea virginica]

HT_RI

-9.46806142

caspase-1-like [Crassostrea virginica]

HT_RI

10.97406116

caspase-14-like isoform X2 [Crassostrea virginica]

HT_RI

-3.233698531

caspase-7-like [Crassostrea virginica]

HT_RI

-10.00654536

caspase-7-like [Crassostrea virginica]

HT_RI

-3.686137851

caspase recruitment domain-containing protein 14-like isoform X5 [Crassostrea

HT_RI

Apoptosis

240

virginica]

6.279723333

baculoviral IAP repeat-containing protein 2-like isoform X1 [Crassostrea

HT_RI

virginica]
10.35840243

baculoviral IAP repeat-containing protein 2-like isoform X2 [Crassostrea

HT_RI

virginica]
-9.552992158

baculoviral IAP repeat-containing protein 3-like [Crassostrea virginica]

HT_RI

-10.01313701

baculoviral IAP repeat-containing protein 3-like [Crassostrea virginica]

HT_RI

-7.12622932

baculoviral IAP repeat-containing protein 7-like isoform X3 [Crassostrea

HT_RI

241

virginica]
11.86479373

Apoptosis inhibitor IAP [Crassostrea gigas]

HT_RI

5.960093895

LOW QUALITY PROTEIN: apoptosis-inducing factor 3-like [Crassostrea

HT_RI

virginica]
2.788401176

protein kinase C iota type-like isoform X4 [Crassostrea virginica]

HT_RI

20.80442465

multiple epidermal growth factor-like domains protein 10 [Crassostrea virginica]

HT_RI

-6.43860015

multiple epidermal growth factor-like domains protein 10 [Crassostrea virginica]

HT_RI

-7.224748576

multiple epidermal growth factor-like domains protein 10 [Crassostrea virginica]

HT_RI

10.58406136

multiple epidermal growth factor-like domains protein 10 isoform X2

HT_RI

[Crassostrea virginica]
7.215833061

multiple epidermal growth factor-like domains protein 10 isoform X2

HT_RI

[Crassostrea virginica]
5.064940886

multiple epidermal growth factor-like domains protein 10 isoform X2

HT_RI

[Crassostrea virginica]
242

2.789935488

multiple epidermal growth factor-like domains protein 10 isoform X2

HT_RI

[Crassostrea virginica]
8.594189834

multiple epidermal growth factor-like domains protein 6 [Crassostrea virginica]

HT_RI

-10.50534165

multiple epidermal growth factor-like domains protein 6 [Crassostrea virginica]

HT_RI

10.20740385

multiple epidermal growth factor-like domains protein 6 isoform X1 [Crassostrea

HT_RI

virginica]

10.20312945

multiple epidermal growth factor-like domains protein 6 isoform X1 [Crassostrea

HT_RI

virginica]
7.471679862

multiple epidermal growth factor-like domains protein 6 isoform X1 [Crassostrea

HT_RI

virginica]

243

8.053324948

programmed cell death protein 2-like isoform X1 [Crassostrea virginica]

HT_RI

11.33719413

cell death abnormality protein 1-like [Crassostrea virginica]

HT_RI

11.40372414

GTPase IMAP family member 7-like isoform X1 [Crassostrea virginica]

HT_RI

-10.0861395

DNA damage-regulated autophagy modulator protein 2-like [Crassostrea

HT_RI

virginica]
Cytoskeletal reorganization
9.029226712

LOW QUALITY PROTEIN: septin-2-like [Crassostrea virginica]

HT_RI

5.82670463

LOW QUALITY PROTEIN: septin-2-like [Crassostrea virginica]

HT_RI

4.705387778

LOW QUALITY PROTEIN: septin-2-like [Crassostrea virginica]

HT_RI

Others

-9.657810466

lysosomal acid lipase/cholesteryl ester hydrolase-like [Crassostrea virginica]

HT_RI

14.2444413

lysosomal alpha-glucosidase-like isoform X1 [Crassostrea virginica]

HT_RI

-10.73769432

lysosomal-trafficking regulator-like isoform X4 [Crassostrea virginica]

HT_RI

10.97945875

glutathione S-transferase C-terminal domain-containing protein-like isoform X1

HT_RI

[Crassostrea virginica]

244

-6.354844406

glutathione-independent glyoxalase HSP31-like [Crassostrea virginica]

HT_RI

4.264547363

maleylacetoacetate isomerase-like [Crassostrea virginica]

HT_RI

11.70064297

Heat shock 70 kDa protein 12A [Crassostrea gigas]

HT_RI

-6.944842925

Heat shock 70 kDa protein 12A [Crassostrea gigas]

HT_RI

-6.695090302

heat shock 70 kDa protein 12A-like [Crassostrea virginica]

HT_RI

-10.35513436

heat shock 70 kDa protein 12A-like [Crassostrea virginica]

HT_RI

-10.53471861

heat shock 70 kDa protein 12A-like [Crassostrea virginica]

HT_RI

-10.66480031

heat shock 70 kDa protein 12A-like [Crassostrea virginica]

HT_RI

10.32935057

heat shock 70 kDa protein 12A-like isoform X1 [Crassostrea virginica]

HT_RI

245

5.822952857

heat shock 70 kDa protein 12A-like isoform X1 [Crassostrea virginica]

HT_RI

3.278219628

actin

HT_RI

11.26723475

actin-3-like isoform X1 [Crassostrea virginica]

HT_RI

-3.288605929

tripartite motif-containing protein 2-like [Crassostrea virginica]

HT_RI

-28.23091398

tripartite motif-containing protein 2-like [Crassostrea virginica]

HT_RI

11.97821512

tripartite motif-containing protein 2-like isoform X1 [Crassostrea virginica]

HT_RI

6.138377301

tripartite motif-containing protein 3-like [Crassostrea virginica]

HT_RI

4.616161652

tripartite motif-containing protein 3-like [Crassostrea virginica]

HT_RI

-5.355761746

tripartite motif-containing protein 3-like [Crassostrea virginica]

HT_RI

20.95857011

tripartite motif-containing protein 3-like isoform X1 [Crassostrea virginica]

HT_RI

-6.051600924

tripartite motif-containing protein 55-like [Crassostrea virginica]

HT_RI

-12.53777229

protein phosphatase 1 regulatory subunit 11-like [Crassostrea virginica]

HT_RI

7.873357051

protein phosphatase 1 regulatory subunit 12B-like isoform X13 [Crassostrea

HT_RI

virginica]

7.282656314

protein phosphatase 1 regulatory subunit 12B-like isoform X13 [Crassostrea

HT_RI

virginica]
-12.67858882

protein phosphatase 1 regulatory subunit 12B-like isoform X13 [Crassostrea

HT_RI

virginica]
14.50001928

protein phosphatase 1 regulatory subunit 37-like [Crassostrea virginica]

HT_RI

-3.004388061

protein phosphatase 1 regulatory subunit 37-like [Crassostrea virginica]

HT_RI

-6.650729756

protein phosphatase 1 regulatory subunit 42-like isoform X5 [Crassostrea

HT_RI

246

virginica]
6.602761261

multidrug resistance-associated protein 5-like isoform X2 [Crassostrea virginica]

HT_RI

-10.91470969

multidrug resistance-associated protein 5-like isoform X2 [Crassostrea virginica]

HT_RI

-13.24809012

multidrug resistance-associated protein 5-like isoform X2 [Crassostrea virginica]

HT_RI

9.2023305

cytochrome b5 reductase 4-like isoform X3 [Crassostrea virginica]

HT_RI

16.35993502

cytochrome c oxidase subunit III (mitochondrion) [Crassostrea virginica]

HT_RI

-12.35764438

cytochrome P450 27C1-like [Crassostrea virginica]

HT_RI

-10.85697882

cytochrome P450 2C42-like [Crassostrea virginica]

HT_RI

2.675102652

Cytochrome P450 3A11 [Crassostrea gigas]

HT_RI

-4.440107252

cytochrome P450 3A29-like [Crassostrea virginica]

HT_RI

-7.518489118

cytochrome P450 4V2-like isoform X1 [Crassostrea virginica]

HT_RI

-12.02720282

Ig-like and fibronectin type-III domain-containing protein 2 [Crassostrea

HT_RI

virginica]

247

7.683007501

macrophage migration inhibitory factor-like [Crassostrea virginica]

HT_RI

2.309585304

histone H2B-like [Crassostrea virginica]

HT_RI

-9.231433964

perlucin-like isoform X2 [Crassostrea virginica]

HT_RI

9.231041006

perlucin-like protein [Crassostrea virginica]

HT_RI

9.062890569

perlucin-like protein [Crassostrea virginica]

HT_RI

-4.500074021

perlucin-like protein [Crassostrea virginica]

HT_RI

-6.333143999

Chitin synthase C [Crassostrea gigas]

HT_RI

